ibl-brain-wide-map-public1000trueaggregates/2022-11-11T00:13:49.000Z"d41d8cd98f00b204e9800998ecf8427e"07d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2022_Q4_IBL_et_al_BWM/2022-11-11T00:18:47.000Z"d41d8cd98f00b204e9800998ecf8427e"07d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2022_Q4_IBL_et_al_BWM/clusters.pqt2023-12-20T09:07:43.000Z"ee6617bb2e61468f07a554e3f608144d-5"412404367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2022_Q4_IBL_et_al_BWM/trials.pqt2023-12-20T09:07:44.000Z"53fd7a5d98a1836d37fd7ecd3bcbd182-3"236469067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2023_Q4_IBL_et_al_BWM_2/clusters.pqt2024-03-27T14:53:05.000Z"ae10d01377f39d7a5d1837ab1b00da7b-7"520999967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2023_Q4_IBL_et_al_BWM_2/trials.pqt2024-04-26T13:37:30.000Z"9916868d900f8156e8d2bbf46ee5d3da-3"242125107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2024_Q2_IBL_et_al_BWM/2024-06-10T19:20:58.000Z"d41d8cd98f00b204e9800998ecf8427e"07d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2024_Q2_IBL_et_al_BWM/clusters.pqt2025-03-13T17:22:54.000Z"b89fac76289f3a3d585910711f1eef41"CRC64NVMEFULL_OBJECT915555297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2024_Q2_IBL_et_al_BWM/trials.pqt2025-03-13T18:15:21.000Z"eafa5476b9938819a2a089c8d4ae32a1-2"CRC64NVMEFULL_OBJECT242125107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2026_Q2_IBL_et_al_BWM/acgs_log.times.npy2026-06-02T13:20:28.000Z"c331a024cedb4ffa30304dc40af5a703"CRC32FULL_OBJECT11527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2026_Q2_IBL_et_al_BWM/clusters.acgs_log.npy2026-06-02T13:20:11.000Z"de65a61f61903f5432422933bd95314f-19"CRC32COMPOSITE1591637767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2026_Q2_IBL_et_al_BWM/clusters.pqt2026-06-02T14:37:41.000Z"bca8430bc556ca348578f8a1c89766a6-7"CRC64NVMEFULL_OBJECT1123257317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2026_Q2_IBL_et_al_BWM/clusters.waveforms_peak.npy2026-06-02T13:19:55.000Z"e8522a3e554e924ab8f81c34e14c5c9e-19"CRC32COMPOSITE1591637767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/2026_Q2_IBL_et_al_BWM/trials.pqt2026-06-02T13:19:38.000Z"9916868d900f8156e8d2bbf46ee5d3da-3"CRC32COMPOSITE242125107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T1/#2024-08-21#/_ibl_subjectTrials.table.068cc0b7-8aa2-49f7-b8f8-919c50f8634d.pqt2024-09-16T15:08:06.000Z"f99f4dc047e6721c21bd372c77f395d6-2"111563317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T1/_ibl_subjectSessions.table.90d1447d-8979-4870-b448-5827745b735b.pqt2025-02-20T19:37:39.000Z"ba91a76bf94a3d4e7fd3765f9cf99f12"CRC64NVMEFULL_OBJECT98787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T1/_ibl_subjectTraining.table.51cd0dcf-868a-4c5b-9026-b5ac25606c85.pqt2024-09-16T15:08:06.000Z"9c6dd0f78c2279f7f979c3bf49ce23b3"32577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T1/_ibl_subjectTrials.table.d609c416-444b-4ef8-b3f0-7db7bda5e2f8.pqt2023-12-20T09:07:45.000Z"323cd06abf6aecda256b685ed37f5f75"72520157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T2/#2024-08-21#/_ibl_subjectTrials.table.1b386241-ccb3-40b2-b80c-3c52a9e9845e.pqt2024-09-16T15:08:06.000Z"d44f9494e9aa6f83ae443356a26efd3c"83388507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T2/_ibl_subjectSessions.table.9c46d787-77f7-417f-8db8-c8189e94e3e4.pqt2025-02-20T19:37:39.000Z"af1e78d02aeca9e8e4be3b980a8eb07d"CRC64NVMEFULL_OBJECT96377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T2/_ibl_subjectTraining.table.9316931c-4cb8-4502-909a-9668330a175b.pqt2024-09-16T15:08:06.000Z"f447e8e0050fd6ac26dc2afc2329397e"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T2/_ibl_subjectTrials.table.2e81f059-9c35-42c2-b553-78b778a7df60.pqt2023-12-20T09:07:45.000Z"8ef3401930feb6b1507a8e7f13a1c9b4"52054647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T3/#2024-04-10#/_ibl_subjectTrials.table.5194d620-4ace-497d-9a67-9e003123506f.pqt2024-09-16T15:08:06.000Z"ccf43d1175907aab6663a502d5ed9fe7"83386887d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T3/_ibl_subjectSessions.table.c2c9d53b-f30b-40b7-bf27-c85970620c00.pqt2025-02-20T19:37:39.000Z"f608b200fc5c208f87b84b8ebbb6e905"CRC64NVMEFULL_OBJECT97517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T3/_ibl_subjectTraining.table.bd9665fa-1699-4484-8dab-439093c510e6.pqt2024-09-16T15:08:06.000Z"d26877977f7495643ac2078b350a5bff"31227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T3/_ibl_subjectTrials.table.20db61ba-33d5-4c3b-a6ce-4b43e540365c.pqt2023-12-20T09:07:46.000Z"417149966d2ec522bb25347528e50206"53696297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T4/#2024-04-10#/_ibl_subjectTrials.table.08d1f242-1fdc-4d0c-9964-8a29472f8ec1.pqt2024-09-16T15:08:06.000Z"5b693a3dd89c7a20aad02a4de0b72ca3"73937427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T4/_ibl_subjectSessions.table.ee8aea43-948f-4abe-af35-76a0e917c30f.pqt2025-02-20T19:37:39.000Z"ee729333fa686733058c6ae80167a5c8"CRC64NVMEFULL_OBJECT98247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T4/_ibl_subjectTraining.table.3418f754-462f-4f24-b6a4-96f8fe5841fc.pqt2024-09-16T15:08:06.000Z"3516f527505bd106d31fb6fe91c8f2df"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/IBL-T4/_ibl_subjectTrials.table.cb8a4f4a-acdc-4f74-8ca7-c2db1f4973e9.pqt2023-12-20T09:07:46.000Z"ac697b7c61ce548f7b2a5c047ad2d328"47837667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-01/#2024-04-11#/_ibl_subjectTrials.table.a96c0cd5-6af4-4ef4-8835-2f48c3d0549d.pqt2024-09-16T15:08:07.000Z"af360f06aef1e4fd059b1984a0594a1b"82957127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-01/_ibl_subjectSessions.table.4c77d754-e6df-4756-bfbe-83fb72e7028d.pqt2025-02-20T19:37:39.000Z"1512d30c2294df3f1b686190e598d9b4"CRC64NVMEFULL_OBJECT102317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-01/_ibl_subjectTraining.table.aa6f519c-f2d1-403b-8a57-03e81a6fcd21.pqt2024-09-16T15:08:06.000Z"ae47531869b5ac69ff920ab681080ac5"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-01/_ibl_subjectTrials.table.cd572170-8a71-41f1-bb67-8b8faafa515a.pqt2023-12-20T09:07:46.000Z"8d460090c8d2a1983e3912c5e29b2684"56157877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-02/#2024-08-21#/_ibl_subjectTrials.table.55509485-18ac-437b-b6ff-59b95640b913.pqt2024-09-16T15:08:07.000Z"348c6b5d8e34b0c029a72b6042ccc0ff"78003337d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-02/_ibl_subjectSessions.table.d033a30b-3c8e-4da3-99a0-bba76d4d8d1d.pqt2025-02-20T19:37:39.000Z"0329d35cbc20fc11bac15640c80ec835"CRC64NVMEFULL_OBJECT102107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-02/_ibl_subjectTraining.table.ed40fdb5-c110-42e2-853e-643c0f449244.pqt2024-09-16T15:08:07.000Z"f6c46880abc4fd759c07d67090b01917"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-02/_ibl_subjectTrials.table.bf801cd4-57ad-4c2b-aeff-d56a22ec588a.pqt2023-12-20T09:07:46.000Z"f4d88c0eb72d291be88da55570232240"53296907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-04/#2024-08-21#/_ibl_subjectTrials.table.2f28724c-0906-4fcd-94fb-86088a5e8016.pqt2024-09-16T15:08:07.000Z"1717909ffb757513a79592fdb7fb7b8a-2"109801787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-04/_ibl_subjectSessions.table.a80637cd-34c5-49e3-bd21-fcfca901f5c7.pqt2025-02-20T19:37:39.000Z"06f2d0757f0012d89c82d2ff317a888a"CRC64NVMEFULL_OBJECT103937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-04/_ibl_subjectTraining.table.3a28c767-304f-4a37-8389-9672c56525a8.pqt2024-09-16T15:08:07.000Z"3d570a19848f98dc86bd1a459f7c95e1"31387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-04/_ibl_subjectTrials.table.38927f95-0b5b-4ca8-bc2b-9c844b156d53.pqt2023-12-20T09:07:46.000Z"82ebf47efd98a942fb2432b27546f03d"73322147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-06/#2024-08-21#/_ibl_subjectTraining.table.b2f26a23-5acf-4717-bc86-b4b6f56cabd4.pqt2024-09-16T15:08:08.000Z"637fffcb0a76576bd836ed44b0e0d072"31327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-06/#2024-08-21#/_ibl_subjectTrials.table.d5483fad-daf4-4986-82cb-23d3e412378a.pqt2024-09-16T15:08:08.000Z"b3073f1e18191e64b1b59526a1becab9"58533847d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-06/_ibl_subjectSessions.table.a1eea7b9-c8d7-4e00-9785-9d972a1a2f21.pqt2025-02-20T19:37:39.000Z"55d8a0fbec183397e2400204fd21d5a8"CRC64NVMEFULL_OBJECT81677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-06/_ibl_subjectTraining.table.03c6dfd4-5929-4ac8-a895-1f7c95c3952a.pqt2023-12-20T09:07:46.000Z"37b98b0b5a1871a01445f4ba337b25c7"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-06/_ibl_subjectTrials.table.13c86b23-98db-41c3-9a74-ae3a70af9d26.pqt2023-12-20T09:07:47.000Z"abe634a756ec37f84bc3b31161f547e5"38315777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-07/#2024-08-21#/_ibl_subjectTrials.table.9c0ab7f3-9ad0-46ff-a9ea-5e9e52fedee8.pqt2024-09-16T15:08:08.000Z"05f98ce871e3f18875f59fbfccaca389"42879897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-07/_ibl_subjectSessions.table.caadbf14-83ed-4a2a-bb8e-e21f6fceabad.pqt2025-02-20T19:37:39.000Z"8619c5016cef764b5bedabbf7689bdf1"CRC64NVMEFULL_OBJECT82927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-07/_ibl_subjectTraining.table.2a22be11-8787-4703-92a7-db6a4f1a4aa0.pqt2024-09-16T15:08:08.000Z"17293512650c12a81520a6caafe67326"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-07/_ibl_subjectTrials.table.6abeea99-67cd-4641-b56c-e8fd4469b1b1.pqt2023-12-20T09:07:46.000Z"daf326231c42274603dc4a4f470622f8"28911137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-09/#2024-04-11#/_ibl_subjectTrials.table.4eef8179-4e6d-4589-a479-5338f900af04.pqt2024-09-16T15:08:08.000Z"f96c660a231ac143a8520b731e824d27"72695867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-09/_ibl_subjectSessions.table.5638fa98-f296-4d09-a661-2ed972fbc0f5.pqt2025-02-20T19:37:40.000Z"03b0bce8789f2539bdcdd0c3a90a399e"CRC64NVMEFULL_OBJECT86797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-09/_ibl_subjectTraining.table.e7a4ace5-8c79-4f45-b057-a88f73adbb42.pqt2024-09-16T15:08:08.000Z"44e051bff34685da6ec9ee63e330f25b"32567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-09/_ibl_subjectTrials.table.580b0985-1a1a-448f-8761-eebbecfdb217.pqt2023-12-20T09:07:46.000Z"48e40584d0d1bbb86669d4375831bb7e"30646287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-11/#2024-04-11#/_ibl_subjectTrials.table.aad437e0-ed83-42f0-bdf6-cea3aa5b2f7e.pqt2024-09-16T15:08:08.000Z"86161c40c76e34a103d5ba82d56d1bf5"52618117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-11/#2024-08-02#/_ibl_subjectTraining.table.1649ed69-a380-4a99-a3b7-3278555a699b.pqt2024-09-16T15:08:08.000Z"bd97aada287abfa288d61d77ade38bdd"31937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-11/_ibl_subjectSessions.table.35e9e6e3-8d27-4183-9ab4-210dfe19596e.pqt2025-02-20T19:37:40.000Z"3eae7e031f09f9c551541b7e3c998419"CRC64NVMEFULL_OBJECT84957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-11/_ibl_subjectTraining.table.0806bbe6-5018-4e20-83ec-a73f6e283ed2.pqt2023-12-20T09:07:46.000Z"898542f73f5ab064265d4b15b4502643"31457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-11/_ibl_subjectTrials.table.d4fe1be6-a058-4c83-a3c6-4d4cc9d1c092.pqt2023-12-20T09:07:47.000Z"61f722ba92e93ecaf3aacc3b000581b5"21866347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-12/#2024-04-11#/_ibl_subjectTraining.table.bb6eb5b3-7f1c-4fd2-b6e7-e26ba05cd6f1.pqt2024-09-16T15:08:08.000Z"a697482e0a56e2a809df14e622108ebf"32577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-12/#2024-04-11#/_ibl_subjectTrials.table.b8614fb4-bc0d-4c36-9aa9-6b37f618c13c.pqt2024-09-16T15:08:08.000Z"46a0b10ba4aacc07533e7541374b4751"51195537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-12/_ibl_subjectSessions.table.da2c14fe-71dc-42b5-aa29-d906ae86fbab.pqt2025-02-20T19:37:39.000Z"071d935f9d4917ce39e1ed09e4cc58fa"CRC64NVMEFULL_OBJECT75247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-12/_ibl_subjectTraining.table.9ce49c12-6824-4cc6-9ad1-f93a7574d0fe.pqt2024-02-14T17:07:23.000Z"847944b6066a5d64badcbcdcdc9d9d9f"31417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-12/_ibl_subjectTrials.table.a1972529-0b35-444f-97bc-3a41b8631a65.pqt2023-12-20T09:07:47.000Z"0e55b0c48ccca75a3f7dffccf3f7d93f"12567377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-13/#2024-04-11#/_ibl_subjectTrials.table.7e62a801-bf63-492b-baca-10a2b89b46b7.pqt2024-09-16T15:08:08.000Z"d77de2399508dafd9ca45ac38958db19"54558327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-13/_ibl_subjectSessions.table.565a5dbd-2bd1-4aca-8feb-a0bc4de5a9e4.pqt2025-02-20T19:37:39.000Z"07963ab53b87a07b4e8d456dbb3f194b"CRC64NVMEFULL_OBJECT76677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-13/_ibl_subjectTraining.table.cd115532-0132-41bc-a335-7e3394deda75.pqt2024-09-16T15:08:08.000Z"52d98d02737f1150fe4649a2f453754c"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-13/_ibl_subjectTrials.table.b4fd9d07-c1f7-4fd9-8ae5-682d395e4d71.pqt2023-12-20T09:07:47.000Z"827eb9cf109295eab76c3eeece7e4d9b"15819257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-14/#2024-04-11#/_ibl_subjectTrials.table.c818da54-dee0-4674-b409-d316fa7b3e24.pqt2024-09-16T15:08:08.000Z"d21030b40331a8e51382cddfb6ccccbc"51080977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-14/_ibl_subjectSessions.table.fb2eabe5-ccb8-42e6-94f2-28c343431557.pqt2025-02-20T19:37:39.000Z"a4ff26271cf172cb9352241e4c39f7e2"CRC64NVMEFULL_OBJECT82487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-14/_ibl_subjectTraining.table.04939592-70c7-437b-ba50-823710225463.pqt2024-09-16T15:08:08.000Z"facc7adc8b75aec7712dced8ec33f1d2"32037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-14/_ibl_subjectTrials.table.32835a2a-67a1-414f-b65c-717b1718f02d.pqt2023-12-20T09:07:47.000Z"3f2a0fa15a441b28f4b24f5aba25bba8"20289167d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-20/#2024-08-21#/_ibl_subjectTrials.table.2718294a-4c2a-4949-ac0f-162b5a603987.pqt2024-09-16T15:08:09.000Z"c9f1a230519d745b676eb0f1dc70f352"30332227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-20/_ibl_subjectSessions.table.ec278955-836c-4d6a-9215-059472dd5efb.pqt2025-02-20T19:37:40.000Z"1c84a08e071c841c15b64450dc388bd4"CRC64NVMEFULL_OBJECT70177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-20/_ibl_subjectTraining.table.dcdfb068-fd81-4671-9ca1-38739721ab2c.pqt2024-09-16T15:08:09.000Z"db8ec18b6a8fcf13936a93b4aee822fd"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-20/_ibl_subjectTrials.table.497b8c0c-0735-4446-a93a-eec1fada3667.pqt2023-12-20T09:07:47.000Z"417abe917289cce8e2aa8cc9912e2fff"17532237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-21/_ibl_subjectSessions.table.c99fdae2-ac43-4ba0-8803-3f49b581e1a3.pqt2025-02-20T19:37:40.000Z"d5e367f244fec241bf62b6e931c61ea4"CRC64NVMEFULL_OBJECT93177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-21/_ibl_subjectTraining.table.5c507ba0-11df-4273-9c2d-f9d5188c10d7.pqt2024-02-14T17:07:24.000Z"bdedad7f08246b98c3c7dd2373eab521"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-21/_ibl_subjectTrials.table.3f30b8a1-874a-44e3-9ab5-45d1b288aefe.pqt2023-12-20T09:07:47.000Z"52bc55c6b7f65fcc1025e9860535dc88"43405037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-23/_ibl_subjectSessions.table.e4f3f748-3273-4bce-91ff-b6c331de0633.pqt2025-02-20T19:37:40.000Z"6fbb3b7798b7a0b3f71fc9e6c4dcb5db"CRC64NVMEFULL_OBJECT108857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-23/_ibl_subjectTrials.table.238914c4-b2ab-4796-80c0-81ffb1d46db4.pqt2023-12-20T09:07:47.000Z"8c5e102eb1c68028f416714dbaf7b840"33891107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-24/_ibl_subjectSessions.table.1f1106bc-2d8c-4f51-8bd9-5ed003dc017f.pqt2025-02-20T19:37:40.000Z"58895003987fd438e583af9ab4127556"CRC64NVMEFULL_OBJECT78327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-24/_ibl_subjectTrials.table.df0951f4-e3e8-4742-92de-108000f85b61.pqt2023-12-20T09:07:47.000Z"57a83ba2dd4250c81e9fdb9da998ad70"16099807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-25/_ibl_subjectSessions.table.b0c6e317-8c96-498e-b9a9-641442ec4166.pqt2025-02-20T19:37:40.000Z"87e7b8cbe1848261d1e669eee6187353"CRC64NVMEFULL_OBJECT104597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-25/_ibl_subjectTrials.table.feb89e8f-8ff7-487b-aa11-68eb52db2290.pqt2023-12-20T09:07:47.000Z"53b32914fee438e9d308ab22461d6f78"53209787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-26/_ibl_subjectSessions.table.9d4e1eab-8220-42bc-b203-630a0e4555a4.pqt2025-02-20T19:37:40.000Z"0672229e07467241db57b49750ad7421"CRC64NVMEFULL_OBJECT91047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-26/_ibl_subjectTrials.table.610cdece-8a84-4cb0-9e4d-304b906121c0.pqt2023-12-20T09:07:47.000Z"6ad1098cf6e9ff60be21bef5661afb7a"46563267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-27/_ibl_subjectSessions.table.c0531ffa-68ae-45c4-aa9f-34cb39dd48da.pqt2025-02-20T19:37:40.000Z"fbdd7e0014161c9f321e3675e9091d5c"CRC64NVMEFULL_OBJECT78997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-27/_ibl_subjectTraining.table.4e7d4f6e-bc73-460b-957d-8977e6d71d9f.pqt2023-12-20T09:07:47.000Z"f329df6d4b85063b7583332ee088cf36"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-27/_ibl_subjectTrials.table.0bd14248-5efb-42b1-8240-e0dc35f9cd56.pqt2023-12-20T09:07:47.000Z"739a87636c0df769f0adc7649a35dbd5"32008657d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-30/_ibl_subjectSessions.table.42a0c8bc-edb9-47b1-bdba-f969342ac26f.pqt2025-02-20T19:37:40.000Z"f4d2a6cd4e8b3b62382bed6168f47aa3"CRC64NVMEFULL_OBJECT86057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-30/_ibl_subjectTraining.table.4b78e9a8-eb5f-4ed0-bb5c-ddc573a11068.pqt2023-12-20T09:07:47.000Z"7e6a22fbe83b5f58536e64c0d237a6f4"33117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-30/_ibl_subjectTrials.table.02b444f7-2e89-43d2-81d7-e3b5584b1928.pqt2023-12-20T09:07:47.000Z"db8d165427240b7a69ba15a9e148e6b3"36515417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-37/_ibl_subjectSessions.table.e1474198-0da4-458e-b103-9db5021d26dd.pqt2025-02-20T19:37:40.000Z"2d1de67666124bfbab6fda61e050f464"CRC64NVMEFULL_OBJECT76597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-37/_ibl_subjectTraining.table.8a52b8aa-80c7-4d68-9aa6-79b607af1999.pqt2023-12-20T09:07:47.000Z"973c95fa6b88b56433f0f5a022d62e4b"32567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-37/_ibl_subjectTrials.table.7a4a22e8-cd05-4409-ad14-7060a3552015.pqt2023-12-20T09:07:47.000Z"6eb050e5496e0426b7fb2c05b73d116a"23049947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-39/_ibl_subjectSessions.table.02463297-34ad-4e56-aa2c-65110e227843.pqt2025-02-20T19:37:40.000Z"f4b1efd7eef8a40ea97a17189a5a209b"CRC64NVMEFULL_OBJECT80147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-39/_ibl_subjectTraining.table.e60f0fc8-fdf8-4a8f-aeb5-e352901c78f3.pqt2023-12-20T09:07:47.000Z"7267430ef5133fc2ca570e6ddf936706"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-39/_ibl_subjectTrials.table.55587d91-ba90-408c-b1b5-5edfe6bc2b37.pqt2023-12-20T09:07:48.000Z"12fcf2f2dd63e64da2030d5468ffdcbc"26644157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-40/_ibl_subjectSessions.table.ed9daac4-0c06-4f75-92c1-68aed47a94b9.pqt2025-02-20T19:37:40.000Z"91aa554271a2a5ae4d1311ed3bda2c4c"CRC64NVMEFULL_OBJECT73937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-40/_ibl_subjectTraining.table.66278be8-05f1-40b2-a7ac-2edb7f08dd2b.pqt2023-12-20T09:07:47.000Z"abbb19ce679d59d05b1710c32991cf2a"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-40/_ibl_subjectTrials.table.3f886742-05d0-4128-8af3-aeb061af5ae4.pqt2023-12-20T09:07:48.000Z"cf14d5490a2bd479dea92782592def2b"20651617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-45/_ibl_subjectSessions.table.9ea92582-81fe-484f-ad5b-646219cb1b60.pqt2025-02-20T19:37:40.000Z"d853a925eed868fdfc8c832b302d8d3e"CRC64NVMEFULL_OBJECT83067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-45/_ibl_subjectTraining.table.67a3ee92-a47b-43f3-9567-63a4d90f41f1.pqt2023-12-20T09:07:48.000Z"342e7de437dec617830bbda380c4b6c4"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-45/_ibl_subjectTrials.table.54fe9cf4-4c67-4b6d-8c92-afa2dbba2b48.pqt2023-12-20T09:07:48.000Z"00b0e847dc2d80396712372a057429f6"35058327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-46/_ibl_subjectSessions.table.66b0985e-74a8-4032-8045-feddebcecdbb.pqt2025-02-20T19:37:40.000Z"8fc0382411660bd5ccb28a2bc2a143af"CRC64NVMEFULL_OBJECT73817d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-46/_ibl_subjectTraining.table.0cec0394-192c-4a1b-9a82-0ee42b74568a.pqt2023-12-20T09:07:48.000Z"a3424a694bc2cde710966b8fc195dece"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-46/_ibl_subjectTrials.table.3ca2cc40-8e2b-425f-9925-554c89dfef1f.pqt2023-12-20T09:07:48.000Z"76e3f4e7ec3009d37364c8467b829724"21529357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-47/_ibl_subjectSessions.table.0b45184a-b5bd-4d20-937a-e6dcd629ff5c.pqt2025-02-20T19:37:40.000Z"42929a3cb942e3051a876ef80d53dce2"CRC64NVMEFULL_OBJECT74607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-47/_ibl_subjectTraining.table.1f24253c-139d-4342-b9c1-45912155d66e.pqt2023-12-20T09:07:48.000Z"b3816a9c63f7d1b8bb438fc8d5b9ed03"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-47/_ibl_subjectTrials.table.7d9ae5b1-46c8-43cc-9f4a-9dc73cddfaed.pqt2023-12-20T09:07:48.000Z"7a0f5079ecc859c3c54acc3342b77c98"27011637d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-48/_ibl_subjectSessions.table.d254534a-1857-4714-b8e3-90c5073fef09.pqt2025-02-20T19:37:40.000Z"8682f9cc247d4fe785ac25509ecf8025"CRC64NVMEFULL_OBJECT74327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-48/_ibl_subjectTraining.table.3312e849-dcc6-445b-9def-37778993cc00.pqt2023-12-20T09:07:48.000Z"fd363156a2de7f5081abd6d2eb70e962"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-48/_ibl_subjectTrials.table.b870bc7b-b780-4d8f-b3f4-76ad15aa52dd.pqt2023-12-20T09:07:48.000Z"a02934f9a91ca058daa0270cd63b83be"28409957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-65/_ibl_subjectSessions.table.6f25cb15-45d4-4759-a4f8-c74fdb27f06e.pqt2025-02-20T19:37:40.000Z"6292faf97de99a7a6a986af07f472d3e"CRC64NVMEFULL_OBJECT71307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-65/_ibl_subjectTraining.table.f29ddaf2-bc77-41c9-bcaf-2f8f1e57d0b7.pqt2024-02-14T17:07:24.000Z"7d8c548b98c908f748e0e1d8c2ad72c8"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/angelakilab/NYU-65/_ibl_subjectTrials.table.b96ccbbb-7114-479b-ad44-cab8521e192d.pqt2024-02-14T17:07:24.000Z"8153ee558b965efdae998c2e8f343d22"22368227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL034/_ibl_subjectSessions.table.7bfc4c68-172c-41b4-9420-6d9d24631f19.pqt2025-02-20T19:37:40.000Z"9a022a7c88a04529c8c498545a437365"CRC64NVMEFULL_OBJECT64907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL034/_ibl_subjectTrials.table.cdc2b686-f0b8-426c-9fd5-ebcfac482f79.pqt2023-12-20T09:07:48.000Z"39a28ef36cb20f0e5140167e4d246ac7"3669307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL045/#2024-04-10#/_ibl_subjectTrials.table.92e149ba-e844-4340-9f20-9314c65a3459.pqt2024-09-16T15:08:09.000Z"88a07ea06f175be9dbad8a311852f91b-2"92747507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL045/#2024-08-21#/_ibl_subjectTraining.table.218f375c-31ce-471d-907b-9f3364bc9f79.pqt2024-09-16T15:08:09.000Z"bfa55902c386954a6ced1764b9b2442e"32667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL045/_ibl_subjectSessions.table.e7c7ebb9-66d7-4427-8503-718469b602b1.pqt2025-02-20T19:37:40.000Z"323dd387d3bd47b3c6d2592cf81d8170"CRC64NVMEFULL_OBJECT89767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL045/_ibl_subjectTraining.table.071cc005-bcd5-40c6-b7af-b716baabf7e5.pqt2023-12-20T09:07:48.000Z"4032dc63de1ae0653fb983c2d6f9cfc1"32647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL045/_ibl_subjectTrials.table.f7443f06-84c3-4d2d-9f24-0d3d876793c2.pqt2023-12-20T09:07:48.000Z"0f90c60d599d8d4b0eabe4707ad2f8ba"54717797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL046/#2024-08-21#/_ibl_subjectTrials.table.e3760e8f-79aa-4582-a48d-e94c25964fed.pqt2024-09-16T15:08:09.000Z"e1497bd358ebaa4e82f97267bd2ed23f-2"111358247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL046/_ibl_subjectSessions.table.6e9c18e3-6492-434f-b4f5-60dda1dd5737.pqt2025-02-20T19:37:41.000Z"327328a732cf12d789d8b1ce1c4b8e7f"CRC64NVMEFULL_OBJECT101847d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL046/_ibl_subjectTraining.table.b7bbfcd1-ca4e-429a-889e-39d60a4cac38.pqt2024-09-16T15:08:09.000Z"07d318f54e48d9b3f560de470accead0"32587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL046/_ibl_subjectTrials.table.27776b4c-fde1-431c-ab03-54ede1edcf62.pqt2023-12-20T09:07:48.000Z"6cd69ae7316ae2617226eefd774c4f2c"65910187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL047/#2024-08-21#/_ibl_subjectTraining.table.3df421aa-16f0-4167-9488-25914825974f.pqt2024-09-16T15:08:09.000Z"fe3a6a8f5512ed46b92141894e040a03"31417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL047/#2024-08-21#/_ibl_subjectTrials.table.463d016d-83b7-42b4-bbb4-be58ce80807a.pqt2024-09-16T15:08:09.000Z"92c3836dc377b723251f86c41ecd5dff"61463217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL047/_ibl_subjectSessions.table.373e68d1-e9d9-4eb4-b742-f5e0fc2b5eeb.pqt2025-02-20T19:37:41.000Z"a52941bd23281e34a5d3e5ef99fc00f8"CRC64NVMEFULL_OBJECT79877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL047/_ibl_subjectTraining.table.a526fc25-4917-4d1c-8f68-81610b679727.pqt2023-12-20T09:07:48.000Z"ce13fead23e8a9b4a1755c10d14071c2"32067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL047/_ibl_subjectTrials.table.5d57eb13-3974-4dad-b0ef-ed3c535f1324.pqt2023-12-20T09:07:48.000Z"9b4c72a7ad3add0536e35e7e735f7283"36132137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL049/#2024-08-21#/_ibl_subjectTraining.table.a9546bd9-0919-426b-8b31-d93f8580d3dc.pqt2024-09-16T15:08:09.000Z"610ee0aaf43746dc392707c8ef04fc22"32467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL049/#2024-08-21#/_ibl_subjectTrials.table.878c88de-5179-4cca-a7ba-19db64de12d9.pqt2024-09-16T15:08:09.000Z"d126da2a07d225252fc933f84cbfae4a"45739747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL049/_ibl_subjectSessions.table.1106bda6-1ddc-47b9-8ba5-755b55fde220.pqt2025-02-20T19:37:41.000Z"cf7cd340082f4e706acb6d4fb396930b"CRC64NVMEFULL_OBJECT76127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL049/_ibl_subjectTraining.table.6135727a-ed6c-421b-91b2-026cf7af8690.pqt2023-12-20T09:07:48.000Z"3adf1a2c52b99be82d5988ea9e442410"32487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL049/_ibl_subjectTrials.table.ef177f3f-f423-42b5-859e-199f80d7993c.pqt2023-12-20T09:08:37.000Z"89b6fd9348e2cb725b6ebc5a6338861e"28076067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL051/#2024-08-21#/_ibl_subjectTraining.table.e14375a5-d83e-473b-bd21-78ec8016eaf8.pqt2024-09-16T15:08:09.000Z"015a0254eca2518d8c0a814cd55142e8"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL051/#2024-08-21#/_ibl_subjectTrials.table.47d08221-6632-47d4-926b-427dd3892a0d.pqt2024-09-16T15:08:09.000Z"442bfeaf20acfcc51799a2b453da4ded"56754907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL051/_ibl_subjectSessions.table.acd8c74b-ee07-4d7e-9190-16899e908bd4.pqt2025-02-20T19:37:41.000Z"a20db03ebd55012abad8fbb8a56883ec"CRC64NVMEFULL_OBJECT80097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL051/_ibl_subjectTraining.table.36c137bd-f28f-4b10-8d0b-2e199ac59f46.pqt2023-12-20T09:07:48.000Z"9fcd4ebf2fc7a902aab4301e41d83f8a"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL051/_ibl_subjectTrials.table.b54a27a7-3d69-4ce4-837c-49ef4772e4f3.pqt2023-12-20T09:07:48.000Z"c1b9a321c9a56e0078ce259d6115a52f"33648877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL052/#2024-04-10#/_ibl_subjectTrials.table.ec981453-23e9-4715-b78d-af0e3a0f5ef9.pqt2024-09-16T15:08:09.000Z"ef27c8293bdaba5ec319fb229daa1b02"73830317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL052/#2024-08-02#/_ibl_subjectTraining.table.87633ca7-6ca8-4542-bcf8-904efef3f58b.pqt2024-09-16T15:08:09.000Z"7bc9387cf57a483ad73aa4b967dd8eb4"32107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL052/_ibl_subjectSessions.table.fd0a29e5-6ae1-47fa-9480-05510a96e2da.pqt2025-02-20T19:37:41.000Z"78ad76e2545ee1c47af2f8efc6a633a1"CRC64NVMEFULL_OBJECT85997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL052/_ibl_subjectTraining.table.62c0279f-b23a-4145-b548-a8d869f749f4.pqt2024-02-14T17:07:24.000Z"aae119cbdeff0c7f0d5c288575f0a08f"32677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL052/_ibl_subjectTrials.table.98345427-1c16-4db5-8f75-3979ed51b264.pqt2023-12-20T09:08:37.000Z"1e684201c90710ba6138291f06c7907d"43734127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL053/#2024-08-21#/_ibl_subjectTraining.table.751bc5f5-cc27-4d34-b576-ff3f713e5b35.pqt2024-09-16T15:08:09.000Z"21aa364a7ded7eaa6c6abd50045136ca"32557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL053/#2024-08-21#/_ibl_subjectTrials.table.cd3f97b7-fc78-4dc0-a93d-d97f7a266c9e.pqt2024-09-16T15:08:10.000Z"0aa3af43a6c81cb9ad25c231725b1fa5"56458007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL053/_ibl_subjectSessions.table.5739c5d6-5e19-41b4-b44c-3c38d05cf232.pqt2025-02-20T19:37:41.000Z"ce920c73b3f8b16790fdd3770136a6e6"CRC64NVMEFULL_OBJECT79447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL053/_ibl_subjectTraining.table.96c27266-0641-4031-939a-b923953f1012.pqt2023-12-20T09:07:48.000Z"847a8ccb97ec36e3e026e10b9d1644ac"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL053/_ibl_subjectTrials.table.f6ce225d-9366-42ec-b2f3-645ce8b531a1.pqt2023-12-20T09:08:37.000Z"69c1e42bd7414fa961a1e5d010ddd43c"33340127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL054/#2024-08-21#/_ibl_subjectTraining.table.56115a05-8912-4ee3-9391-bca3b57f6899.pqt2024-09-16T15:08:10.000Z"e2dd71d4556c30f9df4f3e43ad7555a7"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL054/#2024-08-21#/_ibl_subjectTrials.table.fec9aeb6-402e-4516-87d5-8051ebfcf5a6.pqt2024-09-16T15:08:10.000Z"05a4d40d1a1d548651c0361b01693143"59117327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL054/_ibl_subjectSessions.table.4e116cee-08b3-446d-ba02-f14e518100f6.pqt2025-02-20T19:37:41.000Z"96a108d499ed63de15b71d87c52a251b"CRC64NVMEFULL_OBJECT81357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL054/_ibl_subjectTraining.table.4a70e3de-c299-4710-8faa-cfab8af28536.pqt2023-12-20T09:08:38.000Z"a4b9f24d4babc662b8f4b956de54887f"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL054/_ibl_subjectTrials.table.41e890ee-19bb-4d69-a8d5-cc4c3cbe0a7d.pqt2023-12-20T09:08:38.000Z"d4b398c44cea66e21d203785519cbeb6"35121297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL055/#2024-08-21#/_ibl_subjectTraining.table.2795c8d4-550a-4347-8762-072005401f49.pqt2024-09-16T15:08:10.000Z"b6fb4646c4b642dde93c0187cb3bcaae"31447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL055/#2024-08-21#/_ibl_subjectTrials.table.c70ea0f0-f4df-47e7-a6e6-78f6e002ed8a.pqt2024-09-16T15:08:10.000Z"87218a9e8e6502c26bfa82fc5a3940d0"81494677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL055/_ibl_subjectSessions.table.a190c2cb-7154-4b9f-95de-5bf470e8f068.pqt2025-02-20T19:37:41.000Z"bbf4ad05ae5dda0e22992cccd121f4bd"CRC64NVMEFULL_OBJECT82787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL055/_ibl_subjectTraining.table.44567413-2196-4097-aa23-af36e88df065.pqt2023-12-20T09:08:38.000Z"1671a53d6df286f68ff9c989707742b4"31447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL055/_ibl_subjectTrials.table.3033ca53-7492-46e3-ae69-078bc882dbb9.pqt2023-12-20T09:08:38.000Z"c70e23aaaaa0424a69c0cb94240ad058"48538977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL056/_ibl_subjectSessions.table.57a94e71-f0ed-4052-99f1-a63f225ccfe7.pqt2025-02-20T19:37:41.000Z"e4e307f3a13683a3889e64765db0ae79"CRC64NVMEFULL_OBJECT57947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL056/_ibl_subjectTrials.table.0fb5b0e0-2879-4ceb-9655-602d67cd2005.pqt2023-12-20T09:08:38.000Z"db934c2f50002a85e370f49f0abf19fb"3429497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL057/_ibl_subjectSessions.table.8d028ee7-2d52-466f-87b6-59b14c11d186.pqt2025-02-20T19:37:41.000Z"8a65fe9c51d0ff95ce50616a17bdbf0a"CRC64NVMEFULL_OBJECT59007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL057/_ibl_subjectTrials.table.8e7e3f6d-fbcd-44d0-8a11-d82de04d0fce.pqt2023-12-20T09:08:38.000Z"695665e5d220402c7ac6c34e63528a1d"4507357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL058/#2024-04-10#/_ibl_subjectTrials.table.cc71fc91-33b8-4332-90b8-a95b648b3a65.pqt2024-09-16T15:08:10.000Z"aec3cb7ef97fbfbc95014eeebfb4f356-2"86511077d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL058/#2024-08-21#/_ibl_subjectTraining.table.385433b2-f2f3-44c0-bde5-bcc17052368d.pqt2024-09-16T15:08:10.000Z"8c198c5217cf8720d81fbb1b410b72f8"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL058/_ibl_subjectSessions.table.ff6cab75-8b31-4665-bffc-6a3a18a5ccaf.pqt2025-02-20T19:37:41.000Z"f13243f2de8f870e7a01deb7ef91882f"CRC64NVMEFULL_OBJECT90007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL058/_ibl_subjectTraining.table.74314013-6a64-490d-a539-b192e09ad7fd.pqt2023-12-20T09:08:38.000Z"d3c07e1290d510699896376594beb2bd"32457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL058/_ibl_subjectTrials.table.bfcbba98-b7e3-45f0-a63d-020bd7e94fc6.pqt2023-12-20T09:08:38.000Z"a122c944b6e164dadf7c23ea775be573"44958687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL059/#2024-08-21#/_ibl_subjectTraining.table.958f7ad6-b62a-4dfe-a14a-f2d979ad4e19.pqt2024-09-16T15:08:10.000Z"e8ea56a5be958b17451d71c144d81257"31377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL059/#2024-08-21#/_ibl_subjectTrials.table.d581839a-1921-4dee-acde-5e812aa0dae5.pqt2024-09-16T15:08:10.000Z"5bd755e4772b0256aaac9bf6f9504e0f"40561237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL059/_ibl_subjectSessions.table.069693ff-0dd4-4447-ad63-1414f47eb9c8.pqt2025-02-20T19:37:41.000Z"b61f5f1cda16ec47d37f0e8d6501993d"CRC64NVMEFULL_OBJECT71717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL059/_ibl_subjectTraining.table.51884631-7c9a-4b54-bd72-06dd3984bc7d.pqt2023-12-20T09:08:38.000Z"97cc2193830115a5a2808901fad73b97"31377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL059/_ibl_subjectTrials.table.82dc2379-a7be-4acb-9dd9-65b80c475f67.pqt2023-12-20T09:08:38.000Z"bf78593082b94cceac2f442f76321b82"23956667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL060/#2024-08-21#/_ibl_subjectTraining.table.707ed14c-06c3-495e-90f0-f7653973f10d.pqt2024-09-16T15:08:10.000Z"4171ab7658d5545c3399d91ec043aeae"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL060/#2024-08-21#/_ibl_subjectTrials.table.dc4d4609-2475-48d0-97b7-b9c700110a48.pqt2024-09-16T15:08:10.000Z"55e374f011a35391ad8b0d5077cfbbc9"56535007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL060/_ibl_subjectSessions.table.b872a666-7956-4885-98a9-133d6065d94b.pqt2025-02-20T19:37:41.000Z"77d7f0f1b3d57c0780258825a421448d"CRC64NVMEFULL_OBJECT75117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL060/_ibl_subjectTraining.table.8ba2b98f-0a40-4423-b95d-96f6f1fb909a.pqt2023-12-20T09:08:38.000Z"9ef00922646b391c12007138b5be8026"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL060/_ibl_subjectTrials.table.23db8622-0932-4d6e-ac08-fddb73b5b1f6.pqt2023-12-20T09:08:38.000Z"c042b225eff8b6e38c20ddb0d046a208"32916147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_001/#2024-08-21#/_ibl_subjectTraining.table.dd979432-5355-4b05-b81d-ab85922bfc4d.pqt2024-09-16T15:08:10.000Z"17270cc726b174b0b1dee7377eac884e"31947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_001/#2024-08-21#/_ibl_subjectTrials.table.0df9a5fc-bd7a-4fc7-91e5-092a119d4611.pqt2024-09-16T15:08:10.000Z"ae117ab5d811072b758438393dbd50e6"81158307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_001/_ibl_subjectSessions.table.9291b9e8-d1eb-4952-a780-f71e00250d1b.pqt2025-02-20T19:37:41.000Z"c38a8b413d7d2c8ceed011f09941800e"CRC64NVMEFULL_OBJECT94247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_001/_ibl_subjectTrials.table.0edac9e6-f359-404b-80e8-4c9dffa6d548.pqt2023-12-20T09:08:38.000Z"5e125146be97baf318a07c2ba96977d6"54036367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_002/#2024-08-21#/_ibl_subjectTraining.table.b29d8a71-ca0c-404b-8a49-0d9111a81a11.pqt2024-09-16T15:08:10.000Z"28016f3185eb54e5056f40e74281b61d"32087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_002/#2024-08-21#/_ibl_subjectTrials.table.b066eb76-0e4e-484e-9320-160b5cd90e6d.pqt2024-09-16T15:08:10.000Z"63841e0aab74a9e2a4dad14c325d6523-2"91640527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_002/_ibl_subjectSessions.table.37b5f24f-84df-4e3c-8286-6699891f8c3c.pqt2025-02-20T19:37:42.000Z"08ff80dfe9e19e8fae10e136bc17d6e0"CRC64NVMEFULL_OBJECT93647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_002/_ibl_subjectTrials.table.2b4d3f66-4caa-4fbd-8bb9-7576e0375917.pqt2023-12-20T09:08:38.000Z"b3a3aa910f4902680e6e076066fec730"62071467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_003/#2024-08-21#/_ibl_subjectTrials.table.6c045eb7-1750-4506-b341-66d3ea898417.pqt2024-09-16T15:08:11.000Z"581ce20c148212016ad383e8ffdd1031"79041477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_003/_ibl_subjectSessions.table.4c261480-bc9b-4235-a183-e0cc2d8ee105.pqt2025-02-20T19:37:42.000Z"3906a6e12b4ad7548cc57621f7908527"CRC64NVMEFULL_OBJECT97957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_003/_ibl_subjectTraining.table.1fbaac69-c83b-4564-aeef-7fcbaae8a1f5.pqt2024-09-16T15:08:10.000Z"994633cd347f301d0bc29b115bbabe69"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_003/_ibl_subjectTrials.table.5c47ddf7-b4d3-4351-8b00-9c6094623048.pqt2023-12-20T09:08:39.000Z"291a18a0ae232947d624537683fe3766"52813307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_004/_ibl_subjectSessions.table.211e489e-a145-4b14-afaa-c787ac4bcd0d.pqt2025-02-20T19:37:42.000Z"f215133af7ef02b5ab48cd143ef7a7fa"CRC64NVMEFULL_OBJECT80117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_004/_ibl_subjectTraining.table.5d274465-eccf-4821-9712-f782675c4c90.pqt2024-09-16T15:08:11.000Z"1f5adc9fb19917feacf9cbbe397c1e5e"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_004/_ibl_subjectTrials.table.096053c0-28fe-4499-93a7-59d13ae2a51b.pqt2024-09-16T15:08:11.000Z"26fd57185da54d34b86b3414ce983baa"40444237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_005/#2024-07-22#/_ibl_subjectTrials.table.7389b893-9bc3-48b9-bab9-9db5a40914c4.pqt2024-09-16T15:08:11.000Z"65a4bd3d119e3d4b3177f21fd52be079-2"86714397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_005/_ibl_subjectSessions.table.ca477438-aeb0-413b-aaa9-39fabad681e8.pqt2025-02-20T19:37:42.000Z"d955ff9265f174e4487f7cfa470d4198"CRC64NVMEFULL_OBJECT88867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_005/_ibl_subjectTraining.table.c7a37afe-32d4-474a-9c9c-23fc48fbd8c3.pqt2024-09-16T15:08:11.000Z"bb0affeda1eb174c61c89a40c048c350"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_005/_ibl_subjectTrials.table.04b07b35-ef00-4d7f-8e47-f47830205d63.pqt2023-12-20T09:08:39.000Z"ff2961fe3b0433e9d5e86c460395b358"57838847d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_006/_ibl_subjectSessions.table.2647a287-f6e2-4b5f-8b25-2d5a91843c68.pqt2025-02-20T19:37:42.000Z"9eb99cbfdb6ee660251bc0163e7b3204"CRC64NVMEFULL_OBJECT81347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_006/_ibl_subjectTraining.table.0df05019-62e9-460a-bd9e-9ce3e16e5f6e.pqt2024-09-16T15:08:11.000Z"1f32d1b8da96db0c60df578234fb49ef"30757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_006/_ibl_subjectTrials.table.568fc68c-7a5e-4842-b6ee-d0227908ea57.pqt2024-09-16T15:08:11.000Z"1b68eef0a6ceec3786f0239c137a0c24"37310647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_007/#2024-08-21#/_ibl_subjectTraining.table.b878554f-a258-418e-85d1-951e8b2fafa5.pqt2024-09-16T15:08:11.000Z"1cf3da39318a2a9f85f33e9c0851edeb"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_007/#2024-08-21#/_ibl_subjectTrials.table.da09db4f-a927-4560-b74f-cd6f2a582502.pqt2024-09-16T15:08:11.000Z"64eec25316e9d5deeb5d94325482b642"39140747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_007/_ibl_subjectSessions.table.1c6f4c7d-e484-42d5-9eca-7b9f2be19d83.pqt2025-02-20T19:37:42.000Z"cbe82a24aa9e3b978c8a4eff9bdc1354"CRC64NVMEFULL_OBJECT91197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_007/_ibl_subjectTraining.table.d4f8faae-86e8-4528-aca1-303b8dc5a039.pqt2023-12-20T09:08:39.000Z"6a558a48b6a76513565160f544fd40eb"32587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_007/_ibl_subjectTrials.table.fd572a5c-7617-41e8-b66f-254b823c11ac.pqt2023-12-20T09:08:39.000Z"8b3301d33da507580d87a9db7c607172"28173107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_008/#2024-08-21#/_ibl_subjectTrials.table.b8e0caf0-2265-4fed-80fe-2a2ecd611a2c.pqt2024-09-16T15:08:11.000Z"2b452d4710baf60db02e87754225f51c"49575317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_008/_ibl_subjectSessions.table.765c8f01-b9e7-4a9d-8ffa-78d103b82267.pqt2025-02-20T19:37:42.000Z"de814a19fa626f9e890b319abf062802"CRC64NVMEFULL_OBJECT88237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_008/_ibl_subjectTraining.table.01d10454-dbf4-4359-bb9e-d56f5abcda2d.pqt2024-09-16T15:08:11.000Z"965efb885361be260dd0b6b23be18149"31367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_008/_ibl_subjectTrials.table.a6616d34-001f-47e9-8497-b2d3bdadfdc3.pqt2023-12-20T09:08:39.000Z"4e3f01fade6835c516bd2866c4d6e38c"34772947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_010/#2024-07-22#/_ibl_subjectTrials.table.560302cd-2998-4c2b-ada2-603000c5b73c.pqt2024-09-16T15:08:11.000Z"65ec49f9ea1eb626fd226329ece88dd4"46720027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_010/_ibl_subjectSessions.table.7af1f621-8973-4f76-8d9d-cf7496efba45.pqt2025-02-20T19:37:42.000Z"691eb90b977ffbb322b193f3dfe10eec"CRC64NVMEFULL_OBJECT89707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_010/_ibl_subjectTraining.table.cc742264-ef7c-4def-92c8-43625fb03686.pqt2024-09-16T15:08:11.000Z"f0ffd14b1eab4961e0f3c2935fe1bca6"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_010/_ibl_subjectTrials.table.6135af44-34f7-463e-8f45-c457b92bd614.pqt2023-12-20T09:08:39.000Z"04ff3cf412ead2ace92a9453ee0d5a6e"33112467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_011/_ibl_subjectSessions.table.7585edf7-3ed2-418c-8d0b-493d6be4d9ee.pqt2025-02-20T19:37:42.000Z"423a40c0d944b15010fa43737d2af8d3"CRC64NVMEFULL_OBJECT76897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_011/_ibl_subjectTrials.table.64d17e6c-76b9-4bda-8ccf-ccd8d83c2a02.pqt2023-12-20T09:08:39.000Z"26b72a5aed3ea864eb459fb2f4b1ce28"26898747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_012/#2024-08-21#/_ibl_subjectTrials.table.b95ecf92-7a6b-425b-848b-83f27896c973.pqt2024-09-16T15:08:11.000Z"eb5eacab89a915595303d0b1993c4e6b"55702717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_012/_ibl_subjectSessions.table.da665464-61b6-4499-b470-3bfe76f23af9.pqt2025-02-20T19:37:42.000Z"1c325942fc5ea4c57df667df8110ba70"CRC64NVMEFULL_OBJECT89027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_012/_ibl_subjectTraining.table.b3a6786b-1065-49b2-bae9-e30760ee4302.pqt2024-09-16T15:08:11.000Z"88f6550f0bc955cd164e571b5ef46166"31337d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_012/_ibl_subjectTrials.table.503fc12f-58bc-4e71-a14c-6e2f073846a4.pqt2023-12-20T09:08:39.000Z"74f34fe376a7fa4e71ec6f0fcb24ec99"34585947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_013/_ibl_subjectSessions.table.73d7d73b-5482-421c-a910-f74a0f49bfed.pqt2025-02-20T19:37:42.000Z"0d76b792e57060b55ce844ff2269f5e4"CRC64NVMEFULL_OBJECT74757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_013/_ibl_subjectTrials.table.bcda5943-f5e8-487c-9244-0ea10fbf53bc.pqt2023-12-20T09:08:39.000Z"8dbb98d193807cd156a986a44409bc43"22095767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_014/#2024-08-21#/_ibl_subjectTraining.table.6a7770fc-02b2-4609-90d5-a8624239202c.pqt2024-09-16T15:08:12.000Z"ee1380f1a2d600162294409a13f08d6b"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_014/#2024-08-21#/_ibl_subjectTrials.table.6c1e1f8c-b54e-4b34-a159-54a6bd132c22.pqt2024-09-16T15:08:12.000Z"54d7b8de82ebacfe8b5c6ba7eece9643"79433097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_014/_ibl_subjectSessions.table.af9e628a-01e7-4e49-8542-cb5e87416601.pqt2025-02-20T19:37:42.000Z"38f0f853059e50bfc14059039233278c"CRC64NVMEFULL_OBJECT90057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_014/_ibl_subjectTraining.table.5425413d-824a-4e5d-853d-cab4df4200f4.pqt2023-12-20T09:08:39.000Z"e399690f2d763fdc4639d1820b0086a4"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_014/_ibl_subjectTrials.table.61f6982a-40fb-44a6-8f2f-170235951e26.pqt2023-12-20T09:08:39.000Z"bcda517f1c765e920fbba1cf9b811a6c"49647387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_015/#2024-08-21#/_ibl_subjectTraining.table.f9549d94-cb1d-4b71-a356-d45a058ca8d8.pqt2024-09-16T15:08:12.000Z"620e806c80789f10da54e62161840a31"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_015/#2024-08-21#/_ibl_subjectTrials.table.ab1c0ead-525f-413b-a06f-267dead48fc5.pqt2024-09-16T15:08:12.000Z"ff0694473fd07b6190d0af2e3a383934"79410837d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_015/_ibl_subjectSessions.table.e9fdd3bd-472f-44cb-93e6-ab20e9ca594b.pqt2025-02-20T19:37:42.000Z"e008c111748b2d58a57c073991fc7677"CRC64NVMEFULL_OBJECT87217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_015/_ibl_subjectTraining.table.4d713c58-4e12-476c-b718-44b1c9277918.pqt2023-12-20T09:08:39.000Z"cc26667646779123824f6e377ec88421"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_015/_ibl_subjectTrials.table.c049f1e8-1fef-436a-b855-752110e1c0c8.pqt2023-12-20T09:08:39.000Z"2febf41f3e3ae8329847c8042892942c"49987097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_020/_ibl_subjectSessions.table.aaf3d33f-02ef-4975-ae4a-661d547f817e.pqt2025-02-20T19:37:42.000Z"cfe4ff7b3d178e02c2b3170b6a3595a3"CRC64NVMEFULL_OBJECT74567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_020/_ibl_subjectTraining.table.aec32dc1-eeb1-473c-86cc-bb190567ac83.pqt2023-12-20T09:08:40.000Z"4106f44c9a7a9a1340285b473c6ed980"30787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab/CSHL_020/_ibl_subjectTrials.table.33dc661d-b1d7-4f5c-9709-cb6191145d88.pqt2023-12-20T09:08:40.000Z"345cc4e16dfe5e6db42b237f97f9b8bd"17589017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_05/_ibl_subjectSessions.table.772d4ee1-a24b-40e2-b299-71c6fb630b2e.pqt2025-02-20T19:37:42.000Z"153d4307d5fe0883ffd1d685f0670070"CRC64NVMEFULL_OBJECT80037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_05/_ibl_subjectTraining.table.73dbde93-5355-47c1-9d46-91d45180bfa4.pqt2024-02-14T17:07:25.000Z"2b4adab00d8935e822663076979512ac"32497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_05/_ibl_subjectTrials.table.eb3a0739-b895-4cde-91f5-f387d38c4d8e.pqt2024-02-14T17:07:26.000Z"1c412fb9b847a2bde6370ebd55fc9d72"33206507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_06/_ibl_subjectSessions.table.67c00f63-51bb-4cad-94eb-25b4a9b09273.pqt2025-02-20T19:37:43.000Z"e35238941c83c72c544e15eea6afec36"CRC64NVMEFULL_OBJECT82257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_06/_ibl_subjectTraining.table.50dab295-b0e0-4d86-8c4c-ae1fae17ecab.pqt2024-02-14T17:07:25.000Z"a6fbbbdd48bc2cba20e5184340d29b1a"32537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_06/_ibl_subjectTrials.table.a4005d18-47d8-4953-8529-d2aa55e15d3d.pqt2024-02-14T17:07:31.000Z"f28e7b93e6af825442f5d12105670b4c"40904747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_07/_ibl_subjectSessions.table.c65c5f8e-9fe2-4b75-8ab2-532cedc5d8fe.pqt2025-02-20T19:37:43.000Z"ee7ad6b2d7492cfaba21c65049628e16"CRC64NVMEFULL_OBJECT81607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_07/_ibl_subjectTraining.table.39c66a87-c3d7-4a9d-9fed-f5e772e8789c.pqt2024-02-14T17:07:25.000Z"74d067ae3371863e14cc06bdcb932290"32417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_07/_ibl_subjectTrials.table.a7b33449-ef7a-4c95-98a5-604ee4c2151f.pqt2024-02-14T17:07:26.000Z"9022e793f57d37ea129d28b45ff36501"40595907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_08/_ibl_subjectSessions.table.3526699d-306e-41ef-bd05-ddcec65e0cdb.pqt2025-02-20T19:37:43.000Z"eae3d15d77bb1dddb9ae9fd773e1c109"CRC64NVMEFULL_OBJECT82997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_08/_ibl_subjectTraining.table.b29ebd4d-af77-4f9e-b282-fdbef23fbc6e.pqt2024-02-14T17:07:26.000Z"5efb06d8edf7d4cc10d82f850bb4d8b5"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_08/_ibl_subjectTrials.table.16fc04b8-01a4-4807-82fe-8512484869c4.pqt2024-02-14T17:07:26.000Z"507406738081cb2ea213273368bde4ab"40084427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_09/_ibl_subjectSessions.table.0d105f76-9d84-473c-9ff9-a3f7f8a93f15.pqt2025-02-20T19:37:43.000Z"16b78d70cdf01dd58247c91081f10cb5"CRC64NVMEFULL_OBJECT81637d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_09/_ibl_subjectTraining.table.586825df-4de0-4076-834b-d8f59092af1f.pqt2024-02-14T17:07:31.000Z"5716ea5af61f9dbb168a7bd6a648d193"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/MFD_09/_ibl_subjectTrials.table.5178ea07-ed2b-4500-84c8-a855229de8e1.pqt2024-02-14T17:07:25.000Z"01c28d6af6001b7ae74289823d5a5d2b"35049007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA005/_ibl_subjectSessions.table.3c35781b-4e83-4322-b456-7f94e6a4665e.pqt2025-02-20T19:37:43.000Z"b4f6482557d96abce9a53171e227d214"CRC64NVMEFULL_OBJECT86687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA005/_ibl_subjectTraining.table.4459bef6-076d-4630-b3da-681a6a4b1c0a.pqt2023-12-20T09:08:40.000Z"a984095b4dce26f9d439f8ddeb64c3d4"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA005/_ibl_subjectTrials.table.4110ed7d-8135-45a3-a72e-27bf247386cf.pqt2023-12-20T09:08:40.000Z"5a0ff0f2b20781d4afa0859e1954b1b0"50571727d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA006/_ibl_subjectSessions.table.e655625c-f16f-443a-8627-0e824581d83d.pqt2025-02-20T19:37:43.000Z"df609e6f0e44185dd1aff85125b19dc8"CRC64NVMEFULL_OBJECT119857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA006/_ibl_subjectTraining.table.2cd3df89-4984-4b88-a575-7b5765c93301.pqt2023-12-20T09:08:40.000Z"0e5c6f5b7c227cbe9bff2b619338f2f0"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA006/_ibl_subjectTrials.table.acc0eadc-38bf-451c-9074-1f1253382df1.pqt2023-12-20T09:08:40.000Z"0904591094ec207565ee4843da1652bf-2"98823677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA011/_ibl_subjectSessions.table.83cec217-90a5-46ed-ab9e-afa84550e119.pqt2025-02-20T19:37:43.000Z"7c235b4720469b4e70c7d0041bbe5172"CRC64NVMEFULL_OBJECT82467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA011/_ibl_subjectTraining.table.a138d5b8-ec7c-4edb-b01a-767e0366794c.pqt2023-12-20T09:08:40.000Z"95e036b858c3b5e5da22af48db747510"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA011/_ibl_subjectTrials.table.031965d6-0723-4aff-86f0-eb494d5bd5bc.pqt2023-12-20T09:08:40.000Z"37c5ef507eba293d87ffb78f08f80593"41434997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA012/_ibl_subjectSessions.table.29522141-7167-4f97-8ebd-7169dd056f3b.pqt2025-02-20T19:37:43.000Z"2b8afa027f8aacf8082ec27ffe63da3e"CRC64NVMEFULL_OBJECT77367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA012/_ibl_subjectTraining.table.df7d664b-235b-4522-8dd1-12e86a9f2b81.pqt2023-12-20T09:08:40.000Z"739b0f856dc9463d9d53b33bbbc6b811"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA012/_ibl_subjectTrials.table.2b14cf13-4a1a-42e8-b973-9bee59a1c67b.pqt2023-12-20T09:08:40.000Z"2d77f2bd89f0ffe84a9cd1c358b12b23"35743327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA014/_ibl_subjectSessions.table.e712fef8-76fb-4cb8-a501-794a53ee0219.pqt2025-02-20T19:37:43.000Z"1b47e0bd1e9bf48b1da663b78fc08ac9"CRC64NVMEFULL_OBJECT77987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA014/_ibl_subjectTraining.table.40566552-457d-41e1-a017-9a2455a102ca.pqt2023-12-20T09:08:40.000Z"40e6b8e79fd7372ddfd23e02a752d688"32367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA014/_ibl_subjectTrials.table.5998065f-66c4-4f19-b2e2-38d5f659cbde.pqt2023-12-20T09:08:40.000Z"7204a1479d0913580440a8d25d11ac6f"34394227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA015/_ibl_subjectSessions.table.09ffe3b7-147d-4995-9998-5740198d54d6.pqt2025-02-20T19:37:43.000Z"0f62b0dd8b805ede0843e3a35399a09e"CRC64NVMEFULL_OBJECT135477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA015/_ibl_subjectTraining.table.871ac4a0-1b98-43ec-abeb-d1f3674d1de6.pqt2024-02-14T17:07:26.000Z"8595e3491407d8ac740d2a5bd9f78536"32587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA015/_ibl_subjectTrials.table.3e9d6a83-67bb-4306-a8ec-fd79925471b6.pqt2024-02-14T17:07:26.000Z"30dbda3a4152339d5b60441ce69769a5-2"130322177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA017/_ibl_subjectSessions.table.fd801894-5902-4711-9f98-485dc8f28793.pqt2025-02-20T19:37:43.000Z"e4d55e05570db628332389d7e12aeaa7"CRC64NVMEFULL_OBJECT103517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA017/_ibl_subjectTraining.table.67f69bce-c1f6-492d-ab4f-e34b6a58de14.pqt2023-12-20T09:08:40.000Z"cff3af9e96b1d6193b0ade4c0c75e78b"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA017/_ibl_subjectTrials.table.1d44b7f3-5e68-4d42-948f-fe4939c0490b.pqt2023-12-20T09:08:40.000Z"c236eb500c791558113bfc928b16c828"54361127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA030/_ibl_subjectSessions.table.6f1bd38a-ed2b-4cd9-b18a-a834fa44178e.pqt2025-02-20T19:37:43.000Z"4fbd266dd39fa6220b2d44f9f5c11d0b"CRC64NVMEFULL_OBJECT98947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA030/_ibl_subjectTraining.table.ff3c9da4-8080-4830-a0c3-044c9e060f51.pqt2024-02-14T17:07:26.000Z"66a269bf6bb3851cc634abcc84e618ff"32037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA030/_ibl_subjectTrials.table.529638d9-2d26-450f-ae82-6b3c722b682c.pqt2024-02-14T17:07:26.000Z"8822b9871ee41ef9b97a2cb75a19ea70"69934447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA033/_ibl_subjectSessions.table.bb50f298-0d14-4bf8-adb8-d48667d6ac52.pqt2025-02-20T19:37:43.000Z"70361cffd1ae26cb400ae2aa622dd997"CRC64NVMEFULL_OBJECT84277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA033/_ibl_subjectTraining.table.9b7a5dd9-24f7-4bc8-b271-d7198fe44299.pqt2023-12-20T09:08:40.000Z"a6e806da2b821ad389dcbd8568aa7fd3"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA033/_ibl_subjectTrials.table.63c4f605-43d9-4248-a9d5-03edaf843c58.pqt2023-12-20T09:08:40.000Z"3ab6d09ab729b0c428224004e65e183c"44220447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA034/_ibl_subjectSessions.table.653db645-4c62-4c77-8f33-3727c6d90f50.pqt2025-02-20T19:37:43.000Z"f7412d806250b79c3880394a4e94f2c0"CRC64NVMEFULL_OBJECT70207d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA034/_ibl_subjectTraining.table.96b8f920-f802-4c4f-850c-e3891670453e.pqt2023-12-20T09:08:40.000Z"78b598194fec13335ab0e74cf767a1e9"32567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA034/_ibl_subjectTrials.table.31abd382-f448-400e-8738-323c62e48e11.pqt2023-12-20T09:08:40.000Z"ea640e7fca8385d18306f0f7f480ed27"21941767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA035/_ibl_subjectSessions.table.6b051efd-f39f-4d3b-a165-66665ecdaea2.pqt2025-02-20T19:37:43.000Z"928d339cf12451401966f204c4db69c4"CRC64NVMEFULL_OBJECT77107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA035/_ibl_subjectTraining.table.9bd00f09-9425-44f7-95bc-a167dd1727c0.pqt2023-12-20T09:08:40.000Z"cfa32b8609404b0158a9219fcb524d5b"32057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA035/_ibl_subjectTrials.table.ac02ad63-8b0f-4f5d-aca6-0844392d07bb.pqt2023-12-20T09:08:41.000Z"fd02575bd11b312eb09bfa57672cf64a"32186097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA036/_ibl_subjectSessions.table.3d8a284a-7653-4801-a460-c53416b5f1e0.pqt2025-02-20T19:37:43.000Z"b7b5867cbf1eac4d34851ce814cefd0e"CRC64NVMEFULL_OBJECT82597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA036/_ibl_subjectTraining.table.173c87a5-7186-493b-9d7d-6d02e7b245f1.pqt2023-12-20T09:08:41.000Z"b4d0ae4281bc4e1053d8fd0a1a98f09e"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA036/_ibl_subjectTrials.table.6287ca64-fe33-421a-a850-4d24fb0b8f66.pqt2023-12-20T09:08:41.000Z"b6d16f29925a91a46a3251f373c55681"42261397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA037/_ibl_subjectSessions.table.86326536-8eac-44c2-bc67-020d7a77b33f.pqt2025-02-20T19:37:43.000Z"1abb1f3bc1d8c2a8619ba2d5422e45b3"CRC64NVMEFULL_OBJECT72037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA037/_ibl_subjectTraining.table.a0984451-42b2-49fa-a736-8b4d060cea11.pqt2023-12-20T09:08:41.000Z"33c7e6fdaecb75d30612ebb983c56fb2"32557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA037/_ibl_subjectTrials.table.68cd67fd-7a24-4e2e-9db1-ee9a6f1ed75e.pqt2023-12-20T09:08:41.000Z"506513745a51ecb3b8e691001ae4751c"24615037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA044/_ibl_subjectSessions.table.e4e97ae0-c52c-495e-a538-6176e5612b30.pqt2025-02-20T19:37:43.000Z"cd3636d462734e97b7bdfdd47e0d2a10"CRC64NVMEFULL_OBJECT86937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA044/_ibl_subjectTraining.table.4d3bfd47-febd-42ab-a5f7-a4072451c50b.pqt2024-02-14T17:07:26.000Z"ae92704620402aa46fd5030e046cf4b6"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA044/_ibl_subjectTrials.table.cc45d06a-16db-4c49-b18d-1c2df250d078.pqt2024-02-14T17:07:27.000Z"e0fc5e96fe44b026eecdd7f7bead389e"43299147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA048/_ibl_subjectSessions.table.acdee427-ab6d-423a-a239-444a6cde5b3c.pqt2025-02-20T19:37:43.000Z"d0b441741b423ad03a36cf2b761d1a32"CRC64NVMEFULL_OBJECT91267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA048/_ibl_subjectTraining.table.c6af04f9-741f-4484-b05f-e1693bbafa2f.pqt2024-02-14T17:07:27.000Z"7603e45a382f636e43d37e4e558e3465"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA048/_ibl_subjectTrials.table.f091658e-facd-4cee-8e2e-1f2a534a8c60.pqt2024-02-14T17:07:27.000Z"94d9a356827ad01666332bd539063799"67755787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA049/_ibl_subjectSessions.table.7a271816-6718-4daa-8532-47433b401b2c.pqt2025-02-20T19:37:43.000Z"2a925a2aa701ed0a4ea53f187627c13c"CRC64NVMEFULL_OBJECT88667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA049/_ibl_subjectTraining.table.22a64462-6286-44ca-8b2c-40303e758467.pqt2024-02-14T17:07:27.000Z"b578e27c5a4af02ebd6ed3f453b155c9"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA049/_ibl_subjectTrials.table.e7a4db3b-2b8d-4d60-8730-30d7b607fa26.pqt2024-02-14T17:07:27.000Z"600d8e12a8e9d63aa52187ffe1cdb178"43871387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA052/_ibl_subjectSessions.table.97b07051-74cb-47a3-ba17-38e9cee0d7db.pqt2025-02-20T19:37:43.000Z"bfc168fadf99b9ed0ef46613117ec2ed"CRC64NVMEFULL_OBJECT81427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA052/_ibl_subjectTraining.table.73f91f2e-c354-4560-8295-38d012420a88.pqt2024-02-14T17:07:27.000Z"f0424e3d3a369f0e2a90bdb0ccac9caf"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/churchlandlab_ucla/UCLA052/_ibl_subjectTrials.table.0857863e-2416-4eb3-9524-b670b34f7ecc.pqt2024-02-14T17:07:28.000Z"d5e41a37e021d06104488b1b63fb39a6"35016477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS002/_ibl_subjectSessions.table.9818b53f-ccc9-4dc9-9e70-64bab0b7e5bb.pqt2025-02-20T19:37:44.000Z"e99ef7bd7c1df42b4f9479c69f3f552d"CRC64NVMEFULL_OBJECT95347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS002/_ibl_subjectTraining.table.1dec851a-0b39-475e-90ac-8f491944a4e5.pqt2024-09-16T15:08:12.000Z"d56d4ad5d1a27ca884c29626dd1a49f0"32607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS002/_ibl_subjectTrials.table.243a011c-1f2b-4622-882a-e9a6fbf2edf4.pqt2024-09-16T15:08:12.000Z"fed3474aec3525545e14de1342ae93bf"75811267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS004/_ibl_subjectSessions.table.52d60107-97ab-4f96-8858-1e2233f762a3.pqt2025-02-20T19:37:44.000Z"9080c7ea25af70355fa1199e78837eff"CRC64NVMEFULL_OBJECT93287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS004/_ibl_subjectTraining.table.88001af9-fc1a-444c-a535-0d7c762f0887.pqt2024-09-16T15:08:12.000Z"6b56b134655ff50dc0dab36ad7a5b6e4"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS004/_ibl_subjectTrials.table.4e6a5259-763b-4de4-839a-a3052d6ad342.pqt2024-09-16T15:08:12.000Z"51b6f9a3cc25d931cdb0e3eb67661046"45192197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS005/_ibl_subjectSessions.table.f7bb2f82-a3a1-4fa9-acab-52c7951adf51.pqt2025-02-20T19:37:44.000Z"1e72e15666915f2ffc892a7e6f6b1ff4"CRC64NVMEFULL_OBJECT90957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS005/_ibl_subjectTraining.table.c4979115-c08b-4ad0-8d1f-b1e27fd8759f.pqt2024-09-16T15:08:12.000Z"ddb502cb810353dbee4c33869057cd60"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS005/_ibl_subjectTrials.table.568bfcd4-b73d-4f27-b9fb-365548171013.pqt2024-09-16T15:08:12.000Z"2615e8d103851492174f2c499689077b"69196187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS014/#2024-04-11#/_ibl_subjectTrials.table.835c8230-76e4-4ffc-a77a-a2568cc67e81.pqt2024-09-16T15:08:12.000Z"68d4bd020a518dbb91774c6d5f88ae96"50327177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS014/#2024-08-21#/_ibl_subjectTraining.table.cb914485-ce24-4330-a625-66235e93ff24.pqt2024-09-16T15:08:12.000Z"6304b3d351fba00eb804035bade4e065"31937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS014/_ibl_subjectSessions.table.977cea32-8d30-40e7-86c5-daaf03164163.pqt2025-02-20T19:37:44.000Z"a6cd583eaa19e27f54f1a59fdcee843b"CRC64NVMEFULL_OBJECT78957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS014/_ibl_subjectTraining.table.eae64301-8164-490a-9f4d-2b9c4f33c1cc.pqt2023-12-20T09:08:41.000Z"92a17b9521f6c1183285a22679062554"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS014/_ibl_subjectTrials.table.450249e6-04cd-4610-b748-200f0d592a11.pqt2023-12-20T09:08:41.000Z"5a4df060c4a0050ce1d6b3ffb68cb236"28235337d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS015/#2024-07-22#/_ibl_subjectTrials.table.664f7905-f291-4311-953a-38cefa9ca547.pqt2024-09-16T15:08:12.000Z"0d3e73dd349bc68ea7fe5919fe9eb5f2"33581157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS015/#2024-08-21#/_ibl_subjectTraining.table.a1d01cb5-55a4-4bb9-915d-5ae890f39214.pqt2024-09-16T15:08:12.000Z"9eccbc41a7299ab168c79d2cb85a186e"31347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS015/_ibl_subjectSessions.table.37887f45-1043-4bff-aec3-5ce92b638ef2.pqt2025-02-20T19:37:44.000Z"3e9ba67b166793992be7c0a676f8d468"CRC64NVMEFULL_OBJECT71027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS015/_ibl_subjectTraining.table.8e621c72-7a7a-4e80-830a-f161384e5117.pqt2023-12-20T09:08:41.000Z"f551779b1f9fcd4be966ba4ed69d64e7"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS015/_ibl_subjectTrials.table.0ddd4d98-6242-4637-900b-604eb8602697.pqt2023-12-20T09:08:41.000Z"341f0c32a4e0f1d87ea4666ca875b397"19896857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS016/#2024-07-22#/_ibl_subjectTrials.table.b4e77404-e812-4374-826b-4270abc3bff8.pqt2024-09-16T15:08:12.000Z"5192bd47439fa658f9b85d020eece763"51672137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS016/#2024-08-21#/_ibl_subjectTraining.table.7e015ec2-0158-4985-a323-0f900fab30ef.pqt2024-09-16T15:08:12.000Z"2a6d9f4c7dbb94a9efc4f69aaf796a57"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS016/_ibl_subjectSessions.table.17092220-061a-4fbd-b7f4-41dc152014bd.pqt2025-02-20T19:37:44.000Z"454284acb53303cb426ece7d128f16c7"CRC64NVMEFULL_OBJECT77697d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS016/_ibl_subjectTraining.table.6f9671c8-48a4-4366-98f7-7587f5663985.pqt2023-12-20T09:08:41.000Z"52afdbc884506aa52ee665ae3f2deadf"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS016/_ibl_subjectTrials.table.25cb9012-95e8-4a00-937a-5d1478b70bb9.pqt2023-12-20T09:08:41.000Z"5e20075773ef93087251182ef0b3157d"28853907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS017/#2024-07-22#/_ibl_subjectTrials.table.e9a066db-02d3-439b-af3c-1c96d1605909.pqt2024-09-16T15:08:12.000Z"dbab4581ab7402c9421f327e3ab8120b"32430877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS017/#2024-08-21#/_ibl_subjectTraining.table.f21adabb-3acf-45c6-8973-d65408438e20.pqt2024-09-16T15:08:12.000Z"1fcecb2c41b0bfd43ec5ff56c06c8635"31267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS017/_ibl_subjectSessions.table.8ff60e62-4ce8-4191-bedd-c2b5c44b40b8.pqt2025-02-20T19:37:44.000Z"a5d0d9d683cadda6e83b789c4fe4f1f1"CRC64NVMEFULL_OBJECT79827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS017/_ibl_subjectTraining.table.78eef3ce-aaa0-4b84-a6e7-259bbd9127a1.pqt2023-12-20T09:08:41.000Z"87860b0dd6b3b24148a485a55fa7c117"31267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS017/_ibl_subjectTrials.table.dbcbc5c6-1fcc-4565-a128-5a066fcb619e.pqt2023-12-20T09:08:41.000Z"39c4eca9de8479794de82dd6b2478ef2"18888397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS018/_ibl_subjectSessions.table.fa6ca05b-6ea8-446b-a798-407b33d28fba.pqt2025-02-20T19:37:44.000Z"50f63092d6fc520b0a533c72a17fa56a"CRC64NVMEFULL_OBJECT90477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS018/_ibl_subjectTraining.table.3aa93b93-ff27-4e53-87c2-fd2b22948a8b.pqt2024-09-16T15:08:12.000Z"9af070cde27f2cba2311a024b69a6f7f"30737d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS018/_ibl_subjectTrials.table.3df781ed-24cf-449f-9fcb-60b994d07054.pqt2024-09-16T15:08:12.000Z"f3643824ab2a5ab467832621f402c69e"51108617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS019/#2024-07-22#/_ibl_subjectTrials.table.bf700e86-170a-48cf-a22e-e1c0ffeca377.pqt2024-09-16T15:08:12.000Z"3a258f61768b320ed2f266118de27d22-2"100815597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS019/#2024-08-21#/_ibl_subjectTraining.table.008a80d5-3c8f-41db-91ca-ac6e7f3415c0.pqt2024-09-16T15:08:12.000Z"b2214db9d44f5193d03613ad05856f09"31947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS019/_ibl_subjectSessions.table.c87fbcd6-20d5-4774-8581-7b7abace2a87.pqt2025-02-20T19:37:44.000Z"ad62a2d2f4fda7520b0e664b5f121e4f"CRC64NVMEFULL_OBJECT97177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS019/_ibl_subjectTraining.table.0d84b632-6b6f-499e-9e9f-072305efb0c8.pqt2023-12-20T09:08:41.000Z"b5ee394e3971db6c9d63f94028037304"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS019/_ibl_subjectTrials.table.5fc252fe-348a-4f4f-b55c-273b565a9894.pqt2023-12-20T09:08:41.000Z"e48273b6be249ab07a95607740a7d632"60269807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS020/_ibl_subjectSessions.table.8225b351-ec80-4288-92b0-b5a9942c4d77.pqt2025-02-20T19:37:44.000Z"81a5acd6a70db9b897d95238bb9bb1a1"CRC64NVMEFULL_OBJECT87117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS020/_ibl_subjectTraining.table.c3165312-ee3e-4779-81ef-20fd43b91567.pqt2024-09-16T15:08:13.000Z"9e834134f284e54d298dc3e2b6021b2f"32047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS020/_ibl_subjectTrials.table.a3c41d89-c1bb-4594-b4a0-193eb3428435.pqt2024-09-16T15:08:13.000Z"23d8b5fe75f341563cad819449bcee15"52793257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS021/#2024-07-22#/_ibl_subjectTrials.table.0878a893-b159-49e0-a9ab-e596528d4207.pqt2024-09-16T15:08:13.000Z"17c2214499fdb39f77cf3cfd6cc13642"63837167d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS021/#2024-08-21#/_ibl_subjectTraining.table.d32d5f50-d6dc-4578-8e1d-d41f65a87f1b.pqt2024-09-16T15:08:13.000Z"99da29b24f77c627b85426b84f9d9436"31347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS021/_ibl_subjectSessions.table.9031072f-16a1-4aec-9f29-d4aac739ee3c.pqt2025-02-20T19:37:44.000Z"07686591f4897a9ed04c3248a3d5360a"CRC64NVMEFULL_OBJECT86097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS021/_ibl_subjectTraining.table.3946404c-34bd-4f0d-a0df-0b99e8150ed2.pqt2023-12-20T09:08:41.000Z"d48798aa90c477ef41cfbf4e94753f74"31347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS021/_ibl_subjectTrials.table.6a4b70ec-9e34-46fc-b975-b05e6cc16402.pqt2023-12-20T09:08:41.000Z"557dfd1dc2bf2053ad7edb9a38bd339d"40299137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS022/#2024-08-21#/_ibl_subjectTraining.table.f35a4654-08b4-41a5-9b7c-e8763d653776.pqt2024-09-16T15:08:13.000Z"c8765b6d575959caaa5c5fb9a69ef242"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS022/#2024-08-21#/_ibl_subjectTrials.table.0991fbaf-aef6-433e-9eb1-24cfb4ac9d28.pqt2024-09-16T15:08:13.000Z"9a18d9946609efa71361381298ef4a13"38427127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS022/_ibl_subjectSessions.table.cf52a7e4-06e0-4da8-9fd8-f6095836dc74.pqt2025-02-20T19:37:44.000Z"e35eefc2e40383acf0392f070334a7fd"CRC64NVMEFULL_OBJECT77007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS022/_ibl_subjectTraining.table.59f1fc3d-b649-4ed3-a6d7-c31b68c4d3a3.pqt2023-12-20T09:08:41.000Z"7410a498176ae0028db05ff7220cd823"31907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS022/_ibl_subjectTrials.table.9c10f88c-f96a-46cb-a824-670d886cf640.pqt2023-12-20T09:08:41.000Z"0b7f2cfa62b5f6bb92129b1a5f4c5e48"22841577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS023/#2024-08-21#/_ibl_subjectTraining.table.1e812c61-23f4-44b7-b6ea-45e307159bb1.pqt2024-09-16T15:08:13.000Z"ae156a9921f5f633c754f44112a10492"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS023/#2024-08-21#/_ibl_subjectTrials.table.83bdd5f6-558e-406b-a0f7-2c922bda7364.pqt2024-09-16T15:08:13.000Z"5db17db36c8785818b4a8ff3dfa85355"30167437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS023/_ibl_subjectSessions.table.822e8412-5b7e-4a31-8344-b759912e6f97.pqt2025-02-20T19:37:44.000Z"57113d4eb4164227db09a09269fed9ba"CRC64NVMEFULL_OBJECT73247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS023/_ibl_subjectTraining.table.0349a46f-c73f-45b5-9d8f-5a87cf576b3a.pqt2023-12-20T09:08:41.000Z"e70b8dec42b0575b90ba3ae9b6d130a3"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS023/_ibl_subjectTrials.table.ec01ae89-3cd4-4769-b84d-f7400b349d0e.pqt2023-12-20T09:08:42.000Z"1f2b4ddefd9fe5efa9c84dce51e8540a"17808107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS024/_ibl_subjectSessions.table.746333e3-eb25-49f8-bcf2-a21be841c5ab.pqt2025-02-20T19:37:44.000Z"6258f3bece66a863a2b6fa426bfcd9a4"CRC64NVMEFULL_OBJECT75717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS024/_ibl_subjectTraining.table.4b0d5015-a605-4af2-972b-2ade2d1ab80e.pqt2024-09-16T15:08:13.000Z"5b1d28f0e3494bfbbfec1dc7aab8a5ff"31947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS024/_ibl_subjectTrials.table.138dfab1-df4e-45a0-97dc-b2f346a33ad2.pqt2024-09-16T15:08:13.000Z"b8905e3374370cfbb1221e7dc16ef60c"33374637d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS025/_ibl_subjectSessions.table.c8b7c62a-113f-4f12-892d-ef6f0c85e1d9.pqt2025-02-20T19:37:44.000Z"0e44cd8612aff13c7b75e40afdbe61aa"CRC64NVMEFULL_OBJECT65377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS025/_ibl_subjectTraining.table.273079c7-df8a-4f39-878f-cc3d96fb6820.pqt2024-09-16T15:08:13.000Z"3a05bd931be77c85cb10195248559850"31287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS025/_ibl_subjectTrials.table.2d219fe5-b06e-4244-9ed3-0cb8da60e215.pqt2024-09-16T15:08:13.000Z"4a5fd37d2bcfdb8618650062ecf1928c"18974097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS042/_ibl_subjectSessions.table.9284bcc9-ef28-43bd-ae0a-619b8f44196d.pqt2025-02-20T19:37:45.000Z"a09cc5e1f4b1568de9709bbc01ee2679"CRC64NVMEFULL_OBJECT74447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS042/_ibl_subjectTraining.table.d3248f6f-34f1-4454-bdaa-3a38cb99566b.pqt2023-12-20T09:08:41.000Z"89b9453c4022448f955962e293b39016"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS042/_ibl_subjectTrials.table.ab52e8e3-4913-4dce-b8d8-3c15290fd2f3.pqt2023-12-20T09:08:41.000Z"1179abc20b1799352f04e9b7cbf6efaa"18294147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS043/_ibl_subjectSessions.table.5743de22-e240-4ed0-86fa-3664da0956a7.pqt2025-02-20T19:37:45.000Z"181984bcb436a5145bb4edcfd2df2af8"CRC64NVMEFULL_OBJECT78537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS043/_ibl_subjectTraining.table.8c94fd79-d1f1-4cf0-920a-961d77c4e1ff.pqt2023-12-20T09:08:42.000Z"b4c8de0be5ee22ba8d1fed7c99cf2c60"31397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS043/_ibl_subjectTrials.table.f856f170-23e6-4665-8839-2add0b2870b7.pqt2023-12-20T09:08:42.000Z"7ff7d1c07072fa29488908ba2996c116"35299547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS044/_ibl_subjectSessions.table.9b624c0d-f89a-4e69-ae66-358ec66319e7.pqt2025-02-20T19:37:45.000Z"bf4d663a45f2244bf6b119a59d0aa5ae"CRC64NVMEFULL_OBJECT78917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS044/_ibl_subjectTraining.table.76e39705-e3d0-4e6e-925e-083a45b7dcdb.pqt2023-12-20T09:08:42.000Z"3b2dfff92d8ac545d04eb350153cbd31"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS044/_ibl_subjectTrials.table.729aaec8-b6f4-4fad-bd9b-cf629250484d.pqt2023-12-20T09:08:42.000Z"72ffd8aaaf427de3241099dc9e3ce3dd"40503067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS045/_ibl_subjectSessions.table.e7ecddef-a5d3-4fab-a304-a53223ec9dab.pqt2025-02-20T19:37:45.000Z"43181cb165ff6b02e519affa9fde0bf3"CRC64NVMEFULL_OBJECT76027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS045/_ibl_subjectTraining.table.0e21ccb4-293e-4f40-a26e-7ae4ba395e85.pqt2024-02-14T17:07:27.000Z"d90862e64ceda0dd0751856e69ce85ef"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS045/_ibl_subjectTrials.table.0eb6e8e7-afa9-44f6-b014-f93e6dd047f6.pqt2024-02-14T17:07:27.000Z"2ac8622c7238158cd96b8c1dbbff28ec"24296717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS046/_ibl_subjectSessions.table.7e6bd8e1-92b8-41c2-9338-003250bb641b.pqt2025-02-20T19:37:45.000Z"8aaa90cdb9abdb1ac06fabfc2521d418"CRC64NVMEFULL_OBJECT74917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS046/_ibl_subjectTraining.table.0ae0dd86-6127-436f-a211-fbb74d97660d.pqt2023-12-20T09:08:42.000Z"b4513fda12e51eb4ab9331f8c5598ccb"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS046/_ibl_subjectTrials.table.434136f7-fa26-4058-9032-86d4ea0ac4c5.pqt2023-12-20T09:08:42.000Z"5daecaf613bcdd48e6318df96e252bb9"27528287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS051/_ibl_subjectSessions.table.f11ba1cd-a278-4c18-b1f8-6172bdbc3ff9.pqt2025-02-20T19:37:45.000Z"a7945237ea5e276e512bbc4b4332511e"CRC64NVMEFULL_OBJECT82187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS051/_ibl_subjectTraining.table.942ba2db-e968-4f67-b860-98d7fc4ea539.pqt2023-12-20T09:08:42.000Z"108ca20e460a473e9c5fba4c9955d9d6"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS051/_ibl_subjectTrials.table.3ef042c6-82a4-426c-9aa9-be3b48d86652.pqt2023-12-20T09:08:42.000Z"25de44421b910cc5c4f8d287b24c1bb8"24837287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS052/_ibl_subjectSessions.table.538dea4d-832e-4adf-af7f-61361e069572.pqt2025-02-20T19:37:45.000Z"224065078a34364f0b2e2f4c0bceab17"CRC64NVMEFULL_OBJECT80807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS052/_ibl_subjectTraining.table.af21c5e9-d1e1-4e61-bd57-d7ff2ecf10a1.pqt2023-12-20T09:08:42.000Z"6857dad2ec2ba1a6f9494a06b7a9b87a"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS052/_ibl_subjectTrials.table.0f96af29-99bc-47d2-b6ed-7b1e357724b0.pqt2023-12-20T09:08:42.000Z"a8f21b2c3f7a8f2c1d6b66dcba39b7a8"29014627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS055/_ibl_subjectSessions.table.4af1e875-f86c-44b1-a444-3fc666b670b0.pqt2025-02-20T19:37:45.000Z"42f4b8aef327678c7d3a8b628fed0462"CRC64NVMEFULL_OBJECT78357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS055/_ibl_subjectTraining.table.1236263c-4ce0-44db-8e6e-785c0be087f9.pqt2023-12-20T09:08:42.000Z"3f407f94fbda637a3ff312fa6f299e29"31427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS055/_ibl_subjectTrials.table.87b11dd7-50b7-46e9-b07d-c975b7fa407f.pqt2023-12-20T09:08:42.000Z"ab6561c65da0b2cbcc72e558fbe0b7c5"26359807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS084/_ibl_subjectSessions.table.fdcf1e61-7ce2-4909-88b8-ba582966e269.pqt2025-02-20T19:37:45.000Z"324660a1ce4730e0e425cbffc6be0f50"CRC64NVMEFULL_OBJECT73887d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS084/_ibl_subjectTraining.table.911dcd7a-2c1a-4331-a80a-704ba29df5dd.pqt2023-12-20T09:08:42.000Z"7ab35a7626fcdd22b6a8d6064343aee9"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS084/_ibl_subjectTrials.table.34393eb6-f831-4299-872b-4d91db85b6da.pqt2023-12-20T09:08:42.000Z"02257b9b316d48d8743389866ce65fbb"19354897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS086/_ibl_subjectSessions.table.a2ddc1d6-dc7a-4d67-836e-661f0da2bf49.pqt2025-02-20T19:37:45.000Z"6a3f5a214c657c975749731c1029eab9"CRC64NVMEFULL_OBJECT89457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS086/_ibl_subjectTraining.table.4491c3fe-7b58-46ad-adb1-49beb71bcb31.pqt2023-12-20T09:08:42.000Z"5d04d3ccc4c8b95b5730d3665c73160e"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS086/_ibl_subjectTrials.table.92825aa0-2e3d-4670-8b45-f22c4cae2e40.pqt2023-12-20T09:08:42.000Z"2fe4018d136a87488087ddbf90d392da"36145367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS091/_ibl_subjectSessions.table.3824bce9-ccdd-4dbf-a168-e934803ae0bb.pqt2025-02-20T19:37:45.000Z"3b3e8b5e0e4f80e607f7bee7086accb3"CRC64NVMEFULL_OBJECT85907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS091/_ibl_subjectTraining.table.ca411e1a-a35e-4f14-89b3-587886c4a666.pqt2023-12-20T09:08:42.000Z"4f999dc41ae2a8224d72e7326c50a916"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS091/_ibl_subjectTrials.table.aee8f0ed-f571-4b4f-a616-c1cc7e6ec6af.pqt2023-12-20T09:08:42.000Z"33711a77f9c400f4a218d1f6a0ba4fe9"38790817d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS094/_ibl_subjectSessions.table.66f9a16e-1e5a-4753-acad-bb89c5ca8021.pqt2025-02-20T19:37:45.000Z"be449cfd264e2ef8f972d120322c58b1"CRC64NVMEFULL_OBJECT72487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS094/_ibl_subjectTraining.table.0afb9fb4-cbf6-4597-88c5-c81f9800b1a9.pqt2023-12-20T09:08:42.000Z"b1adfefc7952e2fbefa7274eef51a1eb"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS094/_ibl_subjectTrials.table.21979763-d55e-415a-8f64-cea8cc12ed76.pqt2023-12-20T09:08:42.000Z"a7236413fb7e79196cd790bd6ea831ce"23029977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS096/_ibl_subjectSessions.table.21f7db14-448a-4638-8ad8-57a32eb80aa0.pqt2025-02-20T19:37:45.000Z"ec89a2e2d56f27b3d45ce9d93b5af60f"CRC64NVMEFULL_OBJECT70197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS096/_ibl_subjectTraining.table.6617443c-bd27-47bf-93f5-873d752169a8.pqt2023-12-20T09:08:42.000Z"3a4d15cb0156510c4a8f854f87c55b4d"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/cortexlab/KS096/_ibl_subjectTrials.table.67c057ac-c2e3-465d-9cbf-d5fe2922cdf3.pqt2023-12-20T09:08:42.000Z"61a9e5c27e1209b8ac76b4c50d66e81a"19431357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_001/#2024-07-22#/_ibl_subjectTrials.table.a3b5ab93-3523-4825-a7ea-b0412f80db3d.pqt2024-09-16T15:08:13.000Z"8d07725706603b84ef32aa7fc3ed3f4d"27505647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_001/_ibl_subjectSessions.table.d2153f52-4ddc-4f77-9559-07fabafad6a9.pqt2025-02-20T19:37:45.000Z"deaac5e435f61a6bb69fc61f266863d7"CRC64NVMEFULL_OBJECT77137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_001/_ibl_subjectTraining.table.0aa4bd19-6862-47a3-8cf7-330e4871026d.pqt2024-09-16T15:08:13.000Z"9fbf04a46db0dac9bc4bdb77d2fdcdfa"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_001/_ibl_subjectTrials.table.1023f349-ee17-44fd-8318-448950f00621.pqt2023-12-20T09:08:42.000Z"d61749a33d11eb4c065b7c56d4d13678"19654557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_002/#2024-07-22#/_ibl_subjectTrials.table.8720513a-d3c2-4590-a2c0-a466b9b22984.pqt2024-09-16T15:08:13.000Z"a9a4e930f0fae32b200bc308795e13bd"20930937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_002/_ibl_subjectSessions.table.e31e0348-59e8-4a61-a732-0ff3bfdee731.pqt2025-02-20T19:37:45.000Z"077d38f83f5c77a2b04e30275626aaf6"CRC64NVMEFULL_OBJECT76007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_002/_ibl_subjectTraining.table.7a45016c-7b67-47a2-827e-2ccca8617410.pqt2024-09-16T15:08:13.000Z"56d87766230259dee160227f033debc7"31287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_002/_ibl_subjectTrials.table.2e315dea-2c6f-4b7f-af53-808c882bd2c8.pqt2023-12-20T09:08:42.000Z"8b2c4f392cf3d61726e221759b610867"15089307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_003/#2024-07-22#/_ibl_subjectTrials.table.ae74ecbb-d8ac-4e85-afb4-e8a89bba8016.pqt2024-09-16T15:08:13.000Z"5fb33352d603a7b81a61e4bad7487ec7"23699927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_003/_ibl_subjectSessions.table.1074b577-306a-484a-a73d-b9c33b520fcb.pqt2025-02-20T19:37:45.000Z"522150283f78ff1074acfb25652ff786"CRC64NVMEFULL_OBJECT72397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_003/_ibl_subjectTraining.table.52ec17d0-9865-48d4-aa07-977e82c092e0.pqt2024-09-16T15:08:13.000Z"a1753f6502af9ef8eeda8dd9b64c1f81"31327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_003/_ibl_subjectTrials.table.00d7473b-32c5-414e-bda9-9d8a1c93a2f3.pqt2023-12-20T09:08:42.000Z"7903ad709e160b9dd2492f0ebe9e5da1"16834927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_005/#2024-07-22#/_ibl_subjectTrials.table.5609c1fd-14f8-4268-9eb0-3d3d5f65d174.pqt2024-09-16T15:08:14.000Z"5e090cfc5b78f2348464fff4ac8f0721"19242747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_005/_ibl_subjectSessions.table.655a41c4-bcd1-49f6-b7b0-35aafb6af058.pqt2025-02-20T19:37:45.000Z"1dbe7e5cc5125fcb94cf9f57137bf474"CRC64NVMEFULL_OBJECT72407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_005/_ibl_subjectTraining.table.d04b500e-fd11-4860-91b9-6d21d02cdb07.pqt2024-09-16T15:08:13.000Z"01f668c47ec3763e3d75531a97a239e8"30737d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_005/_ibl_subjectTrials.table.3dce1367-6bd6-4baf-af75-e700b5a263bf.pqt2023-12-20T09:08:42.000Z"804d2682896431140f7c2b073336641e"13849867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_006/#2024-08-21#/_ibl_subjectTrials.table.0186a713-6c85-4024-96af-be8c6436a1cc.pqt2024-09-16T15:08:14.000Z"6bf965ccffc7bb32b3aa22f3e7b1ea41"31781527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_006/_ibl_subjectSessions.table.fce09f23-5fee-4e43-b440-32844eb43fc4.pqt2025-02-20T19:37:45.000Z"d400290a40227df217c3b481433e9a07"CRC64NVMEFULL_OBJECT76987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_006/_ibl_subjectTraining.table.fc4ac8e6-be61-44eb-8fb3-9e997132cddf.pqt2024-09-16T15:08:14.000Z"6965f784e1b99f29106265e507263b82"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_006/_ibl_subjectTrials.table.79b0884e-ba5d-48ca-ba52-9681f6946798.pqt2023-12-20T09:08:43.000Z"f83fc7181c20180b8292882513d928df"20170527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_007/#2024-08-21#/_ibl_subjectTrials.table.e1c48776-00b9-4292-a099-a4b48880a00a.pqt2024-09-16T15:08:14.000Z"f1176e769a737b10a9cb1ff1826c1834"30741097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_007/_ibl_subjectSessions.table.00137051-d28f-4c3d-839d-e59d857aae1e.pqt2025-02-20T19:37:45.000Z"04323f1f9ca63b3c729b2834efa1ff65"CRC64NVMEFULL_OBJECT73087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_007/_ibl_subjectTraining.table.b0beb213-bf7f-4150-bcb3-105d6d664cfe.pqt2024-09-16T15:08:14.000Z"5d8d0b711ec4af56dce6db4ae673dacf"30787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_007/_ibl_subjectTrials.table.238e6afa-56dc-4250-9524-a2934fd87e38.pqt2023-12-20T09:08:43.000Z"495acdbbb35a4e1670313744a971ea82"20087197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_008/#2024-08-21#/_ibl_subjectTraining.table.401ebaff-96f3-4330-8c6e-b2efda5c15c8.pqt2024-09-16T15:08:14.000Z"004267a0a3af24cac5cfb365a618a4ad"32577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_008/#2024-08-21#/_ibl_subjectTrials.table.b1ba72c2-9d03-4333-a17b-0e0f72e242f5.pqt2024-09-16T15:08:14.000Z"f88b1eba21cde933b4da110d53cd3b34"45159957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_008/_ibl_subjectSessions.table.63ac0853-dbfd-4b90-82cf-e62edb485765.pqt2025-02-20T19:37:46.000Z"c56e1b11e95c7619b3f6747c4f101e1c"CRC64NVMEFULL_OBJECT90297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_008/_ibl_subjectTraining.table.7c4e6df5-49a3-4142-ac63-a3a94fa7dc96.pqt2023-12-20T09:08:43.000Z"1d0d6bd3f186a635416b926bf2005b89"32557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_008/_ibl_subjectTrials.table.0a148449-6ae7-45ed-a0ae-d9b776b8c9b6.pqt2023-12-20T09:08:43.000Z"6c6176eee323a717c4eec230ec0c9e39"27068897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_009/#2024-08-21#/_ibl_subjectTraining.table.f2eca6c1-e357-4a3e-b606-17b9e3fc6db0.pqt2024-09-16T15:08:14.000Z"1d887c0888c7390ffcf652a9d60a0c42"32537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_009/#2024-08-21#/_ibl_subjectTrials.table.7e42b895-fcf9-4fd8-a38c-bbaa4173a979.pqt2024-09-16T15:08:14.000Z"4e8b548ea12825c6179628736896a722"54764377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_009/_ibl_subjectSessions.table.2ef63d48-cbaf-43e6-9101-c3f20b5a34fb.pqt2025-02-20T19:37:46.000Z"02e446e4792859b51a9bee8dcd6acd12"CRC64NVMEFULL_OBJECT90627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_009/_ibl_subjectTraining.table.4bec9c20-2a5d-4d84-8bbd-c365ac50154b.pqt2023-12-20T09:08:43.000Z"b106b89c68110a4f111cfe0d91d4946f"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_009/_ibl_subjectTrials.table.3ecd75ea-9f3c-4978-bafb-6c2441f17ffe.pqt2023-12-20T09:08:43.000Z"109abded9202714acb2e95b8b1351fd3"33009897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_010/#2024-08-21#/_ibl_subjectTrials.table.39188fd9-27aa-46f4-a8a7-251883d0ec09.pqt2024-09-16T15:08:14.000Z"1aa03349185eb22c64959e4033b63191"43297157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_010/_ibl_subjectSessions.table.6bf59c56-1c2d-490f-a63f-df01fd1e9b24.pqt2025-02-20T19:37:46.000Z"f242389925b7012780fb74befb7803b3"CRC64NVMEFULL_OBJECT78997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_010/_ibl_subjectTraining.table.cd02ea67-c32c-482b-8746-f7e61a07a3b8.pqt2023-12-20T09:08:43.000Z"e5e2b66cf9e0620c84bb5ab3290ca31a"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_010/_ibl_subjectTrials.table.894269cf-9db2-4ce5-8f7d-cee9519e01fb.pqt2023-12-20T09:08:43.000Z"ad58ab9151c7e81d035d7e878060f5d2"26147237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_011/#2024-08-21#/_ibl_subjectTraining.table.7a8e67c0-a5ee-41aa-b7f9-efd616922c33.pqt2024-09-16T15:08:14.000Z"3a40b675b9f6223b1bbf285a3e249a5c"32577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_011/#2024-08-21#/_ibl_subjectTrials.table.105f4606-06b6-4dfb-a920-884085a27c12.pqt2024-09-16T15:08:14.000Z"d4ca1d5e2ad33639810a560ab1131c3e"42116507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_011/_ibl_subjectSessions.table.a2ac73a3-6a34-4fc5-b1c0-1d7ee30299ab.pqt2025-02-20T19:37:46.000Z"f9f2b83f55a97fb8346b115a603c05c8"CRC64NVMEFULL_OBJECT80217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_011/_ibl_subjectTraining.table.23088b21-1549-4558-ab64-48fb2d20a8d2.pqt2023-12-20T09:08:43.000Z"6a769476789748ebaa436422d8a1ed80"32567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_011/_ibl_subjectTrials.table.52b8fe1d-8ca9-4594-b8b4-2f8eb5efd39e.pqt2023-12-20T09:08:43.000Z"8fe41576aa4c603f01943db4c2f9a31e"25454337d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_012/_ibl_subjectSessions.table.eff28c12-e2ec-4c27-8313-9d066ce022c2.pqt2025-02-20T19:37:46.000Z"1cc20702d812c5c23784c3a63085f939"CRC64NVMEFULL_OBJECT68687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_012/_ibl_subjectTrials.table.0c520eaa-e116-45ec-a07e-e3873e9f2580.pqt2023-12-20T09:08:43.000Z"a725b4f280ca87bdf1c2014b940d6853"16577627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_013/#2024-08-21#/_ibl_subjectTraining.table.bf960835-5d01-45ef-bda2-96121014f2dc.pqt2024-09-16T15:08:14.000Z"0e7cc99564d1d758f832d996e2714ed2"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_013/#2024-08-21#/_ibl_subjectTrials.table.7177f158-f14c-4937-89e6-21d75c8dad4d.pqt2024-09-16T15:08:14.000Z"40c323bf0a8c7d43bfba1bb07fd02275"22273967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_013/_ibl_subjectSessions.table.7ef43ee6-208e-45fe-932a-a4444680c144.pqt2025-02-20T19:37:46.000Z"8704212f3e72210c5392aba1611d114d"CRC64NVMEFULL_OBJECT68717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_013/_ibl_subjectTraining.table.fc9f8970-c86b-4b63-8465-91ae91181689.pqt2023-12-20T09:08:43.000Z"bfbe362ff701303a620754feda663dad"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_013/_ibl_subjectTrials.table.14e83892-025d-49c9-ae76-2529e07d03d4.pqt2023-12-20T09:08:43.000Z"bb8bbd47b922984b5387cd83d938b920"13011927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_014/#2024-04-10#/_ibl_subjectTrials.table.f0989302-0be3-4521-9cff-1c8beb1e4dd2.pqt2024-09-16T15:08:14.000Z"94d93282c40d188222ddc264518d3b4f"39766207d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_014/#2024-08-21#/_ibl_subjectTraining.table.91822d9b-f437-42d3-983f-a8b274789894.pqt2024-09-16T15:08:14.000Z"5d0d434daa35dd0a763edf45ed3e5ad5"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_014/_ibl_subjectSessions.table.0c7f9d5a-b506-446c-a4f4-31c176cd3c4a.pqt2025-02-20T19:37:46.000Z"618ea8e7e22010ed42b63b88b2e63df6"CRC64NVMEFULL_OBJECT77967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_014/_ibl_subjectTraining.table.b0ceac7d-1694-47c2-9dc1-8b0233214d78.pqt2023-12-20T09:08:43.000Z"0b2eaeb2121f9b9a0899824fde632051"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_014/_ibl_subjectTrials.table.d5932e8f-cbc0-4a5c-8711-3cdad0b4ae00.pqt2023-12-20T09:08:43.000Z"39883f5908f81358d649b3c754fabf36"22410617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_015/#2024-08-21#/_ibl_subjectTrials.table.6b3a2ff2-5893-44a2-befd-d81da5ee86b2.pqt2024-09-16T15:08:14.000Z"0c201b43defa0b9ac3034bdcaa14a7d7"11721907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_015/_ibl_subjectSessions.table.61b96c83-9f6f-4dcd-9337-ecfd481fb8f9.pqt2025-02-20T19:37:46.000Z"fcbdd111a1ed4899708e801d0b9552af"CRC64NVMEFULL_OBJECT68517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_015/_ibl_subjectTraining.table.745cee7f-6703-4849-89e6-b339e3ec9f22.pqt2024-09-16T15:08:14.000Z"0a98b6b3779ab9f39c1d75b0a133e6f0"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_015/_ibl_subjectTrials.table.72ed20bd-4764-498e-8bf4-7a5c2ab5d72c.pqt2023-12-20T09:08:43.000Z"90ce8cc372a169c6115d87bb22a67da0"6831277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_016/_ibl_subjectSessions.table.c6f77498-dc1d-434d-8348-de4ded1588fd.pqt2025-02-20T19:37:46.000Z"9fa42ba5a2733a4d738f5cff742a600e"CRC64NVMEFULL_OBJECT69157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_016/_ibl_subjectTraining.table.74023952-e15e-4c24-b75e-65ca6725ce66.pqt2023-12-20T09:08:43.000Z"39d93956ff85febf571b7e103bb29436"32487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_016/_ibl_subjectTrials.table.9a5eb497-8c75-44ea-a9d6-243035b6ba79.pqt2023-12-20T09:08:43.000Z"96d11b08eb5a89806f0f8d93f2e983d8"13425797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_018/_ibl_subjectSessions.table.344491f7-1bf2-4c4a-97cc-9575ce65b53e.pqt2025-02-20T19:37:46.000Z"6b8151b07c39f6cd326e84c504503406"CRC64NVMEFULL_OBJECT79837d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_018/_ibl_subjectTraining.table.343ab48f-e90b-4ee1-b75f-245bc12a1b4b.pqt2023-12-20T09:08:43.000Z"ffbe019bb7e3f8becf4005d89e51fe86"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_018/_ibl_subjectTrials.table.1a9e4794-0ad1-421a-a7a9-0f50aeea50c1.pqt2023-12-20T09:08:43.000Z"6a9a1053da98dca20ec818901ec5ff3f"26148877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_020/_ibl_subjectSessions.table.8685c42e-3637-4070-88f1-0471c3e38b9a.pqt2025-02-20T19:37:46.000Z"8c07db58556de1eec62bf16571b9576e"CRC64NVMEFULL_OBJECT76017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_020/_ibl_subjectTraining.table.f4adb8e0-0671-4a72-93fb-d4602b7a554b.pqt2023-12-20T09:08:43.000Z"5cc69dff25ead9b60537ebde7209307e"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/danlab/DY_020/_ibl_subjectTrials.table.baaa942f-7e1f-4cee-a5dd-0792c088f899.pqt2023-12-20T09:08:43.000Z"622ce786ce41b29a784733c6acb45496"24321247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL015/_ibl_subjectSessions.table.f9288eda-2f6c-4e34-ae22-b2da75ac9925.pqt2025-02-20T19:37:46.000Z"5b040c40878bf566d691a0496441d83f"CRC64NVMEFULL_OBJECT119677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL015/_ibl_subjectTraining.table.6cdd829d-ba9c-41f2-817f-6bc04552e4ab.pqt2024-02-14T17:07:28.000Z"b5321d8a14e90dbc54bbf9eb8f3bb926"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL015/_ibl_subjectTrials.table.2f22a943-76e8-4667-b6bb-eab926cfe29d.pqt2024-02-14T17:07:28.000Z"c82a98b8e58b0ec9dda7832cb90cce37-2"116374697d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL016/_ibl_subjectSessions.table.fe2b46b4-1da7-47df-ae22-aaac9f192028.pqt2025-02-20T19:37:47.000Z"ed127a61006386c1ab11c89a1bf2f961"CRC64NVMEFULL_OBJECT97687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL016/_ibl_subjectTraining.table.6af70595-f0d3-4273-8fb8-89824d11cb47.pqt2024-02-14T17:07:28.000Z"25bb3eddbf3f582d2903d09ca551bd9f"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL016/_ibl_subjectTrials.table.0221e6be-ba8c-4964-a41a-2f8fde3ce217.pqt2024-02-14T17:07:28.000Z"ce7e37f8601da9785b54fcc3f2ff610b"67858707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL017/_ibl_subjectSessions.table.7cfbd576-1863-4142-a2a9-6b521961c78a.pqt2025-02-20T19:37:46.000Z"ca94e99c69116d63c1305be651b4870c"CRC64NVMEFULL_OBJECT82667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL017/_ibl_subjectTraining.table.48c74cda-1aa5-481a-a6e0-f8aadf93a543.pqt2023-12-20T09:08:43.000Z"869460366d97ae4b408748f6399ddc23"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL017/_ibl_subjectTrials.table.6e9f2e01-22fc-4867-8b08-51e965114440.pqt2023-12-20T09:08:43.000Z"19ab527d869610cb423ce1d5d2daddba"48253607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL024/_ibl_subjectSessions.table.3c1bf3d6-d537-4c2e-81b7-d55af067996f.pqt2025-02-20T19:37:46.000Z"25069ee15a362121dc7e07d58643e434"CRC64NVMEFULL_OBJECT75127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL024/_ibl_subjectTraining.table.ba802f7a-bbc4-4b2c-b115-24742a01feae.pqt2023-12-20T09:08:43.000Z"4a1adcb9f0257a37797a2966fc7f747a"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL024/_ibl_subjectTrials.table.d80a3aba-4980-4828-b096-9820a597e809.pqt2023-12-20T09:08:43.000Z"87ac2f5d3e3c689ecc8f5ed5f4fe184d"30136477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL030/_ibl_subjectSessions.table.24021735-4eee-4b97-b037-078e527d5eda.pqt2025-02-20T19:37:46.000Z"d2d64e5642ec329238b76afd63bce3ac"CRC64NVMEFULL_OBJECT107757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL030/_ibl_subjectTraining.table.9e1c0587-2985-4944-9b06-fda1474acfa1.pqt2024-02-14T17:07:28.000Z"48e51e711bbbf90a1c989d48adcb7c70"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL030/_ibl_subjectTrials.table.74203b34-c02f-4bb9-a66e-e0af7f368a31.pqt2024-02-14T17:07:28.000Z"02097064b587f78e82856aca6611943f-2"110031537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL031/_ibl_subjectSessions.table.8ad0b9a7-45e4-4b11-925d-66c194d15ff4.pqt2025-02-20T19:37:46.000Z"d28d97bb5dc9521d33803160613c4bf6"CRC64NVMEFULL_OBJECT119797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL031/_ibl_subjectTraining.table.53a62ea3-4399-4c8e-8896-ba613b0f2739.pqt2024-02-14T17:07:28.000Z"ddab912864e879a30b5f1817b1b95283"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL031/_ibl_subjectTrials.table.a9754cfb-04b2-403e-af94-e475df94c698.pqt2024-02-14T17:07:28.000Z"b651f63ebbe1cf2b145515cd0d328951-2"114271187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL033/_ibl_subjectSessions.table.79b45604-bbd8-453b-90fa-d6143bd60a52.pqt2025-02-20T19:37:47.000Z"e424ac9f50d8e47b4393a23ec74d4e9c"CRC64NVMEFULL_OBJECT112927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL033/_ibl_subjectTraining.table.3909bd19-0e2a-4c4c-94f2-7ec7b66031c0.pqt2024-02-14T17:07:29.000Z"033fc4b7b3aeb54be8f0da648562dbfe"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL033/_ibl_subjectTrials.table.db95f7e5-aae8-446a-b613-47dcdc8b8040.pqt2024-02-14T17:07:29.000Z"d91737dd656233f7a1ac932c105649bf-2"108644047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL034/_ibl_subjectSessions.table.1208d49e-fb0e-47a0-b042-2eaff818e0d9.pqt2025-02-20T19:37:47.000Z"7fac50ed221e6d6d3d1824861746e8fd"CRC64NVMEFULL_OBJECT65257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL034/_ibl_subjectTraining.table.95417725-e493-4834-9b70-8984c17c10c3.pqt2024-02-14T17:07:29.000Z"0f77eb2b2cd5e87a015f4f05f273676c"30717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL034/_ibl_subjectTrials.table.d5be2e9d-4cc4-485c-abe0-160f02b30a18.pqt2024-02-14T17:07:29.000Z"8682f8bd10c0f8a763141f1bd1c17172"22565747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL035/_ibl_subjectSessions.table.70c37d05-7ec8-43e1-be6e-0d3f5792ea1f.pqt2025-02-20T19:37:47.000Z"aa5c1674d1df91a493a423271e883823"CRC64NVMEFULL_OBJECT103917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL035/_ibl_subjectTraining.table.40ad88b3-f0dc-4a02-a71b-115da562ec64.pqt2024-02-14T17:07:29.000Z"9212037388ec31a5eb6210a91a730d04"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL035/_ibl_subjectTrials.table.a32e11d4-b3ac-4173-acda-4c4a556374d8.pqt2024-02-14T17:07:29.000Z"93a920ac42da48b0b2f8a4151c3f0632"80698567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL037/_ibl_subjectSessions.table.ca5a024e-307d-4bf4-8be0-fc154288db69.pqt2025-02-20T19:37:47.000Z"c6745a4abff2d0763bd1cb9297058f03"CRC64NVMEFULL_OBJECT108287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL037/_ibl_subjectTraining.table.52f2a506-e01b-4dde-b86e-33869366938d.pqt2024-02-14T17:07:29.000Z"dd7dce59fb113f460ebb16e0cc84f46e"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL037/_ibl_subjectTrials.table.f1d4ad96-7551-4b45-b514-050a4c8ed67a.pqt2024-02-14T17:07:29.000Z"95f2e38b77c1e84c277215c52110bf1f-2"98371627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL050/_ibl_subjectSessions.table.4fd20ae2-7fe5-4a52-8173-8e4393db3fe5.pqt2025-02-20T19:37:47.000Z"23650d7732b40fa65bff490b95823c0e"CRC64NVMEFULL_OBJECT74057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL050/_ibl_subjectTraining.table.c8e2d639-7343-4d53-9b5d-0f77d4b878d5.pqt2024-02-14T17:07:30.000Z"ba666dac507c62e4f641d70ce725561d"32497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hausserlab/PL050/_ibl_subjectTrials.table.8aabde8e-6a78-4e8b-a1d7-41171f1b6227.pqt2024-02-14T17:07:30.000Z"daa062f4ee28e46e4599de8a002433fe"28218377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_001/#2024-08-21#/_ibl_subjectTrials.table.c0cba994-2e72-454b-8e2f-f75241823188.pqt2024-09-16T15:08:15.000Z"dc305a06077c9816f818d8b7aafd1639"49693387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_001/_ibl_subjectSessions.table.a25b579a-4e7b-4f80-9964-20cbb11525a5.pqt2025-02-20T19:37:47.000Z"0d09147020e115f55fbea29e76ddfbcf"CRC64NVMEFULL_OBJECT87217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_001/_ibl_subjectTraining.table.abac2c67-8601-4793-a8b3-2edf80f75cc5.pqt2024-09-16T15:08:15.000Z"a392ac35ad0380e4ba084899148578ce"30747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_001/_ibl_subjectTrials.table.9ceab15e-f177-485f-a74c-b4ad49b1d3b3.pqt2023-12-20T09:08:44.000Z"dd2773ebb56d1adb5b4399b244c2436e"31665137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_002/_ibl_subjectSessions.table.6d802c75-df93-4ab5-a55c-b0ffd81d04ee.pqt2025-02-20T19:37:47.000Z"c2c719b92b1daffedcc766a56d44896f"CRC64NVMEFULL_OBJECT86267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_002/_ibl_subjectTrials.table.eb8ab396-543f-400e-b95b-a507bf564000.pqt2023-12-20T09:08:44.000Z"375547f11868a40d3b0b0dfa16a23040"27361327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_003/_ibl_subjectSessions.table.2bb9b400-279b-41d8-95ae-56d0311dcece.pqt2025-02-20T19:37:47.000Z"7533eb32c20222397b6feb8215b51b98"CRC64NVMEFULL_OBJECT86477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_003/_ibl_subjectTrials.table.96f967d5-2734-4c62-b896-44f0bc59834b.pqt2023-12-20T09:08:44.000Z"cd443b29faf36d1e986ac5ef3d0fa45b"23859447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_006/_ibl_subjectSessions.table.13d1582a-b203-47ac-818a-a7a4ae92131f.pqt2025-02-20T19:37:47.000Z"9296102d8a4d8565f2617f0ada6fb16f"CRC64NVMEFULL_OBJECT63847d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_006/_ibl_subjectTrials.table.4065694f-36b0-4e77-95f4-8c9caa12907b.pqt2023-12-20T09:08:44.000Z"a2c27930e3e32b454fa0b471be85a5b9"10091647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_007/_ibl_subjectSessions.table.072a3d41-a64d-402d-a1c8-0483b0c4a40c.pqt2025-02-20T19:37:47.000Z"c587f337b37980b6cb3d6c95942825ce"CRC64NVMEFULL_OBJECT55807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_007/_ibl_subjectTrials.table.d7efd3d0-b796-4cd6-ba41-b2500abe1ed1.pqt2023-12-20T09:08:44.000Z"834bd002fbc836c180fb7660e4aa5be4"339197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_010/_ibl_subjectSessions.table.c0e2e8b8-a0ed-47c4-a668-2003be6a9a6b.pqt2025-02-20T19:37:47.000Z"5fb1819aa756b2f8be29a8dc684679fa"CRC64NVMEFULL_OBJECT60067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_010/_ibl_subjectTrials.table.6285f607-149e-46f4-b47a-59f9cbfbd6ee.pqt2023-12-20T09:08:44.000Z"f76520b3b9019b35361d747351b2e020"1681617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_011/_ibl_subjectSessions.table.90d6e978-cfdf-4540-9c0a-69517c9714f9.pqt2025-02-20T19:37:47.000Z"2689354552513e063717768f0cc37846"CRC64NVMEFULL_OBJECT77217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_011/_ibl_subjectTrials.table.64f9e279-9f44-4f6a-9ff3-fa141053c3c0.pqt2023-12-20T09:08:44.000Z"87473218fabe4232b7631a52abb15455"15829117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_013/#2024-04-11#/_ibl_subjectTrials.table.86e35a3e-e1cf-4f2e-a929-d545891fcc97.pqt2024-09-16T15:08:15.000Z"6d0bba949646f4e14618dc970a39f760"49740487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_013/_ibl_subjectSessions.table.7a0c49af-6aef-4e1f-9ae1-92b50a58e4ae.pqt2025-02-20T19:37:47.000Z"83e85ab8825f34058283960d9ef0b330"CRC64NVMEFULL_OBJECT78127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_013/_ibl_subjectTraining.table.7ccd86a1-8f14-4d88-9ac0-3f7baeae49a1.pqt2024-09-16T15:08:15.000Z"50bb0a74161e1ce64735cd599faf6c3e"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_013/_ibl_subjectTrials.table.598ac55c-19b5-422f-b863-eb6d885a0697.pqt2023-12-20T09:08:44.000Z"86126409ae27006cd59155300a4e5bb6"15111627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_014/#2024-04-11#/_ibl_subjectTrials.table.706000ed-9872-43d3-993c-784153517270.pqt2024-09-16T15:08:15.000Z"4cc0bf0d345a11ce6c520e35041bdac6"43169037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_014/_ibl_subjectSessions.table.04ab6c08-2285-4076-9c85-a4f695f2700d.pqt2025-02-20T19:37:47.000Z"8898c86e3dd486b9b05990c0b10799c4"CRC64NVMEFULL_OBJECT78117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_014/_ibl_subjectTraining.table.e93483f9-5fba-4a94-93d6-c3211551adb4.pqt2024-09-16T15:08:15.000Z"514657edfe57e301015b7fd018c5a2ff"32497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_014/_ibl_subjectTrials.table.61710914-ea88-49cb-932a-e4a50bd41a9b.pqt2023-12-20T09:08:44.000Z"a1436d8de60dbf38f1115deceb627493"18552617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_015/#2024-04-11#/_ibl_subjectTrials.table.1d5e9252-0fbd-47f1-a4e3-87099ac7388f.pqt2024-09-16T15:08:15.000Z"9c9c9a6a369ffe8f2c2bfc26fc021a84"80933497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_015/_ibl_subjectSessions.table.edbcd8b5-f78e-4527-8ab9-635be6d0089d.pqt2025-02-20T19:37:47.000Z"d9360ca22257d4e3246ddab4039432f3"CRC64NVMEFULL_OBJECT95397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_015/_ibl_subjectTraining.table.4f774eef-537a-480b-a206-a135d0c98193.pqt2024-09-16T15:08:15.000Z"c42e22f86bfc1b54bd6c9a62e5da78d0"31917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_015/_ibl_subjectTrials.table.86aa743b-d1a8-44f7-9043-22af2aa7a674.pqt2023-12-20T09:08:44.000Z"b181d6befb549e7dd0d2d56530d4e202"26895867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_019/_ibl_subjectSessions.table.1ed17458-3632-4d08-b3e8-f62fe284e899.pqt2025-02-20T19:37:47.000Z"c070190e2e8faa4649ecd05cf06cb958"CRC64NVMEFULL_OBJECT64867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_019/_ibl_subjectTrials.table.102ccde4-6c2a-45cf-8069-9800631e095b.pqt2023-12-20T09:08:44.000Z"aa2b10acfe0921e1f34f666ae489b1bb"6512677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_020/_ibl_subjectSessions.table.938ace0d-7101-492b-9853-d5fccfc980b3.pqt2025-02-20T19:37:47.000Z"10879e5ce0361d934df5012ca4275a78"CRC64NVMEFULL_OBJECT67787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_020/_ibl_subjectTrials.table.c2ed585e-af37-4d2b-88d8-4789ca0f3e88.pqt2023-12-20T09:08:44.000Z"303e2d54c2a79dcad9218e73f809551a"10070187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_021/#2024-04-11#/_ibl_subjectTrials.table.02f8a51a-f313-4171-99d0-88f924384f6c.pqt2024-09-16T15:08:15.000Z"41ab49f9448b3efe3a5e6431f7a3317c-2"89453057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_021/#2024-08-02#/_ibl_subjectTraining.table.c5b8bf20-e7db-4bfe-a21f-a100ab5bc3ca.pqt2024-09-16T15:08:15.000Z"57a601bdd023ddf28c8f6f65fe60a1d4"31427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_021/_ibl_subjectSessions.table.2a7355ea-0ee3-4bb1-8205-f052dc0c3f8d.pqt2025-02-20T19:37:48.000Z"5d37df9c1ece61a047acc37441bc743a"CRC64NVMEFULL_OBJECT94407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_021/_ibl_subjectTraining.table.1c397df3-4caa-4f9e-a694-4ffb8cfc6db3.pqt2023-12-20T09:08:44.000Z"18e9e60d7f53542e91e2453fd43502e2"31397d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_021/_ibl_subjectTrials.table.ba0a1237-de0f-44f6-950d-645992231e71.pqt2023-12-20T09:08:44.000Z"c81af67cc6833e4aef140de247c2f377"40095377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_027/_ibl_subjectSessions.table.a93c6777-367e-4951-bd47-d70f65e5a4c9.pqt2025-02-20T19:37:47.000Z"bf6b228b6f0564c1ef3437147c1e0c08"CRC64NVMEFULL_OBJECT68057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_027/_ibl_subjectTrials.table.4f1e71f0-5add-4e8d-b0bb-706b89862358.pqt2023-12-20T09:08:44.000Z"fcb3253340309804c90d19d7befc03e4"2890367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_028/_ibl_subjectSessions.table.703b27f7-efad-47be-9982-c7e66c3d1ccb.pqt2025-02-20T19:37:47.000Z"12065236ccc4efec1d12d4ae9fbfd33f"CRC64NVMEFULL_OBJECT72897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_028/_ibl_subjectTrials.table.3af77392-c462-4408-9e84-0df688464109.pqt2023-12-20T09:08:44.000Z"4aa955905f4708874b8992fce6beb1f4"6494987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_032/_ibl_subjectSessions.table.0e53d1a2-5b04-47bd-b8a6-39296ea53f39.pqt2025-02-20T19:37:48.000Z"91bbd5f44f977ab3604cf338700414c0"CRC64NVMEFULL_OBJECT78417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_032/_ibl_subjectTrials.table.8a9c7708-3677-4c94-93cb-5af195b9ad7e.pqt2023-12-20T09:08:44.000Z"72fe61e998f7696818902d05ef7b9ffc"20197717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_033/_ibl_subjectSessions.table.783afcfc-7697-4816-8d2b-ae037f1a82f1.pqt2025-02-20T19:37:48.000Z"9f32cb8c55e7b29b251141e82e6539a1"CRC64NVMEFULL_OBJECT79217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_033/_ibl_subjectTrials.table.451a0b9c-45da-42da-9f94-cb14c27ec516.pqt2023-12-20T09:08:44.000Z"a2d9b44188e55ac7b0dc9427947d7ffb"25933107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_034/_ibl_subjectSessions.table.5a951fe9-8a76-46d3-b632-c38e16be2afb.pqt2025-02-20T19:37:48.000Z"ed776ca64c3a8788e47d141515bf8314"CRC64NVMEFULL_OBJECT58037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_034/_ibl_subjectTrials.table.1015dcc1-4019-40e0-93a5-ca8bacdb9aff.pqt2023-12-20T09:08:44.000Z"9dd14a556604ddc9844e8b1d6aedf47a"4259527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_041/_ibl_subjectSessions.table.ab14b7e2-4272-42ee-88d9-2554d3f09a6b.pqt2025-02-20T19:37:48.000Z"ec989f5f1243bf4caface0ae545d846a"CRC64NVMEFULL_OBJECT96357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_041/_ibl_subjectTrials.table.97ef040b-d144-449c-80c2-d5c97bd81563.pqt2023-12-20T09:08:44.000Z"e0229e6257016bf142a012104085647d"69869307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_042/#2024-04-11#/_ibl_subjectTrials.table.9574bc75-fb9e-4465-93f4-58e0b4415d5a.pqt2024-09-16T15:08:16.000Z"7b816c0d219d93a44924b6dec3605251"41808427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_042/#2024-08-21#/_ibl_subjectTraining.table.2aa73df4-9ba5-4afe-a009-b7bf8ad80acf.pqt2024-09-16T15:08:16.000Z"f5fe3c4204c620e1c871da0784a9f985"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_042/_ibl_subjectSessions.table.39f058fd-ecc6-4b7e-81e4-d9aa00b788a8.pqt2025-02-20T19:37:48.000Z"2b2e7a6b6afe0aeafba7e69d1ff45f4a"CRC64NVMEFULL_OBJECT74857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_042/_ibl_subjectTraining.table.8650e2f5-2b72-44e4-a406-2294d8c23ee2.pqt2023-12-20T09:08:44.000Z"79f773f50a5a7259e470c997402cc1d5"31257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_042/_ibl_subjectTrials.table.2ba4020b-a1f6-413b-802d-7ae247048118.pqt2023-12-20T09:08:44.000Z"8333d66f13f90a16f87f3b8eb38b2b5c"19469347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_043/_ibl_subjectSessions.table.0255d9b6-7cb2-46aa-ae47-6cfd8f0195dc.pqt2025-02-20T19:37:48.000Z"424ba111fb7c815fb0428247e66b9d99"CRC64NVMEFULL_OBJECT93447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_043/_ibl_subjectTraining.table.51b8d162-4d46-4248-8867-90bb516f7429.pqt2023-12-20T09:08:44.000Z"f8617560165fe9609abe371dca080419"32417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_043/_ibl_subjectTrials.table.01c9fb98-c542-4999-a48a-5541f8e91252.pqt2023-12-20T09:08:45.000Z"548decb6e633d3769e59153a8f15efd9"43507537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_060/_ibl_subjectSessions.table.abd6c66c-b19b-4b88-a84c-3d5cc21a4170.pqt2025-02-20T19:37:48.000Z"f4cf9780af141774b8fb5e96ddab0091"CRC64NVMEFULL_OBJECT67147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_060/_ibl_subjectTraining.table.4a24d297-f583-42e5-9bf1-22b5c719b1d8.pqt2023-12-20T09:08:45.000Z"3451da0946e1fdb2b4e6becbb878b537"30757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_060/_ibl_subjectTrials.table.68ccf919-4245-442b-a246-67f6dd823807.pqt2023-12-20T09:08:45.000Z"860151fe6313a7f5bed4711cf6556cf9"12847447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_061/_ibl_subjectSessions.table.7ad8d867-7f25-42a2-82eb-32e1d496f187.pqt2025-02-20T19:37:48.000Z"85272e3a905e3f4c31e74753aa4aa09c"CRC64NVMEFULL_OBJECT68277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_061/_ibl_subjectTraining.table.cc910c05-3abc-418f-9273-eba57f3f8a6a.pqt2023-12-20T09:08:45.000Z"414ffd9d8d576e6a59352a76bb33cf9d"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_061/_ibl_subjectTrials.table.4b8c948e-8c7e-47ed-a0bb-d317245d87f1.pqt2023-12-20T09:08:45.000Z"a8997a3289f56078d93437a73cfa1a76"15835277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_066/_ibl_subjectSessions.table.4a0d34c4-3d72-495a-b411-785b719ec74d.pqt2025-02-20T19:37:48.000Z"0716de52f10b396749f2367bafcc5dc6"CRC64NVMEFULL_OBJECT66497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_066/_ibl_subjectTraining.table.50430d8e-11ab-4c8f-87f0-cad4e5cc2376.pqt2023-12-20T09:08:45.000Z"ad8dcd05791c2f4643c77605e9c7f35f"30757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/hoferlab/SWC_066/_ibl_subjectTrials.table.13fb5acf-5640-4db6-86c1-400e5bd89bfa.pqt2023-12-20T09:08:45.000Z"9fc938c2a686d92f5aff1b1dcaf8a7b7"15399937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01575/_ibl_subjectSessions.table.834efe68-e9c7-4ead-ad5b-4db48816d0ab.pqt2025-02-20T19:37:48.000Z"c89ec18b8ab7f87daedb80512bc959eb"CRC64NVMEFULL_OBJECT86387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01575/_ibl_subjectTrials.table.025722e7-b82d-45d3-8234-d4a8dc80fe4d.pqt2023-12-20T09:08:45.000Z"23693931ea73365d41ed7d95468cc099"37692637d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01576/_ibl_subjectSessions.table.677d3c1e-5413-4cff-98f3-d6b366da47f0.pqt2025-02-20T19:37:48.000Z"51578b77e05162b6534719b7b7612a7e"CRC64NVMEFULL_OBJECT84177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01576/_ibl_subjectTraining.table.01cd3170-c2bb-4972-bb60-132d60d2e6e7.pqt2023-12-20T09:08:45.000Z"86f6568f5dc3fd8fc8d672de7fb10b83"32057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01576/_ibl_subjectTrials.table.c82682cd-4c87-4af8-9fa6-e338112b896c.pqt2023-12-20T09:08:45.000Z"d3f7c814a31ec4debb99a9be944256e8"32958437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01577/_ibl_subjectSessions.table.74d103f4-1557-447e-b16d-f74993f474c7.pqt2025-02-20T19:37:48.000Z"d678f18c38fa0adeda197f9116d657fc"CRC64NVMEFULL_OBJECT74857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01577/_ibl_subjectTraining.table.a66475cd-772a-432e-abe9-ef81f88cadcd.pqt2023-12-20T09:08:45.000Z"0811cf33d66bc06c38d67c08fa41c3d8"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01577/_ibl_subjectTrials.table.41bc1cfc-d294-4ca2-8604-b2df3949e34c.pqt2023-12-20T09:08:45.000Z"c5a4aee8a0011f87cb5676e4d751c12e"20413557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01592/_ibl_subjectSessions.table.bb250050-95df-4caf-9871-5ca8528ab0ef.pqt2025-02-20T19:37:48.000Z"e170b29c23d9bfeadf9db46de7f2b5a6"CRC64NVMEFULL_OBJECT67037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01592/_ibl_subjectTraining.table.a5aac2a0-7627-4ee7-8018-1a7cd3ca7fdf.pqt2023-12-20T09:08:45.000Z"7358b7b62fd8e5d9ea969aeada726e3b"31437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01592/_ibl_subjectTrials.table.06205515-f279-4ddf-a628-d951c419a302.pqt2023-12-20T09:08:45.000Z"3c22f23b5f678c7ba7b9bbd114f86930"14257927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01935/_ibl_subjectSessions.table.a45171c4-71f2-4935-81ae-cf4e1a799b0e.pqt2025-02-20T19:37:48.000Z"d0f68a52ba73b9f818cfdae746ef4f90"CRC64NVMEFULL_OBJECT76557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01935/_ibl_subjectTraining.table.ddb2a896-3114-4ab4-bd16-307b48a4be96.pqt2023-12-20T09:08:45.000Z"8d4262a1c203285df7c9e786d8d50454"32537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01935/_ibl_subjectTrials.table.34c67da3-7326-4515-bf3a-6bbb5e0d6f98.pqt2023-12-20T09:08:45.000Z"ceca69fbff107c468d5f86d94b032fe1"26605377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01936/_ibl_subjectSessions.table.dece879b-ade1-4b51-a83c-7558d31f1904.pqt2025-02-20T19:37:48.000Z"77768e71ba660d0a458df187f67c9f33"CRC64NVMEFULL_OBJECT71747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01936/_ibl_subjectTraining.table.6aa5b0ff-c9b3-4899-a477-026359418853.pqt2023-12-20T09:08:45.000Z"b489004b2babe46edb5c85d0b93978c5"31427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01936/_ibl_subjectTrials.table.f1d15bab-042b-4c71-bd98-2f87ff1471ee.pqt2023-12-20T09:08:45.000Z"e7ca3f85e827fd2df6b9b44e54d1527d"19804837d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01937/_ibl_subjectSessions.table.74aa3616-4a0c-43d9-9d75-16661ef0754d.pqt2025-02-20T19:37:48.000Z"8b1e8cf44ecfa58e02027906c727b326"CRC64NVMEFULL_OBJECT96827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01937/_ibl_subjectTraining.table.5a17a9a6-a859-4074-9685-b4b382c262f5.pqt2023-12-20T09:08:45.000Z"00e3e0c29728cbd955df98017632dd1d"32567d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-01937/_ibl_subjectTrials.table.5a8f3654-2bd4-4200-9afe-39339425fda4.pqt2023-12-20T09:08:45.000Z"05b7fdc9ee8a2ee3d0e94ee76e288408"48347987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02368/_ibl_subjectSessions.table.a895c1df-143a-47f9-be11-222373dc268d.pqt2025-02-20T19:37:48.000Z"9eae228ed7885d9ba7e06053787fd3f1"CRC64NVMEFULL_OBJECT78647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02368/_ibl_subjectTraining.table.64eb3c1e-1d83-4e8a-a6bc-9a1e48f5b1ae.pqt2023-12-20T09:08:45.000Z"e95e3883eb65abf33b007985d2d61c7a"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02368/_ibl_subjectTrials.table.24e71641-4997-41d0-bb6a-7c8b5d5d1630.pqt2023-12-20T09:08:45.000Z"146cde7100290798064c0543df782fcd"29641557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02369/_ibl_subjectSessions.table.d239cc43-12ba-4382-84b0-701a412cadf2.pqt2025-02-20T19:37:48.000Z"2017562ad9e3a1ed5c3d2c68e98b463d"CRC64NVMEFULL_OBJECT75127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02369/_ibl_subjectTraining.table.87d919b5-e33f-496d-8a41-87db61a77ab3.pqt2023-12-20T09:08:45.000Z"6e33e0f5b523f4979f6652aece136510"32537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02369/_ibl_subjectTrials.table.01162bca-42c2-4ce3-8a68-2c20dca56282.pqt2023-12-20T09:08:45.000Z"baca50351e3bd5a65005205600add2bd"28985237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02370/_ibl_subjectSessions.table.fec91b7b-60bf-4a0f-9ee9-5a93017647a3.pqt2025-02-20T19:37:48.000Z"9de7132caf116bd2656387b9eae9e21d"CRC64NVMEFULL_OBJECT70697d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02370/_ibl_subjectTraining.table.f4eec1f4-5ef9-4d66-84a4-956804254c52.pqt2023-12-20T09:08:45.000Z"2e48cd10e22b60a7ea27dfe0f980b461"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02370/_ibl_subjectTrials.table.4e77c6e4-ea3c-42f9-8a85-b6bdb902d7e9.pqt2023-12-20T09:08:45.000Z"bd10c6057b30d1a0766cf7d9554b42b7"23744117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02372/_ibl_subjectSessions.table.ca3a8298-ffa6-411a-aa32-e26bab21133f.pqt2025-02-20T19:37:49.000Z"4c62b119a4f0fed7471b2dbbe3ef4866"CRC64NVMEFULL_OBJECT79747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02372/_ibl_subjectTraining.table.088f31b0-2dc5-47d6-9bd3-d49f9695dd8d.pqt2023-12-20T09:08:45.000Z"5356cd295e14ad40d7bb02a0b9007ccd"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02372/_ibl_subjectTrials.table.a94312fd-a09a-42bf-9493-4d65db379b86.pqt2023-12-20T09:08:46.000Z"de0464f1d378a37f6e034f3b207aa125"36481857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02373/_ibl_subjectSessions.table.e8029353-7209-49a7-8d2f-743d1bc9e482.pqt2025-02-20T19:37:49.000Z"cbde6b843b193c369dbe47bf84178d7a"CRC64NVMEFULL_OBJECT84797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02373/_ibl_subjectTraining.table.cdc89fd1-c9de-49a9-afa2-16b8f03d5766.pqt2023-12-20T09:08:46.000Z"901f26e8477a3b557637370d2102c55f"31897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-02373/_ibl_subjectTrials.table.338a5522-36b6-48d6-b41e-bf3791638843.pqt2023-12-20T09:08:46.000Z"62cecb813897697e5fefd7c71163bb93"38609137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-04308/_ibl_subjectSessions.table.2435b472-4ec7-4f16-adac-6e7a96c72f3d.pqt2025-02-20T19:37:49.000Z"e06e8888956d88237b42be35775b6624"CRC64NVMEFULL_OBJECT95257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-04308/_ibl_subjectTraining.table.5baac99c-bb4d-4d3b-b685-6c5aca596ed3.pqt2024-02-14T17:07:30.000Z"eb5e326e4281bc08c788c87e707bc196"32097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-04308/_ibl_subjectTrials.table.0bfa8832-8837-4291-9234-f72273f692b1.pqt2024-02-14T17:07:30.000Z"0dfba4dcdc1203e56b5b7aa0e8454d5b"40180127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-05236/_ibl_subjectSessions.table.61799931-2a80-46db-9d6c-cc1436788496.pqt2025-02-20T19:37:49.000Z"161dc363cbdd850f31ba4629091a5f6f"CRC64NVMEFULL_OBJECT89687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-05236/_ibl_subjectTraining.table.6f2bd0ff-1f9b-45f8-8809-5b24dc00c9cd.pqt2023-12-20T09:08:46.000Z"ef6e30493503b1f166d97f6e0be6990f"31307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZFM-05236/_ibl_subjectTrials.table.dd77ce59-4ea3-40c9-bf8a-df85a0715d8a.pqt2024-01-10T11:25:43.000Z"7f2e9c060d999bf8d5186dad38847a59"40299677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1084/_ibl_subjectSessions.table.d6ce40ae-9bce-4721-b265-1c68f847538f.pqt2025-02-20T19:37:49.000Z"232555726855be462944359948767487"CRC64NVMEFULL_OBJECT58277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1084/_ibl_subjectTraining.table.5cd16e7e-826f-426a-b7ef-51b0a71c934b.pqt2024-09-16T15:08:17.000Z"9e5b53f03da2c749e87e345b15a68236"30777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1084/_ibl_subjectTrials.table.cf7c7373-6171-4450-8bce-5eb39da7af3a.pqt2024-09-16T15:08:17.000Z"a250e2a9d162a0412c7a3f5b08b1e6af"5230487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1085/_ibl_subjectSessions.table.ec91df96-9f69-4705-b2d3-03cf522cb902.pqt2025-02-20T19:37:49.000Z"8a66a65182fc71bc68fcf74dab18a939"CRC64NVMEFULL_OBJECT65277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1085/_ibl_subjectTraining.table.74dfb745-a7dc-4672-ace6-b556876c80cb.pqt2024-09-16T15:08:17.000Z"b4be3002936bca9c06d0542caf893af3"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1085/_ibl_subjectTrials.table.7a5e9e11-d700-47a9-8696-3f0dcffb2257.pqt2024-09-16T15:08:17.000Z"600dae4b52685d0df226be1554740362"21726527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1086/_ibl_subjectSessions.table.951167bc-2758-4142-812b-0639a95845af.pqt2025-02-20T19:37:49.000Z"e1641daba423214fd06a76285523c9f4"CRC64NVMEFULL_OBJECT65557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1086/_ibl_subjectTraining.table.facad2dc-990b-4e2d-9f15-8224f324cf63.pqt2024-09-16T15:08:17.000Z"3cb3c115b5719788fc631e9bb414b5e8"30707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1086/_ibl_subjectTrials.table.286cf30f-3ae0-43e2-a933-ca763952cd54.pqt2024-09-16T15:08:17.000Z"3370d35e32c267c33ed33c5cec55330c"22695157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1087/_ibl_subjectSessions.table.5f91e697-d791-455d-a124-feabeaf1480c.pqt2025-02-20T19:37:49.000Z"766070c88f92fbd0904eccedfe2d58e8"CRC64NVMEFULL_OBJECT65147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1087/_ibl_subjectTraining.table.10924f8a-e198-4690-bef1-323de08892ac.pqt2024-09-16T15:08:17.000Z"6aa6ebb98ce0e4f7548b3867844f56a1"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1087/_ibl_subjectTrials.table.f17ba934-461d-48fe-a82f-f671a16501c1.pqt2024-09-16T15:08:17.000Z"e1d67d29253de2aaba7b44e41ea4a6e6"21970947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1089/_ibl_subjectSessions.table.c2c10efd-1bdb-4c4f-a8c2-e48defc18c8a.pqt2025-02-20T19:37:49.000Z"43b1802405a1357fd14453a6893bc69f"CRC64NVMEFULL_OBJECT65037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1089/_ibl_subjectTraining.table.f3e7bfdf-e3dd-4db6-b1c7-da44f988ce6e.pqt2024-09-16T15:08:17.000Z"01bd47f40f6ecb8efe49b65490f63e96"30737d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1089/_ibl_subjectTrials.table.ea860564-c769-41ab-b216-90c0165db520.pqt2024-09-16T15:08:17.000Z"b1e4608e537dc7d6c34ec88d13e0d8de"23689737d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1091/_ibl_subjectSessions.table.38b05980-82b2-4efe-bda5-3a5c2c495e86.pqt2025-02-20T19:37:49.000Z"7546493d37a4c0058ea298efbb0cb2b9"CRC64NVMEFULL_OBJECT65377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1091/_ibl_subjectTraining.table.565c5354-2996-4619-81fb-150a6dc95820.pqt2024-09-16T15:08:17.000Z"3ec0e2f1c822a9bff1b22959b90f5073"30787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1091/_ibl_subjectTrials.table.0b1b9a91-8b3e-472a-bca3-ef2024964583.pqt2024-09-16T15:08:17.000Z"7ad807059bf4b38397a7c1e90cf285e3"21393907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1092/_ibl_subjectSessions.table.284ab9be-bf4c-4956-b923-1c37da1cddb7.pqt2025-02-20T19:37:49.000Z"445d1055db01d743034795031dc60a4b"CRC64NVMEFULL_OBJECT65187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1092/_ibl_subjectTraining.table.d6671d82-c5b9-4775-8bbd-b1f1344673d6.pqt2024-09-16T15:08:17.000Z"6533a205b0245f422ee437fb1160928b"30787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1092/_ibl_subjectTrials.table.24e99b3a-d91b-4c04-822f-c806d3731ee0.pqt2024-09-16T15:08:17.000Z"618b0c1b127d7b7e52dce69c285fdef9"15667677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1093/_ibl_subjectSessions.table.7b7c31d2-e733-4981-973a-6838b3ef0202.pqt2025-02-20T19:37:49.000Z"9e1030554f264fd7a8d637fd3fe9c43e"CRC64NVMEFULL_OBJECT63257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1093/_ibl_subjectTraining.table.348ff4cf-e1d4-4cd6-98e4-ade53f1f55a4.pqt2024-09-16T15:08:17.000Z"024a0845cc869d035d2f66022a7eb032"30727d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1093/_ibl_subjectTrials.table.d9821461-6113-4376-b4ea-661b2e2ffead.pqt2024-09-16T15:08:17.000Z"45d6837ea128754c92ef551b80af4c7a"12783267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1095/_ibl_subjectSessions.table.98cf5346-9cff-43e7-8d4a-1c81e425eac4.pqt2025-02-20T19:37:49.000Z"f982e8d5b8abcb079bac26c2641baa90"CRC64NVMEFULL_OBJECT63347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1095/_ibl_subjectTraining.table.ac9ae035-b65b-4142-86a0-53b5893311ae.pqt2024-09-16T15:08:17.000Z"6cc0d2719e14465a9b4641d360cec21a"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1095/_ibl_subjectTrials.table.9aa388f6-e612-4854-a38e-b7f28b29869f.pqt2024-09-16T15:08:18.000Z"763c0e3141acd3b16667ce736f3b0576"11207467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1097/_ibl_subjectSessions.table.4e2a42e9-fd4c-4b3f-9048-8b62ef0424df.pqt2025-02-20T19:37:49.000Z"f61606673dbaa21f6d74dcc86329d9b8"CRC64NVMEFULL_OBJECT63327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1097/_ibl_subjectTraining.table.9077c99f-23fd-40e8-acd2-9f3c576fb064.pqt2024-09-16T15:08:18.000Z"e2ca8f9a11934c188e36a061b3aef090"31307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1097/_ibl_subjectTrials.table.263b77e8-0300-41b0-bb76-f16a6b789e17.pqt2024-09-16T15:08:18.000Z"18da3b7b2912eff484a2475c2bd76275"13644547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1098/_ibl_subjectSessions.table.9743a975-97bf-4676-864f-71fdab44ceff.pqt2025-02-20T19:37:49.000Z"fa98375e5454da28bd5cb11b88878e22"CRC64NVMEFULL_OBJECT63717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1098/_ibl_subjectTraining.table.e27254e3-3069-46b3-90c8-8ab0572575de.pqt2024-09-16T15:08:18.000Z"f89ab9c92a0460f7287b2c0011b5c26d"31327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1098/_ibl_subjectTrials.table.7cd0ada7-585d-4576-8d2e-394c6f345ab9.pqt2024-09-16T15:08:18.000Z"068c00f2f8206e1c3d8c51dff45ee196"19897237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1367/#2024-07-22#/_ibl_subjectTrials.table.c4ae00a3-619d-4786-b21f-b597226bf217.pqt2024-09-16T15:08:18.000Z"f75d39455010902cdcdda3ec8e318014"47052017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1367/_ibl_subjectSessions.table.c603ca57-1cb4-4c03-a388-d0adf6a0c772.pqt2025-02-20T19:37:49.000Z"6348989b4f93d3b983526ad750687d57"CRC64NVMEFULL_OBJECT77527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1367/_ibl_subjectTraining.table.b5c5bf51-80b7-4966-ab82-8fcd5e1064d4.pqt2024-09-16T15:08:18.000Z"c0b6e3770be5128e377fb94a415b639f"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1367/_ibl_subjectTrials.table.ae1da9e8-b0b0-44de-b38e-53d9addf4f39.pqt2023-12-20T09:08:46.000Z"596f944ee4153fd6cdab0518394cfba2"40901217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1369/#2024-08-21#/_ibl_subjectTrials.table.551050ac-13f8-4d23-ad1c-04f0d9195b44.pqt2024-09-16T15:08:18.000Z"13c60631e04a57d5c8718c39623bf1f9"45487967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1369/_ibl_subjectSessions.table.25138953-a010-4347-954e-bd6f7e38e8f7.pqt2025-02-20T19:37:49.000Z"26437db829896f6bbe1a5701fbd605ef"CRC64NVMEFULL_OBJECT77767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1369/_ibl_subjectTraining.table.7b9f497e-fd01-41e0-ac9c-ea6ab6c48528.pqt2024-09-16T15:08:18.000Z"c01081a02138926fa26b15f879449bcd"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1369/_ibl_subjectTrials.table.4e8968cf-9894-42e6-b82d-76e3f05f2fd6.pqt2023-12-20T09:08:46.000Z"1919a8b61f9072830e4ee3569146ef2c"40428747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1371/#2024-07-22#/_ibl_subjectTrials.table.e46341ae-8b8e-4fca-aa03-96116c2929b7.pqt2024-09-16T15:08:18.000Z"35c67f9689e4b9dbd39359b095102c1f"42451137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1371/_ibl_subjectSessions.table.33c56657-b1a1-431e-8171-002d83d4584d.pqt2025-02-20T19:37:49.000Z"0a1c315880219ab5391f5b2adee6057e"CRC64NVMEFULL_OBJECT77777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1371/_ibl_subjectTraining.table.b5aafe22-3b6a-4450-90b6-95bb0bee88cf.pqt2024-09-16T15:08:18.000Z"6c000a8acdc79ae23eab0829aee2af3b"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1371/_ibl_subjectTrials.table.94ba3a63-aaa6-4b59-8d6f-76e700ee613c.pqt2023-12-20T09:08:46.000Z"420b55469d40920db93cda9cc5d8a150"40344707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1372/#2024-08-21#/_ibl_subjectTrials.table.67f98b35-97ba-410e-ba12-9549aad056f3.pqt2024-09-16T15:08:18.000Z"7711df6829aa9555dcc0a340ffe69504"51827477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1372/_ibl_subjectSessions.table.553e03e6-fef1-4455-850f-8dca95d2356a.pqt2025-02-20T19:37:49.000Z"9e35f11cee77242de105360173077847"CRC64NVMEFULL_OBJECT78867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1372/_ibl_subjectTraining.table.55bdb466-4d37-42a7-bf81-02dd0797ba14.pqt2024-09-16T15:08:18.000Z"3e79996e2665012cbbf3fc605dcdaef9"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1372/_ibl_subjectTrials.table.e17bbaa5-9e59-4d7b-a496-65ef20f8365d.pqt2023-12-20T09:08:46.000Z"525aea79f2fa0d7ea2ed3f5476b422da"46853947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1373/_ibl_subjectSessions.table.b0c9dec5-a57d-4ae8-956e-6ce5ecf59960.pqt2025-02-20T19:37:49.000Z"c27a3aceac79bbdcc905de8aa1411ee9"CRC64NVMEFULL_OBJECT61187d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1373/_ibl_subjectTraining.table.027f9d8e-38a7-4fd3-95ca-db13ba379512.pqt2024-09-16T15:08:18.000Z"885738659a4fbf3d7694adc73f731dce"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1373/_ibl_subjectTrials.table.47abaa92-8fea-48ef-a051-50fb61ac0645.pqt2024-09-16T15:08:18.000Z"d81de81df3178dae02127090eca8bc9f"9683557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1743/#2024-08-21#/_ibl_subjectTrials.table.c0785f6b-fec0-4ab3-a12c-e3d07b6c1393.pqt2024-09-16T15:08:18.000Z"3ac0804a6e8c2e1f14ff62aa3e57d794"67260387d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1743/_ibl_subjectSessions.table.cbe2ea72-7ff9-4be1-b7d5-d0203f67520b.pqt2025-02-20T19:37:50.000Z"3561a3e46236db60f5772503206fe5a1"CRC64NVMEFULL_OBJECT91507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1743/_ibl_subjectTraining.table.19de9c2d-8430-4217-b26a-97684a394bcb.pqt2024-09-16T15:08:18.000Z"9be09ffa461188d25cfb96ce461af82b"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1743/_ibl_subjectTrials.table.0adc5cc8-634a-4a08-87a3-f1c4b6be8d6c.pqt2023-12-20T09:08:46.000Z"5134665b3d0db6741a2ffe448b19f205"42402787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1745/#2024-08-21#/_ibl_subjectTrials.table.48b7917a-6c93-4d72-8a24-1ce69aa288e2.pqt2024-09-16T15:08:18.000Z"79d06c49154311d06ca95dd349ba1ac0"78667457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1745/_ibl_subjectSessions.table.c621d8f8-da4c-44a8-a8b3-fdafee11bf21.pqt2025-02-20T19:37:50.000Z"e28743fe2a4bc9bbd477403e155c78b1"CRC64NVMEFULL_OBJECT89157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1745/_ibl_subjectTraining.table.28af9159-dc5c-45f9-acb8-c55a5fa976b1.pqt2024-09-16T15:08:18.000Z"22a38863ae66619f9ee714dbbdb30365"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1745/_ibl_subjectTrials.table.f69a1a11-f1a5-4ffe-b1e7-caacf9ddc69d.pqt2023-12-20T09:08:46.000Z"6bb5aa274be8c5812b9fa65c8b534e27"48076487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1746/#2024-04-16#/_ibl_subjectTrials.table.5b2c9f15-c596-40ad-9d8c-c02a6f16e917.pqt2024-09-16T15:08:18.000Z"4d316ef6694669c213d07a4f8db61023"48498827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1746/_ibl_subjectSessions.table.b2bda8ea-c39e-42a6-ad45-db9962f17e78.pqt2025-02-20T19:37:50.000Z"ae5a98f698c61281ede3ff2a6d18b9a4"CRC64NVMEFULL_OBJECT78267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1746/_ibl_subjectTraining.table.27cc5067-c263-465c-a3ff-95b539f15195.pqt2024-09-16T15:08:18.000Z"36e211f3eb258a4ff9fdd7abc83d68e1"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1746/_ibl_subjectTrials.table.070f3b77-3060-468a-86fd-e8edd289c0fb.pqt2023-12-20T09:08:46.000Z"147d69c49f0bedc598813ff08e43bb55"30763377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1897/#2024-08-21#/_ibl_subjectTraining.table.bdef5db3-2e4d-4ecc-ba97-16593b556620.pqt2024-09-16T15:08:18.000Z"58871b06815bf6ab0bdd08384899b24c"32437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1897/#2024-08-21#/_ibl_subjectTrials.table.0809c543-42e0-419a-bb3b-16200bedb72c.pqt2024-09-16T15:08:18.000Z"1f59660725fe0dd461a9f82f36eae590"45104687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1897/_ibl_subjectSessions.table.b2dad5c9-cf3b-4854-be37-40c4f5641268.pqt2025-02-20T19:37:50.000Z"fab4acfd4f6736c5e27d96793f3dea28"CRC64NVMEFULL_OBJECT74277d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1897/_ibl_subjectTraining.table.e356c9c5-c90e-492e-9be4-ad15a7e72cb9.pqt2023-12-20T09:08:46.000Z"80937b4c7480418b6b7d811e668506bb"32437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1897/_ibl_subjectTrials.table.1e58c6a9-f655-400d-bfa6-5c765279cc31.pqt2023-12-20T09:08:46.000Z"4c39181f264bd6bfc35c975512f9bab3"27049057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1898/#2024-08-21#/_ibl_subjectTraining.table.fc9661b3-3713-46b8-8333-bb7b19fca764.pqt2024-09-16T15:08:18.000Z"365716378998994f9668e0747c197088"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1898/#2024-08-21#/_ibl_subjectTrials.table.aff76507-4110-4fc7-8681-2aa1520f3438.pqt2024-09-16T15:08:19.000Z"e5cd2d2f6ef52e4d5f939f3327f4d394"72873427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1898/_ibl_subjectSessions.table.6773281a-2e31-41cd-adfd-2c110640bd0d.pqt2025-02-20T19:37:50.000Z"2ff99619d936d50dfea81ecb77b44929"CRC64NVMEFULL_OBJECT76947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1898/_ibl_subjectTraining.table.91c3da0e-4a15-4c22-81f4-0b5cc929ed7b.pqt2023-12-20T09:08:46.000Z"3a0fcbb20cb2d9c4ba8f46ddeb322a6e"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1898/_ibl_subjectTrials.table.ebe7390c-aa47-4639-b508-4e42d83d4c44.pqt2023-12-20T09:08:46.000Z"a4d4d6c2397a71de8c10e9b9a6a09f64"43949687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1928/#2024-08-21#/_ibl_subjectTrials.table.6954f4c6-3f55-456d-9872-2ac2c785f391.pqt2024-09-16T15:08:19.000Z"bd7bd57f4c93c0334449eb3e6fa4f3d4"51518637d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1928/_ibl_subjectSessions.table.0822207b-1ae3-4656-b3f5-a7b0aec1994c.pqt2025-02-20T19:37:50.000Z"4d7e8dfdb02b6d92544ec3508a40636e"CRC64NVMEFULL_OBJECT76167d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1928/_ibl_subjectTraining.table.98e90bac-951a-469b-8936-75d6775dc03e.pqt2024-09-16T15:08:19.000Z"7c6df71a774feb0033b99be69f852a34"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_1928/_ibl_subjectTrials.table.da1c8772-91b6-4363-ae56-0a16030f3186.pqt2023-12-20T09:08:46.000Z"e7235ebb7f1d25420b74127b17b27d5b"31654007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2106/#2024-08-21#/_ibl_subjectTrials.table.b032d4a3-9744-4608-a507-e59230fc02ff.pqt2024-09-16T15:08:19.000Z"830bbbed7af128418b8fc8d295c5292d"43126937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2106/_ibl_subjectSessions.table.c9a59718-6690-44cf-a2b8-2e6c6de7fb5c.pqt2025-02-20T19:37:50.000Z"dfd0c9d9ac5626bc8a57fc65b9adefee"CRC64NVMEFULL_OBJECT70697d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2106/_ibl_subjectTraining.table.ffd675c0-b753-44d4-a50f-38b0b19af280.pqt2024-09-16T15:08:19.000Z"0ccf8e1773f9de5a6f361d45d1b8d209"30087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2106/_ibl_subjectTrials.table.56f6fecd-a8b9-4220-9691-8e9808e36b62.pqt2023-12-20T09:08:46.000Z"c7d80fb1b1431efe070f06341a973cd4"25231577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2107/#2024-08-21#/_ibl_subjectTrials.table.f59fb1ce-e3d8-4492-ab67-f25e97bc0b31.pqt2024-09-16T15:08:19.000Z"a46f410816a3f6c8cb05d6d1ab900b17"57154097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2107/_ibl_subjectSessions.table.dc348016-9366-4cb3-86ec-dafcdec09feb.pqt2025-02-20T19:37:50.000Z"58cb2a089f3262f985cfd571fc5ab8a3"CRC64NVMEFULL_OBJECT73287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2107/_ibl_subjectTraining.table.e16e5a96-c821-4ef9-8380-f50c8e42e555.pqt2024-09-16T15:08:19.000Z"e0cc637d8e82c4e67c1c50616d4b8a43"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2107/_ibl_subjectTrials.table.7f9e1bb2-e3c8-41d5-a68d-2bc0d7b634d4.pqt2023-12-20T09:08:46.000Z"fd93e0448c15b6fe828ed374bcc8a3e6"33922607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2240/#2024-08-21#/_ibl_subjectTraining.table.bc1fbf13-0207-4316-b489-21733cd0d39f.pqt2024-09-16T15:08:19.000Z"b3bb9062d94bab97accde6f18568218f"32477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2240/#2024-08-21#/_ibl_subjectTrials.table.10af527c-063d-4111-9ad6-113c917e867c.pqt2024-09-16T15:08:19.000Z"06ab18b258d3995a158198cabbbc5fa5"43212217d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2240/_ibl_subjectSessions.table.a8e7676a-4f0f-4d12-80c1-957d0e020794.pqt2025-02-20T19:37:50.000Z"99c96af0267d5f657f3939746f21bdc4"CRC64NVMEFULL_OBJECT71867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2240/_ibl_subjectTraining.table.a2e40e92-f38b-463c-afe4-8b4a8592d620.pqt2023-12-20T09:08:46.000Z"ad7379213d2ddaea6964da472379786a"32477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2240/_ibl_subjectTrials.table.2eb628fd-a5be-432f-b0bb-008de096b175.pqt2023-12-20T09:08:46.000Z"cf8334905095d74006ba795e4d66ece7"25015547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2241/#2024-08-21#/_ibl_subjectTraining.table.ea88ff6a-f9de-4eb5-b149-dd8558df0880.pqt2024-09-16T15:08:19.000Z"c9044d6ca75e5f41e83f742addc07279"32057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2241/#2024-08-21#/_ibl_subjectTrials.table.048be553-a615-4fe5-a856-5d4ed4d660cc.pqt2024-09-16T15:08:19.000Z"51551255a6990376bee22d21a61ef26e"59111157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2241/_ibl_subjectSessions.table.b0ad2f48-7a33-478d-9e24-2905761d5a3d.pqt2025-02-20T19:37:50.000Z"0936e536c87dc059a7a13feeaef56ef8"CRC64NVMEFULL_OBJECT75177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2241/_ibl_subjectTraining.table.263f7c3e-6fd9-4efb-9895-39821e7e8555.pqt2023-12-20T09:08:46.000Z"e6073c0f8d4526f79b13e04344e19f83"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2241/_ibl_subjectTrials.table.3d4edad0-4a19-439e-9c01-f7992c4a2eb5.pqt2023-12-20T09:08:47.000Z"474713916691d0e6dc1a1a4c73726b57"33912887d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2245/#2024-08-21#/_ibl_subjectTraining.table.36271ec7-518d-4737-a9cd-d13d6095e1ef.pqt2024-09-16T15:08:19.000Z"a47175621bb80dc935a487e3028c0cd5"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2245/#2024-08-21#/_ibl_subjectTrials.table.87a3165e-ca94-4038-9266-0f9459db3db0.pqt2024-09-16T15:08:19.000Z"1a498d773541c8592d6074a44f7fabd0"43659947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2245/_ibl_subjectSessions.table.14faa66b-c99b-4b12-87d9-f319d56b5557.pqt2025-02-20T19:37:50.000Z"e693ecd935d71e8c85b94463e31d8cf5"CRC64NVMEFULL_OBJECT70527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2245/_ibl_subjectTraining.table.9deeeb35-f8b9-48c0-9657-191717323909.pqt2023-12-20T09:08:47.000Z"ad88cf43c36fb86bbde8e2d5275ea7c0"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_2245/_ibl_subjectTrials.table.e07e085c-deed-4886-9ac9-d4cce9fe1828.pqt2023-12-20T09:08:47.000Z"da52042d0cefbd282f4401979620b673"26461067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3001/#2024-08-21#/_ibl_subjectTrials.table.9aae4f83-a78c-483a-b1ee-10713de32558.pqt2024-09-16T15:08:19.000Z"f64803df7073638f90aa14d246255449"32050707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3001/_ibl_subjectSessions.table.cb4f9fa2-c39b-4c56-88a1-245ef1cb2898.pqt2025-02-20T19:37:50.000Z"eb0e1dcfda918063f3747c858c5a1471"CRC64NVMEFULL_OBJECT73777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3001/_ibl_subjectTraining.table.821a6010-d2fc-46f7-9b1b-1f80e8bcfea8.pqt2024-09-16T15:08:19.000Z"06e4f81345c94dc87ba8cb6c8f3fbe2f"31957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3001/_ibl_subjectTrials.table.b722a123-b76c-436c-9fdb-e5af45f19db1.pqt2023-12-20T09:08:47.000Z"d2d55c28c3f9fb6a8994f0afa62dbf96"18592987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3002/#2024-08-21#/_ibl_subjectTrials.table.fc26fc6b-503d-4e10-800c-b8e5bc158366.pqt2024-09-16T15:08:19.000Z"b2f900c2094ff2cf5d5c0eafa57d0fd7"46282307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3002/_ibl_subjectSessions.table.4a5c4157-57f8-4aca-9b38-b6276f247498.pqt2025-02-20T19:37:50.000Z"4f65a345fcc31f8f3ebaecc274b1439e"CRC64NVMEFULL_OBJECT74657d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3002/_ibl_subjectTraining.table.10dcfdbf-b5b7-4fc1-9f7d-ec5fbf19d150.pqt2024-09-16T15:08:19.000Z"427995b3db8f24cad46574bbe3660802"30707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3002/_ibl_subjectTrials.table.e25ba0dc-f4e1-4079-9115-a430ff74082c.pqt2023-12-20T09:08:47.000Z"14f20aa392cb06404bcf93460bc79a7d"27777287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3003/#2024-07-22#/_ibl_subjectTrials.table.5f4ae9ab-8dab-4dd1-b03b-1d7f363b93d2.pqt2024-09-16T15:08:19.000Z"4b82161b099b2cd9e9b00e13781f9e59"39334937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3003/#2024-08-21#/_ibl_subjectTraining.table.d618a7cd-dfa3-49b1-b8f8-f5a84b20e8ea.pqt2024-09-16T15:08:19.000Z"1eea2417bff1351ccce329f45441a016"31827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3003/_ibl_subjectSessions.table.59be6688-157a-4be6-bfbc-3d962a9ba9d6.pqt2025-02-20T19:37:50.000Z"e62ed4165a22e5363d5719643e468bf2"CRC64NVMEFULL_OBJECT74087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3003/_ibl_subjectTraining.table.2a972594-673b-4de1-b132-0e2a0273dee6.pqt2023-12-20T09:08:47.000Z"b5c7b28a5415ef17512a3229696c4d4c"31777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3003/_ibl_subjectTrials.table.3cb005b0-7e59-48eb-8a77-246810a269a3.pqt2023-12-20T09:08:47.000Z"447ac2a391dc902b10af0a785e8c2931"23811037d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3004/#2024-08-21#/_ibl_subjectTrials.table.cecab8b1-3c3c-42d4-81ba-82117fc931b3.pqt2024-09-16T15:08:19.000Z"ea21208a03a2ab874c01803d81aad8a0"50340707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3004/_ibl_subjectSessions.table.17e43f48-6754-4147-89da-33c7d01bd1ab.pqt2025-02-20T19:37:51.000Z"41d9cbef4b76ca6086be360470ba172c"CRC64NVMEFULL_OBJECT78677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3004/_ibl_subjectTraining.table.78b16d33-c8e5-4748-b295-2aec72ec1e69.pqt2024-09-16T15:08:19.000Z"4471c8746c4784d503e3d8ab0a5b0fbb"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3004/_ibl_subjectTrials.table.e5790c87-90ac-42d2-8d0c-08c4ab8f5374.pqt2023-12-20T09:08:47.000Z"b84c2123034248fe2a8f42e232304986"28602937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3005/_ibl_subjectSessions.table.eeb0202b-1d7b-4f36-bd2d-30cd9593e06f.pqt2025-02-20T19:37:51.000Z"685b7882fcb71fe593ac9ba679e7f1b7"CRC64NVMEFULL_OBJECT62407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3005/_ibl_subjectTrials.table.8804173e-984c-4ed8-917c-2310079f13ec.pqt2023-12-20T09:08:47.000Z"3b81b54fc057855ab6664dcc420d0ac6"10023297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3006/#2024-08-21#/_ibl_subjectTrials.table.3fcaa25c-8f59-45d9-b9f5-f1b6922e6ea4.pqt2024-09-16T15:08:19.000Z"ca0fadf46ea4d7895489d5184f83cd94"22384307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3006/_ibl_subjectSessions.table.f96864b2-cc23-4052-9c4e-2d86a8d1b893.pqt2025-02-20T19:37:51.000Z"affe3ee300a28d9cc3f81eb943306fd3"CRC64NVMEFULL_OBJECT67477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3006/_ibl_subjectTraining.table.5cff72ad-3e31-4f1c-a692-359cb70575af.pqt2024-09-16T15:08:19.000Z"1094fb7a6bfae7327ba76a60d3333150"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mainenlab/ZM_3006/_ibl_subjectTrials.table.5d76a7e3-bb14-48a9-b858-c109af3b53bd.pqt2023-12-20T09:08:47.000Z"6c057a3559cb32bf80eeda0934418b8f"13080407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_001/#2024-07-22#/_ibl_subjectTrials.table.9576bb89-e6e0-4d04-a984-bac222c9c654.pqt2024-09-16T15:08:20.000Z"ea75014e9b4a666912989a357f81836f"45314497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_001/_ibl_subjectSessions.table.fecae2fb-217f-4c98-9e3f-b4556f71d06c.pqt2025-02-20T19:37:51.000Z"21650feb309e2278904c5eef4e31c8b7"CRC64NVMEFULL_OBJECT80767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_001/_ibl_subjectTraining.table.e2df748f-c14d-4ad6-bdc9-9aba60bd26a9.pqt2024-09-16T15:08:19.000Z"c2784c3f8f11ed91fa1911775e4507d7"31357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_001/_ibl_subjectTrials.table.4e64e1df-bb0f-4f65-97b3-75f0f2cd5562.pqt2023-12-20T09:08:47.000Z"999d05d2042f4c707b48fa0173ce6685"31727677d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_002/#2024-08-21#/_ibl_subjectTrials.table.7b69dca7-c312-44c8-9f96-9719681acb63.pqt2024-09-16T15:08:20.000Z"9ed2d282adcd5c941c646c0424ee52d7"46660917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_002/_ibl_subjectSessions.table.9ac5f6f9-78b4-44a5-afe6-a2379ed6062c.pqt2025-02-20T19:37:51.000Z"4de67d37e62e0da023a8f33f3d0b6bbc"CRC64NVMEFULL_OBJECT79687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_002/_ibl_subjectTraining.table.c60e25f8-2234-472f-a9a0-2e7cc6cbca46.pqt2024-09-16T15:08:20.000Z"13ece10ed02fff53e9a9ed82f5c8b987"30797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_002/_ibl_subjectTrials.table.de7408a7-7ea7-4c72-8daa-e4e9957c5e51.pqt2023-12-20T09:08:47.000Z"c8624dd6457d383254389cccb448b5ff"33844087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_005/_ibl_subjectSessions.table.b2ad30b9-2f42-4e41-ae35-ea636d4f007e.pqt2025-02-20T19:37:51.000Z"a2eddbd1f28ce9be649396cd163192a3"CRC64NVMEFULL_OBJECT66117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/IBL_005/_ibl_subjectTrials.table.7bdb08d6-b166-43d8-8981-816cf616d291.pqt2023-12-20T09:08:47.000Z"b06dffbaf3332e9ee8efc70f2171d995"6016897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_004/_ibl_subjectSessions.table.0165cc05-cf20-462f-9205-a5910bc77fd3.pqt2025-02-20T19:37:51.000Z"789b49b4d5c3703b90c9c8df6dea2a6b"CRC64NVMEFULL_OBJECT65167d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_004/_ibl_subjectTrials.table.39a0b016-11c4-4ed9-be21-c5293fcceecc.pqt2023-12-20T09:08:47.000Z"30b657d4def8ed38d7534cd208f68f8a"5360867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_016/_ibl_subjectSessions.table.5fc7949b-bf00-459f-a60c-0c7c45ba281d.pqt2025-02-20T19:37:51.000Z"437135ea10ae3c90dbb69d838ec5882b"CRC64NVMEFULL_OBJECT69957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_016/_ibl_subjectTrials.table.ba616210-5d34-4c14-ba97-7de159f832b8.pqt2023-12-20T09:08:47.000Z"b7b04d681bc0a7f4a099b0ac53e9d72e"8761437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_017/#2024-08-21#/_ibl_subjectTrials.table.375fd7a1-a3be-4f29-b7a7-eedefae8b8e4.pqt2024-09-16T15:08:20.000Z"75af89e6a96ff19022155b97c07e6ec7"54502587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_017/_ibl_subjectSessions.table.9e1d4c84-89c0-46ef-a4d4-6b6e780b8131.pqt2025-02-20T19:37:51.000Z"65ef0a0c1f496a58ef96dcf4b484bf13"CRC64NVMEFULL_OBJECT95177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_017/_ibl_subjectTraining.table.46b1a47d-5e76-427a-82c7-f043347eff0f.pqt2024-09-16T15:08:20.000Z"1d259c49883705ae4d848d83ea913048"32597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_017/_ibl_subjectTrials.table.665e3e7e-f57e-4451-a44b-107b18c423a0.pqt2023-12-20T09:08:47.000Z"de8f4ddae5f4d11caafb1a6d9be86f74"19976587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_018/#2024-08-21#/_ibl_subjectTrials.table.68ae6608-6240-4388-8026-0a9da3ac800a.pqt2024-09-16T15:08:20.000Z"2b1099394dcfdaf9b5a26da729f6afdb"56957117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_018/_ibl_subjectSessions.table.ff8203c8-e0aa-49fc-ae1e-cbd1aed8938e.pqt2025-02-20T19:37:51.000Z"8d615574688f298163a36dc022e52c61"CRC64NVMEFULL_OBJECT94427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_018/_ibl_subjectTraining.table.d315f401-4f60-4bc4-86fc-cfe2aa464bbb.pqt2024-09-16T15:08:20.000Z"8a9a2bce5e19c8a1ad688bd6e75cb8cf"32057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_018/_ibl_subjectTrials.table.2ffe3503-6177-42d4-94a0-ca943369388d.pqt2023-12-20T09:08:47.000Z"32542948ae70711b9f29617da0f1fe18"25058697d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_022/#2024-08-21#/_ibl_subjectTraining.table.8f181013-33ce-4f65-899e-93acd17f0cbf.pqt2024-09-16T15:08:20.000Z"5884b8d09bbd8150268496a4e765a79c"31347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_022/#2024-08-21#/_ibl_subjectTrials.table.0fbfaf5c-a917-405b-b301-70b3272e989c.pqt2024-09-16T15:08:20.000Z"ead2990d97dfd2a62764bd7293335b00"53119777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_022/_ibl_subjectSessions.table.ec29a682-1b66-4999-9610-c824dfc87163.pqt2025-02-20T19:37:51.000Z"4cc5912793fb341aea32968c6abcff7c"CRC64NVMEFULL_OBJECT75497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_022/_ibl_subjectTraining.table.b68f4dbd-6730-47c6-a9a6-e980033f7608.pqt2023-12-20T09:08:47.000Z"6ceca9b7af4f7e847dad8957e196c431"30737d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_022/_ibl_subjectTrials.table.58a9dfbc-d9d9-46b9-a68e-9c7fc4fb6bad.pqt2023-12-20T09:08:48.000Z"17ff51fb39732569768164ce31de85a1"15632817d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_023/#2024-04-11#/_ibl_subjectTrials.table.25887f36-7238-4e76-a03f-e42c4d2d1862.pqt2024-09-16T15:08:20.000Z"e7369e15156db3db28f27214dd509e25"81638857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_023/#2024-08-21#/_ibl_subjectTraining.table.f87c66f1-4ad2-4fc7-b8a6-93dcdd8d6a96.pqt2024-09-16T15:08:20.000Z"c81ad7644860422b7e6763978583592a"32007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_023/_ibl_subjectSessions.table.dde22956-d9c9-4ebe-b857-d7cc4563436d.pqt2025-02-20T19:37:51.000Z"375eefeedac947d6892910451d52e537"CRC64NVMEFULL_OBJECT84667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_023/_ibl_subjectTraining.table.6c47ef3d-81cb-4619-b238-e6f757bc3db3.pqt2023-12-20T09:08:47.000Z"5b27435e4d38761eae652f3e2fa1d07f"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_023/_ibl_subjectTrials.table.5177b098-2306-4024-ab5a-2c2daa13de6c.pqt2023-12-20T09:08:48.000Z"0df868013ed333e8f2a1836c59086a2e"39664227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_029/#2024-08-21#/_ibl_subjectTrials.table.da1424c9-5a61-4a72-ab48-9e9a462d47ec.pqt2024-09-16T15:08:20.000Z"497ca623223f021d932bae3f350a1648-2"151094877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_029/_ibl_subjectSessions.table.cf1ce044-f12d-4d6d-8c5a-bc355670311f.pqt2025-02-20T19:37:51.000Z"60acadc85c059a4f758e015888586abf"CRC64NVMEFULL_OBJECT120907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_029/_ibl_subjectTraining.table.d48e886c-b046-42a2-8dfc-a05faabeb923.pqt2024-09-16T15:08:20.000Z"8b019a4afc3d463de70f3c6e8cd02717"32617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_029/_ibl_subjectTrials.table.1445394c-233d-46fb-8810-37a59ad3bb98.pqt2023-12-20T09:08:48.000Z"ee9694ebe503ffc0fe132ed1b08a970c"77015867d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_030/#2024-08-21#/_ibl_subjectTrials.table.6c74854f-bda8-4d0d-ae29-9d68c313925c.pqt2024-09-16T15:08:20.000Z"781408a7fa74bcb03175430b65712d35-3"168756427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_030/_ibl_subjectSessions.table.52dd18ad-31c1-46c5-92d3-8cfedb54699d.pqt2025-02-20T19:37:51.000Z"f7df15db6d46a229973e11f80243f6d4"CRC64NVMEFULL_OBJECT127417d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_030/_ibl_subjectTraining.table.80d34edc-df98-4bf1-a666-3957778eaecf.pqt2024-09-16T15:08:20.000Z"2a0d681f2bc8705cad76b391aea73861"32627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_030/_ibl_subjectTrials.table.0fbd8e4d-1d0f-4542-9022-191d7b35d8d2.pqt2023-12-20T09:08:48.000Z"9417090a7af7b8cca8cad3842da067ae-2"87578997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_035/_ibl_subjectSessions.table.f7553538-e4cf-4081-ac2b-19ed40c92a53.pqt2025-02-20T19:37:51.000Z"23296a6b3130cec2f23dc691aad2d660"CRC64NVMEFULL_OBJECT74287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_035/_ibl_subjectTrials.table.1ca423c7-7a54-48a7-98ad-7d3ef63b3342.pqt2023-12-20T09:08:48.000Z"f8ebf401df92d3a529b240381cfada1a"24603507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_036/_ibl_subjectSessions.table.351e8475-55c6-4c9a-9505-592a6d8cd60c.pqt2025-02-20T19:37:51.000Z"4dead7a237d6d860f1e425a36840c588"CRC64NVMEFULL_OBJECT103617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_036/_ibl_subjectTrials.table.898ca67c-1606-4f8a-abe1-9e5fdaddf2c1.pqt2023-12-20T09:08:48.000Z"253790ee4c8b92bccccfba362e81f648"58732107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_038/#2024-04-11#/_ibl_subjectTrials.table.aea82858-b8dc-44be-a2f6-6cd4fc857df8.pqt2024-09-16T15:08:21.000Z"77d44a02d442ed69a1529bfe81bd00e5"73213257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_038/#2024-08-21#/_ibl_subjectTraining.table.611d9aa9-6d5b-4c87-be23-656271cb32d8.pqt2024-09-16T15:08:21.000Z"8231296e3a736a95bc979b61f3e9b66a"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_038/_ibl_subjectSessions.table.b3716f28-8a7f-4dc4-a486-c4ccd1e6e61f.pqt2025-02-20T19:37:52.000Z"f07726219fb10e941bed680291057b61"CRC64NVMEFULL_OBJECT86027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_038/_ibl_subjectTraining.table.29e57b93-b001-4251-ab18-bd4061fe2882.pqt2023-12-20T09:08:48.000Z"878bfd1b1d412ed645335a6dcc7c182d"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_038/_ibl_subjectTrials.table.83277e3c-54eb-4abd-bbba-42d8cdd7df92.pqt2023-12-20T09:08:48.000Z"3696e91bde14acd66860449fdf1a382b"36566707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_039/#2024-04-11#/_ibl_subjectTrials.table.ac3ab6ce-a8cd-4d71-8600-b3eb1ef03882.pqt2024-09-16T15:08:21.000Z"f71777d98eb610edbac806e238cda8c0"80312877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_039/#2024-08-21#/_ibl_subjectTraining.table.545e28a2-0015-430b-ac8a-8483dc07037c.pqt2024-09-16T15:08:21.000Z"517dabc102bb23afeaa649f130a592b9"31237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_039/_ibl_subjectSessions.table.fafac56a-492b-4a9c-9bf1-f977d1a2dcb5.pqt2025-02-20T19:37:52.000Z"b639f2e5d10c3e5b3d129eeace9b7bf0"CRC64NVMEFULL_OBJECT93117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_039/_ibl_subjectTraining.table.72c008db-055e-4ddc-81cd-497ad492e829.pqt2023-12-20T09:08:48.000Z"04da32fcf171745606eec799c437f241"31247d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_039/_ibl_subjectTrials.table.64af3217-7e29-46b9-9462-096b85958d0a.pqt2023-12-20T09:08:48.000Z"5da0bf32be0da0e120d742ee141530c8"42133457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_040/_ibl_subjectSessions.table.475f5247-2a9d-4a3d-a5ec-6bba56a64adf.pqt2025-02-20T19:37:52.000Z"32143ff3da3b6b1e6af2d41e50843446"CRC64NVMEFULL_OBJECT99827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_040/_ibl_subjectTrials.table.cf50c8a1-aedf-420d-8fb4-c3ac6d621017.pqt2023-12-20T09:08:48.000Z"a7e9ff93e22b22f498a6f06928431be0"49236307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_052/_ibl_subjectSessions.table.4e3f4ad8-fcf6-484d-be51-a623aa58df2a.pqt2025-02-20T19:37:52.000Z"98ac0c42aac7e7170c7ec433be79c8a7"CRC64NVMEFULL_OBJECT83777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_052/_ibl_subjectTraining.table.dff09fb2-3d7b-44ee-b39c-aef9765d748e.pqt2024-02-14T17:07:31.000Z"f9fc10bc0d08fe6f7f6d1949bd6bef97"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_052/_ibl_subjectTrials.table.5e8bc752-6891-478b-ae75-040cb8dea55b.pqt2024-02-14T17:07:31.000Z"10956c7c437c899ad415137c48a6c3c3"41072317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_053/_ibl_subjectSessions.table.80eb9db3-f0f9-41c1-9926-75909e91d111.pqt2025-02-20T19:37:52.000Z"e3b6c1118a2f76b6f3a518e38566029b"CRC64NVMEFULL_OBJECT90517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_053/_ibl_subjectTraining.table.af994f2b-7e20-4852-a45b-e25e0465ba70.pqt2024-02-14T17:07:31.000Z"73b4a6e9be05e7693b78e3e57ddcbeb0"31307d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_053/_ibl_subjectTrials.table.0b899116-ea30-4481-a5e6-9af64bccd2ae.pqt2024-02-14T17:07:31.000Z"9a320f6b35ac445ca4037f0b41e362a0"48054067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_054/_ibl_subjectSessions.table.44f69cac-8eac-42c5-b3b4-acdc65fdce39.pqt2025-02-20T19:37:52.000Z"b5bac9fd0da80f624372e49f60eae0f7"CRC64NVMEFULL_OBJECT78767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_054/_ibl_subjectTraining.table.ff05f5f9-c970-4987-9bd5-de4a58d96b08.pqt2023-12-20T09:08:48.000Z"646742a2d11ba6f0123463f03fce5861"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_054/_ibl_subjectTrials.table.4d8163e9-6f87-4d51-80b1-d4ddce0b48c7.pqt2023-12-20T09:08:48.000Z"11d25e85e16f48abf25f152255b538b6"28496197d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_058/_ibl_subjectSessions.table.730cf9e4-9c12-4d7d-8840-265e7041b7aa.pqt2025-02-20T19:37:52.000Z"3898629a35c9e32701e7481f3f5c8e27"CRC64NVMEFULL_OBJECT72327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_058/_ibl_subjectTraining.table.b330a1f6-5e30-452f-8864-847456c22587.pqt2023-12-20T09:08:48.000Z"b31d94ad3e73825e17a5328ecb67314d"30747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_058/_ibl_subjectTrials.table.21db4fea-fb26-40c1-b07e-7ef88f9654d9.pqt2023-12-20T09:08:48.000Z"00ee72747811e28f2307b07c7dae70eb"26691587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_065/_ibl_subjectSessions.table.d11f0ec5-2651-4ff9-9fde-dd30fd4e61f3.pqt2025-02-20T19:37:52.000Z"709b9ea3a65f42d5a8df289103f0e9b7"CRC64NVMEFULL_OBJECT72087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_065/_ibl_subjectTraining.table.b5f776ba-85bf-4f1e-b31c-42a501f4bd7a.pqt2024-02-14T17:07:31.000Z"a7dc97bae4a8e5913262ba00524d7927"30747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/mrsicflogellab/SWC_065/_ibl_subjectTrials.table.af901d28-93ff-460c-9592-4e3c9efe3643.pqt2024-02-14T17:07:31.000Z"050a287fecff3ac34e4f6d8c1f510f3a"25573757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0017/_ibl_subjectSessions.table.9677c320-e441-4e0a-a928-13ab33f35b3f.pqt2025-02-20T19:37:52.000Z"4a2e88bd0dd83e499cd6604409964852"CRC64NVMEFULL_OBJECT93467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0017/_ibl_subjectTraining.table.90576494-b532-4540-85fe-5e9924d56be8.pqt2024-02-14T17:07:31.000Z"9d8798609e335561d981f5563a67af71"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0017/_ibl_subjectTrials.table.e8fc8be7-81ac-4ce0-9dea-b03d0e5a34db.pqt2024-02-14T17:07:31.000Z"35d7a166130d5763f4d7f373e1f5c502"37861157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0019/_ibl_subjectSessions.table.a47f4838-c63c-4860-9064-31cc3d1147a8.pqt2025-02-20T19:37:52.000Z"bc74c7e5c623891be86a21bd34772251"CRC64NVMEFULL_OBJECT86767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0019/_ibl_subjectTraining.table.cc21b99d-d607-4619-91cf-a42caca2f061.pqt2023-12-20T09:08:48.000Z"4fdb65782665c3d192ab85a9f2dea79f"31267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0019/_ibl_subjectTrials.table.00334be1-deb4-4ba5-9758-a8d87b3f6cc0.pqt2023-12-20T09:08:48.000Z"dc9fc4be17645612a2a79d5a3caa82a0"39803477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0020/_ibl_subjectSessions.table.c35d8610-43d3-4489-b2ba-a600cc6123fc.pqt2025-02-20T19:37:52.000Z"b48a2786c2638b42f8e9df3768167fad"CRC64NVMEFULL_OBJECT85357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0020/_ibl_subjectTraining.table.52d6375d-7213-48b0-a2c6-fee4f9734c44.pqt2023-12-20T09:08:48.000Z"c2b3ecfb577ced2ac7d5d234a0794161"32537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0020/_ibl_subjectTrials.table.45a3d85b-8ea2-4f1e-b358-4ad51f746148.pqt2023-12-20T09:08:49.000Z"4b279c5d57cd21c353db43d2f5c7351c"48843287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0021/_ibl_subjectSessions.table.f6a68353-f01f-4fe7-8d23-324e2d62230b.pqt2025-02-20T19:37:52.000Z"76dc165e51e755d3b22189fd4524aad5"CRC64NVMEFULL_OBJECT82067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0021/_ibl_subjectTraining.table.c9e9a09c-509a-441d-8824-106054fe1d6d.pqt2023-12-20T09:08:49.000Z"e6474f7fe1e2e0677018d2d3db0d416d"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0021/_ibl_subjectTrials.table.964cf362-98c8-4b34-b837-19f4665670a8.pqt2023-12-20T09:08:49.000Z"1417f697fd3d4063edb2ae4afdb09a2e"26206807d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0024/_ibl_subjectSessions.table.6dc5ab69-ec35-47e7-b2a0-bbae4f22ac75.pqt2025-02-20T19:37:52.000Z"8201d76018fdc036c33592ee3cb707e8"CRC64NVMEFULL_OBJECT111897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0024/_ibl_subjectTraining.table.031e29c4-412b-4648-9f13-614cd6f293cb.pqt2024-02-14T17:07:32.000Z"d49f6a0c0303dbfd9119f1ee95d19964"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0024/_ibl_subjectTrials.table.e5c5bd87-d3f2-42f6-96af-78c0cf271af0.pqt2024-02-14T17:07:32.000Z"845fd771a6727246130f7c4f00256747"56542587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0027/_ibl_subjectSessions.table.17878530-3c82-440c-8f8c-becf666d60f7.pqt2025-02-20T19:37:52.000Z"799ed5d28140afeddf05d231fa0b1a64"CRC64NVMEFULL_OBJECT75107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0027/_ibl_subjectTraining.table.847c052d-95c4-4590-add5-35f9f29f88aa.pqt2023-12-20T09:08:49.000Z"8f2584042ce406919a3830e2c0e8a84a"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0027/_ibl_subjectTrials.table.a00e5cf6-9c42-44a1-bda6-b437da142911.pqt2023-12-20T09:08:49.000Z"db4912eb8a183ecd4c7b6f066a8d89e3"25312117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0028/_ibl_subjectSessions.table.8715d6c7-0277-4f2e-b337-fe0e9aee416e.pqt2025-02-20T19:37:52.000Z"e2c6a36b3ee6330063c3e909bc7a710b"CRC64NVMEFULL_OBJECT75157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0028/_ibl_subjectTraining.table.39a82588-6087-4412-98cb-5c0d6047358b.pqt2024-02-14T17:07:32.000Z"3185dd7c61afb30e304c73e02a942b21"32477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0028/_ibl_subjectTrials.table.86dd7b4e-8ce4-4a57-869e-29b862d07e4a.pqt2024-02-14T17:07:32.000Z"e3d7c9c661f32f3d1d8fb42b34348b37"25889957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0029/_ibl_subjectSessions.table.46e33236-301f-4864-88d8-f627109d226e.pqt2025-02-20T19:37:52.000Z"fff9a890c2dc798310bd20e02affcf67"CRC64NVMEFULL_OBJECT106047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0029/_ibl_subjectTraining.table.53b93fb5-21f6-4490-a432-3b6048cd7814.pqt2024-02-14T17:07:32.000Z"852d2e0c4bb11b2d6d08503282b254b4"33127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0029/_ibl_subjectTrials.table.da55b60b-45c6-4383-a9fd-51a39acd06da.pqt2024-02-14T17:07:32.000Z"542838807fa3f902bdc3008e57e8fe13"38348007d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0031/_ibl_subjectSessions.table.5be43dae-a581-4228-b257-b7a45a44c6d5.pqt2025-02-20T19:37:52.000Z"5ea96089ed4f996b5f344ddcd3231eb2"CRC64NVMEFULL_OBJECT74627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0031/_ibl_subjectTraining.table.a35033e1-1125-47f4-aaf8-6b7cb27624c8.pqt2024-02-14T17:07:32.000Z"f200e1ca1a6383dc7389e83d6e008e25"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/steinmetzlab/NR_0031/_ibl_subjectTrials.table.aa83d0e1-5a1a-4cd8-91a1-2bc84211004d.pqt2024-02-14T17:07:32.000Z"92ed2d7c9263257a3718d3f7ac1329b5"13770407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_02/_ibl_subjectSessions.table.837a00a6-6f73-4829-9389-5c6f69d74ded.pqt2025-02-20T19:37:53.000Z"3b0aa5d7b591becdc30194c4e6af60c6"CRC64NVMEFULL_OBJECT67257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_02/_ibl_subjectTraining.table.68dc1479-a7f8-4035-9101-9a10c06ad33f.pqt2024-09-16T15:08:21.000Z"a2deb7ff2a378b61ec8f66c380b5e241"30107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_02/_ibl_subjectTrials.table.07f70234-a6fa-4095-9030-a095a901f748.pqt2024-09-16T15:08:21.000Z"56a97efb611382fdb6953ec23877766f"18401407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_03/_ibl_subjectSessions.table.de2bbe52-0ad2-4e1e-a8eb-a68e2135fc37.pqt2025-02-20T19:37:53.000Z"ca441e20964c14e51fd68d8b745b787a"CRC64NVMEFULL_OBJECT66877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_03/_ibl_subjectTraining.table.a2fb03ed-218d-46cd-821a-37474ec1195e.pqt2024-09-16T15:08:21.000Z"65253d5944b21f1f5dd67bba8f2e7361"30747d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_03/_ibl_subjectTrials.table.61474211-70dc-46e6-8e5e-7226d5b48be1.pqt2024-09-16T15:08:22.000Z"ac1f6625b64cae2e92f2de9df91be547"26097767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_04/#2024-07-22#/_ibl_subjectTrials.table.e691bf06-c804-4318-b1b8-425f2e06b52c.pqt2024-09-16T15:08:22.000Z"5cb5e9bb2e4b7e7ea3697c7371d331a9-2"110551027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_04/_ibl_subjectSessions.table.d6f69e05-56b9-4ec3-985d-de378af2f566.pqt2025-02-20T19:37:53.000Z"5d8b63a682a361be5123e1293e55b3f6"CRC64NVMEFULL_OBJECT97577d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_04/_ibl_subjectTraining.table.ffba6bb7-11bf-4d51-8819-b3f5ffc48355.pqt2024-09-16T15:08:22.000Z"07caa8304df2085e43f9900c869aee66"31967d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_04/_ibl_subjectTrials.table.7bfe80c0-23e8-44d1-bbc1-feb1b50021fa.pqt2023-12-20T09:08:49.000Z"da46da61f129680d08d2e70cdf6b23fa"72969067d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_05/#2024-04-10#/_ibl_subjectTrials.table.d1cefee3-c4a1-4d8b-ae28-0a9f56fa5948.pqt2024-09-16T15:08:22.000Z"5b1954e34b2608768bb339cd4ff67906-2"147576977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_05/_ibl_subjectSessions.table.bb128057-ccf4-4da4-af49-4152b45e7459.pqt2025-02-20T19:37:53.000Z"611675497d0e069c8315abf2a275a5d8"CRC64NVMEFULL_OBJECT104917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_05/_ibl_subjectTraining.table.ccbf3496-ba86-436f-9a8e-8c22be2d21b7.pqt2024-09-16T15:08:22.000Z"d264804a0eac2b1ec21aad02aa3fc2aa"30727d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_05/_ibl_subjectTrials.table.611be264-0b18-49f3-8b25-e666c708b46e.pqt2023-12-20T09:08:49.000Z"83fd91823caebdeb498604ac59062f1d-2"90230127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_06/#2024-08-21#/_ibl_subjectTrials.table.714b6af0-03d0-44ad-b6ef-9c44b7fd9299.pqt2024-09-16T15:08:22.000Z"ebfe1e0f4d7c25bd6b2771ec0e9a8057-2"128032587d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_06/_ibl_subjectSessions.table.1c399feb-5f64-429f-9c3b-d5848eeaaf30.pqt2025-02-20T19:37:53.000Z"8ed3cd082ce122e14b3e52998e92c8a1"CRC64NVMEFULL_OBJECT106477d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_06/_ibl_subjectTraining.table.b9980a7b-31b3-42ae-ab55-218c05306e59.pqt2024-09-16T15:08:22.000Z"9e3975a0957c067308f9ab5f19ae5c1f"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_06/_ibl_subjectTrials.table.5685fd08-4526-4dfd-aa9e-bdf1d80f75cf.pqt2023-12-20T09:08:49.000Z"d001e418a821966813626ea81235b4f5"82583557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_07/#2024-04-10#/_ibl_subjectTrials.table.0987576e-85b5-4ed6-be53-677e232f2641.pqt2024-09-16T15:08:22.000Z"09a21889f37ed6c2b87a7324695d4858-2"148429907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_07/_ibl_subjectSessions.table.d3f0e8c5-570c-47c3-af7e-469155cbfcd8.pqt2025-02-20T19:37:53.000Z"db456fb32fecd288123886a2b6521324"CRC64NVMEFULL_OBJECT117047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_07/_ibl_subjectTraining.table.049a1e53-bc58-4a5b-a71f-3da040263b60.pqt2024-09-16T15:08:23.000Z"32ddeb0a25300028e0288834c5b8d53f"32597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_07/_ibl_subjectTrials.table.7ac600c1-f16d-421d-91b6-45b35d2e85df.pqt2023-12-20T09:08:49.000Z"c8f7adba36687369db4c4653753360bd-2"91266957d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_11/_ibl_subjectSessions.table.b9d84d14-2880-4014-8270-ef1c512c6cde.pqt2025-02-20T19:37:53.000Z"9ea5c8e73a95472e759275804a7a482b"CRC64NVMEFULL_OBJECT72757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_11/_ibl_subjectTrials.table.f05078fe-eb41-4c06-a719-accca9e02511.pqt2023-12-20T09:08:49.000Z"e6c86383a34778f98312c2a46817ccf7"20903787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_12/#2024-04-10#/_ibl_subjectTrials.table.b1df217b-4a82-4435-a178-a9a3cbbb4335.pqt2024-09-16T15:08:23.000Z"eb103a552fd7d7bcb863acdf2daff874-2"137224777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_12/_ibl_subjectSessions.table.abc4e2eb-297c-457b-b15e-4b3853463ba2.pqt2025-02-20T19:37:53.000Z"9ecf279a1b1a7e0435ff654d431276ac"CRC64NVMEFULL_OBJECT99347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_12/_ibl_subjectTraining.table.b061345e-fe00-40aa-89e5-b90788fa99ee.pqt2024-09-16T15:08:23.000Z"81cc0e02eeecb68cf60852059b1da170"32517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_12/_ibl_subjectTrials.table.21b5c189-63d1-4fc1-9f68-2c2627b51add.pqt2023-12-20T09:08:50.000Z"d00d08200e8e06600dac89c1dc614491"50459017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_13/#2024-04-10#/_ibl_subjectTrials.table.80680b28-5b34-424f-a88c-831a1fd79c75.pqt2024-09-16T15:08:23.000Z"e9b54b1a5e8e9a11964278fd56a00596-2"89388717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_13/#2024-08-21#/_ibl_subjectTraining.table.55757ff6-5197-441f-ae2f-d52baac79507.pqt2024-09-16T15:08:23.000Z"f277d05dc214d9caaac7188fe1f4ad44"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_13/_ibl_subjectSessions.table.7689cc77-4b49-4424-b53b-80b96158a2b2.pqt2025-02-20T19:37:53.000Z"fd03702e3448bd87485869149f553ca2"CRC64NVMEFULL_OBJECT86357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_13/_ibl_subjectTraining.table.1869467f-6a84-4aca-9bc6-aec0eb896165.pqt2023-12-20T09:08:50.000Z"48bb38ad10c841c4ac8de4433fc9d1e9"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_13/_ibl_subjectTrials.table.f2bb22ad-eda3-4ea5-9634-2af44cb51cc3.pqt2023-12-20T09:08:50.000Z"329f1b1f919e9c2534bb1ecbc7a7986c"54452027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_14/#2024-08-21#/_ibl_subjectTrials.table.2dbd2f7e-6328-4e14-a5e6-505c6142b18c.pqt2024-09-16T15:08:23.000Z"81eca3ee69fe5a9234b3427c815e19a6"77384407d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_14/_ibl_subjectSessions.table.218c6073-62ac-4fd2-ac0c-94494e796890.pqt2025-02-20T19:37:53.000Z"4197b7efe396edb2c93a1d1efaf0fbd3"CRC64NVMEFULL_OBJECT89317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_14/_ibl_subjectTraining.table.c742c6ab-0876-4886-b04f-a6e44799ad28.pqt2023-12-20T09:08:50.000Z"17ce2f819a012af60891af6e6b1b4fcf"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_14/_ibl_subjectTrials.table.62a2d6b7-1d9d-462c-9ac4-1e4358fd6028.pqt2023-12-20T09:08:50.000Z"4198426ba8d4fea4c7cf0d95473ddf1e"39066227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_15/#2024-04-10#/_ibl_subjectTrials.table.58cf393b-6c15-4773-ac3b-5126890ccbb8.pqt2024-09-16T15:08:23.000Z"c5cdc14e7508c0c0f47ceddf5a6ccab2-2"132254367d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_15/_ibl_subjectSessions.table.f99cbcb9-c636-43a4-9891-3394c7cfc0cc.pqt2025-02-20T19:37:53.000Z"c2970d5bb1ac741cb7af1a57b7c473d9"CRC64NVMEFULL_OBJECT95647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_15/_ibl_subjectTraining.table.192fa698-13d1-4037-8f0f-92c2a1d1036a.pqt2024-09-16T15:08:23.000Z"e444df9cc16955a1222a2edc430daca8"30767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_15/_ibl_subjectTrials.table.929eb6d5-0458-4fce-9748-34183b04de06.pqt2023-12-20T09:08:50.000Z"761a21095db2b8f2724ff745aafc8991"35989237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_16/#2024-04-10#/_ibl_subjectTrials.table.23e6af92-62db-4d99-af63-653078d6effb.pqt2024-09-16T15:08:23.000Z"82f6116e9f5ea03e3764880f7c01c0ad-2"114301897d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_16/#2024-08-21#/_ibl_subjectTraining.table.c3edbbce-62cc-4107-b38e-b4aa65289ab9.pqt2024-09-16T15:08:24.000Z"6ff386dc0dd9ca85c4532e7784c4097c"31287d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_16/_ibl_subjectSessions.table.bcb91298-7d07-4a0d-b6d1-4df679388a93.pqt2025-02-20T19:37:53.000Z"7636c9e05fa69db60a4e561e1cf9e348"CRC64NVMEFULL_OBJECT95027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_16/_ibl_subjectTraining.table.5576560d-4381-4fb2-8867-95afcdb9bbbc.pqt2023-12-20T09:08:50.000Z"e41c2b7d9714ea09bdd6f27316a84b8f"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_16/_ibl_subjectTrials.table.a797f2cd-3001-4c46-b195-664c1e28afb4.pqt2023-12-20T09:08:50.000Z"1d0c16c1cf2f8f43b31e3ed0d1aaf5c2"33655887d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_17/#2024-04-10#/_ibl_subjectTrials.table.9a7ff99b-e1c7-4d06-b9a1-dbde844240f5.pqt2024-09-16T15:08:24.000Z"366bbc61d4604480e8997885eb382b48"56841267d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_17/#2024-08-21#/_ibl_subjectTraining.table.81ef7227-ca7e-49d1-bbd2-49e7ccc5629b.pqt2024-09-16T15:08:24.000Z"25aa8c425a53c320112385f819a4cf9f"32437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_17/_ibl_subjectSessions.table.f08403a5-bfad-4692-a9fc-be914d10376f.pqt2025-02-20T19:37:53.000Z"4d769d01fd52e59031f2ff434cc7062c"CRC64NVMEFULL_OBJECT77117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_17/_ibl_subjectTraining.table.a4cb796d-7fe4-4f93-9aba-e2f266fde473.pqt2023-12-20T09:08:50.000Z"6a76d29a9203d2a29445ed68bbfda5c3"32527d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_17/_ibl_subjectTrials.table.fb3df664-a503-4953-a63e-21043b590f3e.pqt2023-12-20T09:08:50.000Z"70c178fb3593bbc43f2cc9cdf7cc85a3"25389617d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_18/_ibl_subjectSessions.table.e00c66bf-d0fe-4bd3-85b2-b16dbc9596bd.pqt2025-02-20T19:37:53.000Z"bf2b00e3eb5aee77d714195b1cd5c5a5"CRC64NVMEFULL_OBJECT83177d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_18/_ibl_subjectTraining.table.972f8b3b-9165-47de-bf32-7db48ed1d97b.pqt2024-02-14T17:07:32.000Z"b88321701a6bf5181a493c0572a52166"31937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_18/_ibl_subjectTrials.table.be0c83c3-f3f4-4e42-a80e-656491cbc310.pqt2023-12-20T09:08:50.000Z"405ce32ff0916ebce1932977f0ef40a5"41404987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_19/#2024-04-10#/_ibl_subjectTrials.table.f33ecaad-5394-40e4-b929-c25216cca5e3.pqt2024-09-16T15:08:24.000Z"5fe717a63ef7696bff82ebc6317436a5"55661647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_19/#2024-08-21#/_ibl_subjectTraining.table.f17f35da-6e30-464b-acdc-2bb8619e4061.pqt2024-09-16T15:08:24.000Z"96a5bc7e4d77709ffac9331f56fbe6b9"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_19/_ibl_subjectSessions.table.cb6c94ce-a0e7-479e-a04f-e359e55205f5.pqt2025-02-20T19:37:54.000Z"e1e6beacba95997822cfbebdb7c96f5e"CRC64NVMEFULL_OBJECT76227d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_19/_ibl_subjectTraining.table.078c49a8-7b09-4c31-969e-ad8b17427e86.pqt2023-12-20T09:08:50.000Z"d179fe6ed422990383a80d9faff63bf6"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_19/_ibl_subjectTrials.table.0cf57691-6042-4db4-a706-136bc0efe227.pqt2023-12-20T09:08:50.000Z"17f28d485635bfee8d0787155feabf4a"24645827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_20/#2024-04-10#/_ibl_subjectTrials.table.3a2a34b5-68b5-4dc3-aa45-54911691614f.pqt2024-09-16T15:08:24.000Z"84b7faa435db438b7faa1136ff8bcc31"82032437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_20/#2024-08-21#/_ibl_subjectTraining.table.71b68936-7db8-4c64-94af-2299666b8652.pqt2024-09-16T15:08:24.000Z"f40308a0729d54313c4959d9d04393b4"32457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_20/_ibl_subjectSessions.table.e3c9b90c-6b80-43c9-a377-1b2afcc8a74f.pqt2025-02-20T19:37:54.000Z"a363b12853159462113849b51c6a0269"CRC64NVMEFULL_OBJECT86887d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_20/_ibl_subjectTraining.table.c600f48c-7567-4e38-b9d2-b17b9e8c974d.pqt2024-02-14T17:07:32.000Z"3485316e285a41edfc6ff82bf4b834c4"32457d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_20/_ibl_subjectTrials.table.149f71bd-28b0-4544-b5b3-56d153a2f0a7.pqt2023-12-20T09:08:50.000Z"d28ed6b847f8274d0ced904758213720"36883377d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_21/_ibl_subjectSessions.table.4f838184-e982-4673-8b8c-25d62b8615e9.pqt2025-02-20T19:37:54.000Z"ccb8536a4426a0f8882e33c8f606c3f6"CRC64NVMEFULL_OBJECT83767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_21/_ibl_subjectTrials.table.598895a4-58c3-41db-bb03-043b01c6ed1a.pqt2023-12-20T09:08:50.000Z"900aba6b6813ae0d1cfd0e5df08f5d63"30238137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_22/_ibl_subjectSessions.table.314f7f73-2f57-4fc3-a2a9-97ea72e0d6e2.pqt2025-02-20T19:37:54.000Z"984db36677689acd3cd9861343177cac"CRC64NVMEFULL_OBJECT70517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_22/_ibl_subjectTrials.table.44976bda-2ee7-48a8-869e-906299c6de03.pqt2023-12-20T09:08:50.000Z"a8b2acedd63ebcba03528c2554844a27"11225117d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_23/_ibl_subjectSessions.table.e50ac3ed-0b0f-43ac-9a90-396705fcfc05.pqt2025-02-20T19:37:54.000Z"87756d783cd22a07613f70d2825db779"CRC64NVMEFULL_OBJECT84627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_23/_ibl_subjectTrials.table.375fc0b2-1b06-48b2-abb1-a56c78e10bfb.pqt2023-12-20T09:08:50.000Z"b175df6c11c67e5c01338098c1cf771a"30745597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_24/_ibl_subjectSessions.table.e6c0d493-efa0-4354-aac6-aaa437f25e3c.pqt2025-02-20T19:37:54.000Z"9f443d79b88b7b3f35b8175f2674c74c"CRC64NVMEFULL_OBJECT82767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_24/_ibl_subjectTrials.table.3131e83d-0178-401d-8e9c-06d7cf73f432.pqt2023-12-20T09:08:50.000Z"6a2942ee506a975af62ed87c69055c5a"34818157d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_25/_ibl_subjectSessions.table.9ce88837-c96b-4954-b37f-d772cb69fa54.pqt2025-02-20T19:37:54.000Z"7189d5c0f7b505ed33a43d9fefc970bb"CRC64NVMEFULL_OBJECT75497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_25/_ibl_subjectTraining.table.5997d0a3-4309-49c6-b299-5fc75e5be14d.pqt2023-12-20T09:08:50.000Z"32b041860db2dbf93db2a94049d24c91"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_25/_ibl_subjectTrials.table.a5c185fe-82c1-4772-9a62-21889c01cf7e.pqt2023-12-20T09:08:50.000Z"8e599cb56fe70537163de640aa151725"26701787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_26/_ibl_subjectSessions.table.513195c8-263e-45b0-8f40-57bef0d17289.pqt2025-02-20T19:37:54.000Z"f916db47220d8af5041e3bc1ec4445b6"CRC64NVMEFULL_OBJECT93467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_26/_ibl_subjectTraining.table.bd455886-6d22-4245-afb4-43a89bfbf56a.pqt2023-12-20T09:08:50.000Z"9c9a3c54de92c2bfb37cc16ee95f23b0"32027d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_26/_ibl_subjectTrials.table.1d5b60f3-9304-4a0e-baad-a4d3967ca958.pqt2023-12-20T09:08:51.000Z"d1e6b3870d1701dd7b2607a36dd171b5"57499797d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_27/_ibl_subjectSessions.table.e32f2cc8-0225-4d1b-8a86-0fae22e35837.pqt2025-02-20T19:37:54.000Z"6acbb12e987b31574b13c2cbc00c8eff"CRC64NVMEFULL_OBJECT84937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_27/_ibl_subjectTraining.table.ef9acd5f-e976-4379-9bf6-21383c0dc593.pqt2023-12-20T09:08:51.000Z"7dd4534847f6e027f1fc1235e5a31b2c"31917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_27/_ibl_subjectTrials.table.a0ef10bc-0369-491a-ba22-1facee61585a.pqt2023-12-20T09:08:51.000Z"8eeac2b3a79fbba534180c8432eb2553"38597107d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_29/_ibl_subjectSessions.table.fa1adc11-b8af-4c41-8d5e-f48df5bee46f.pqt2025-02-20T19:37:54.000Z"bfe708ba6738cd186e347ef7f676857c"CRC64NVMEFULL_OBJECT98137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_29/_ibl_subjectTraining.table.8babd3e3-dd6c-4439-876f-762bbc88a38a.pqt2023-12-20T09:08:51.000Z"297668621423ff6dbd8321fcf0fd7fcd"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_29/_ibl_subjectTrials.table.cdd9a821-a6b7-48c9-8fe0-3ef87aa0b84f.pqt2023-12-20T09:08:51.000Z"cf87c2b41356706339a1bec12c9708f9"81817087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_32/_ibl_subjectSessions.table.27f42808-fc7b-44e5-810a-34740cd7bf70.pqt2025-02-20T19:37:54.000Z"4fe1dc5da825f3dc3b8e83b0222bf5a4"CRC64NVMEFULL_OBJECT106047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_32/_ibl_subjectTraining.table.ad7b52cb-562a-459f-a220-855027646b07.pqt2024-02-14T17:07:33.000Z"ebabff26a7a8c50bb68d15b8f59a725e"32557d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/wittenlab/ibl_witten_32/_ibl_subjectTrials.table.1318b3dc-e625-43fa-a2fb-28d96877af8e.pqt2024-02-14T17:07:33.000Z"015e0a1424aef2ef342504f95de099c0-2"91054467d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_001/#2024-08-21#/_ibl_subjectTraining.table.8a583bfb-87ec-42ed-a224-3a9c64d4f887.pqt2024-09-16T15:08:24.000Z"31bf0d28a5fdf2b889174a2be4d8775d"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_001/#2024-08-21#/_ibl_subjectTrials.table.58c47565-907f-4e65-88d4-aff652a98aea.pqt2024-09-16T15:08:24.000Z"1eedfdcbc94d1020a8c22f526f09dfb6"49666757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_001/_ibl_subjectSessions.table.da028711-77f6-451a-8484-eddd42d5493f.pqt2025-02-20T19:37:54.000Z"ab9a53cddbd08a98f51ac3901d8b65fd"CRC64NVMEFULL_OBJECT78947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_001/_ibl_subjectTraining.table.8816a634-6e2a-42f1-bd4c-c095b41b861c.pqt2023-12-20T09:08:51.000Z"99b20fa4c9c4f858b149ab71e1dbeb0f"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_001/_ibl_subjectTrials.table.300723ac-4776-4770-b6ae-8327b778b5d6.pqt2023-12-20T09:08:51.000Z"1c29f2472da6fb0386daa5cb2bdd235a"29360207d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_002/#2024-08-21#/_ibl_subjectTrials.table.e4661a1c-4ce1-4e77-a6fe-7035deab5c30.pqt2024-09-16T15:08:24.000Z"f98d583502d04d5c34ed0f3e38a9af30"43632257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_002/_ibl_subjectSessions.table.05d83f32-4460-4fbd-94ff-6a8786c02de0.pqt2025-02-20T19:37:54.000Z"7573539082315dbfacaa06c5978234a9"CRC64NVMEFULL_OBJECT77317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_002/_ibl_subjectTraining.table.cebaab35-246b-4b2d-b462-f3c92c4ac9b6.pqt2024-09-16T15:08:24.000Z"218354c7149a7f29ba1409b09a44b6de"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_002/_ibl_subjectTrials.table.ecc42b17-ce44-4269-b2d3-54a9cb9365e6.pqt2023-12-20T09:08:51.000Z"82fd935a9b1fb12b2d286d1953336c7c"26348357d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_003/#2024-04-10#/_ibl_subjectTrials.table.e2d27b49-df95-4268-8931-c7ba0caa2481.pqt2024-09-16T15:08:24.000Z"4ab8ade737d6028c4d259e29374586d1"34388597d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_003/_ibl_subjectSessions.table.070ff40c-0f15-47c0-9e90-76273b567dbd.pqt2025-02-20T19:37:54.000Z"3e0daa223e9607fc2f97236a6f01477b"CRC64NVMEFULL_OBJECT70537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_003/_ibl_subjectTraining.table.63e6a831-714a-4a4e-a1b1-cb14f11107d3.pqt2024-09-16T15:08:24.000Z"3fb0fe0bd73480b564efca23924052bd"30767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_003/_ibl_subjectTrials.table.995e36e2-c038-431a-89f4-64e087e52e65.pqt2023-12-20T09:08:51.000Z"cc58db3b8e9207c5742c89586ee23f9b"18718777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_004/#2024-08-21#/_ibl_subjectTrials.table.5fe92ce8-8271-45c8-a860-46e82bf7122c.pqt2024-09-16T15:08:24.000Z"d268a05211822839cf61fc54bd6f7824"28363147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_004/_ibl_subjectSessions.table.bcbd0f2b-d440-4dce-be99-f077fd33d07a.pqt2025-02-20T19:37:54.000Z"7bfb366acaf22239e40bfe579398deaf"CRC64NVMEFULL_OBJECT69437d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_004/_ibl_subjectTraining.table.b25b2979-108d-44df-b7b2-43ee3cb6d1ae.pqt2024-09-16T15:08:24.000Z"968540fe64ea19be1745312e09091818"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_004/_ibl_subjectTrials.table.92fe93a0-6d9d-4401-bf01-d543a13a8deb.pqt2023-12-20T09:08:51.000Z"486220e3aaff7c039a6c8b1bf98a887b"16887757d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_005/#2024-08-21#/_ibl_subjectTrials.table.26a47426-a2b5-4958-9cef-3d3d4252632b.pqt2024-09-16T15:08:25.000Z"cd1229f7be2946b7b041a49e89309147"43510057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_005/_ibl_subjectSessions.table.52703c65-f54c-4632-bb27-81255ff2034a.pqt2025-02-20T19:37:54.000Z"da0c37b50f04e8baf1c1ea64526b808d"CRC64NVMEFULL_OBJECT77087d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_005/_ibl_subjectTraining.table.818925f7-aaae-47fd-ab93-f4d48a59db79.pqt2024-09-16T15:08:25.000Z"4718ca25c0f366d50d8d3ea2a0c86dc5"30717d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_005/_ibl_subjectTrials.table.e054c9c1-8b0b-4fb1-ac9b-f5a6aca704cd.pqt2023-12-20T09:08:51.000Z"06ea1de30df2fb4fe1feaba019a2efef"25928517d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_006/#2024-08-21#/_ibl_subjectTrials.table.d2e4eced-c76d-4cc3-a29a-c13712e8fda6.pqt2024-09-16T15:08:25.000Z"365b77f05bcd76cb2ebd2b667c8a300c"11403237d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_006/_ibl_subjectSessions.table.35e65a21-1f18-4726-b9ab-41538cbf7fd2.pqt2025-02-20T19:37:54.000Z"5d35defd5f2c09c3c66ce7fac266519c"CRC64NVMEFULL_OBJECT62907d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_006/_ibl_subjectTraining.table.294ed0bd-d790-4d0b-a6b5-e552d99c7860.pqt2024-09-16T15:08:25.000Z"9210feea196a9d768b8ab66d3ddbda18"31317d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_006/_ibl_subjectTrials.table.86668dcd-b27b-4c0f-a271-a5d322e046ec.pqt2023-12-20T09:08:51.000Z"4aba037ae89b5577ae7cf52e2952e69a"6848987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_007/#2024-08-21#/_ibl_subjectTrials.table.5241e92c-d0b3-465b-abe9-c2ba2c5401dd.pqt2024-09-16T15:08:25.000Z"b8cbc8de878cee3b0002fcee7c40e8cb"20500977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_007/_ibl_subjectSessions.table.82146329-36fd-4c06-bd3e-80d4c3472e32.pqt2025-02-20T19:37:55.000Z"e9fd6e647ba2eeccd8332b43d1f17c28"CRC64NVMEFULL_OBJECT64447d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_007/_ibl_subjectTraining.table.9cf10196-47fb-4940-8cbc-060ba9fb7e75.pqt2024-09-16T15:08:25.000Z"19096fcdba9858a894d05dc837a21d68"31297d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_007/_ibl_subjectTrials.table.22503ce4-f227-471c-bba1-9170572e995a.pqt2023-12-20T09:08:51.000Z"ebcbc120c0f187d2a2b6791a7b596bba"12478667d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_009/_ibl_subjectSessions.table.ffe994de-f352-46dc-aaf6-548edf4179e1.pqt2025-02-20T19:37:55.000Z"0c33e4f412942a06ba57bad62fe4c0c0"CRC64NVMEFULL_OBJECT64537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_009/_ibl_subjectTrials.table.41b5df8a-182d-4324-bb17-5d6c0625995d.pqt2023-12-20T09:08:51.000Z"cfaa7f714f8e685f74427145b25eeded"6638707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_010/#2024-08-21#/_ibl_subjectTrials.table.1e1ca95c-73e4-4242-a20b-fe883c566a9c.pqt2024-09-16T15:08:25.000Z"78aa01f779f963252a861f21b0c0075e"13558817d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_010/_ibl_subjectSessions.table.6b8c04f4-caf7-4ff9-803b-2fcf9966f552.pqt2025-02-20T19:37:55.000Z"6de165fdb6d6ade7eddd14ca5864f1d2"CRC64NVMEFULL_OBJECT62827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_010/_ibl_subjectTraining.table.95595f72-fdbb-47fe-9930-10e566a70167.pqt2024-09-16T15:08:25.000Z"ca091cfc5af20012d9b7d2c246f2643c"30767d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_010/_ibl_subjectTrials.table.d6ef5657-288e-4041-bfcd-98f43f985b65.pqt2023-12-20T09:08:51.000Z"58f3b8347b53c6f2571da2350cc6182c"8236257d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_011/#2024-08-21#/_ibl_subjectTraining.table.a5c7a2ae-09f4-4d4d-bab4-8a8c1d8c1d40.pqt2024-09-16T15:08:25.000Z"c4bfdcea51c612b294181fb07b590be9"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_011/#2024-08-21#/_ibl_subjectTrials.table.efe85845-bd51-45d2-83f0-2836ff18d3c3.pqt2024-09-16T15:08:25.000Z"c9428cfdf15f0d435aaddab039d9ae0d"45055127d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_011/_ibl_subjectSessions.table.f4e5ba3e-cbc7-44c3-a4da-2b4f864a253e.pqt2025-02-20T19:37:55.000Z"66ecb077dfba059b2abd3575ae600a4c"CRC64NVMEFULL_OBJECT80787d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_011/_ibl_subjectTraining.table.06a4dd4e-5dd7-41d6-867f-dde3d67fba3d.pqt2023-12-20T09:08:51.000Z"d94eede76893a47e15836975fdab425b"31997d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_011/_ibl_subjectTrials.table.f5702540-7135-47c0-8c0c-5b464a1183cc.pqt2023-12-20T09:08:51.000Z"36cb347d2ee42eb43c1d4ab3321b0f66"26365047d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_015/_ibl_subjectSessions.table.b65e6af2-545c-4ed8-bebf-f9d7e0ce14a1.pqt2025-02-20T19:37:55.000Z"333f74525e09c439d2f1e212c899a616"CRC64NVMEFULL_OBJECT81627d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_015/_ibl_subjectTrials.table.73af49ea-f94e-4c27-b13d-08e8643cedfa.pqt2023-12-20T09:08:51.000Z"0637488de2a2e1ebbb28b69f5d0df4ba"26034537d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_016/_ibl_subjectSessions.table.5aba59fe-281e-49e3-96af-5fd1406a0541.pqt2025-02-20T19:37:55.000Z"884b4f820cedc2637c55f6b7f3c4b4b3"CRC64NVMEFULL_OBJECT70097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_016/_ibl_subjectTrials.table.d213c8dd-462e-40d6-89e3-b2333274bc9e.pqt2023-12-20T09:08:51.000Z"864948f43d2440f1a1ed9a1d7d0623f7"17069207d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_017/#2024-07-22#/_ibl_subjectTrials.table.8794188c-a6b8-40f4-a95c-0558831abb16.pqt2024-09-16T15:08:25.000Z"c53c2cb3ffe12136c46a69893d99d76c"49402917d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_017/#2024-08-21#/_ibl_subjectTraining.table.23347356-97cf-4f27-a959-441e053999af.pqt2024-09-16T15:08:25.000Z"f77a80512b1db2feae47088c87a98412"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_017/_ibl_subjectSessions.table.ce025559-e73e-4a9f-b490-b4670f3f275e.pqt2025-02-20T19:37:55.000Z"8d1a621406eb1c1c0b60c25fd9a049e6"CRC64NVMEFULL_OBJECT75827d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_017/_ibl_subjectTraining.table.d9c71738-a9d6-44c0-befa-6bd4adac7436.pqt2023-12-20T09:08:51.000Z"9a0dcadc75d704d2ed2a388591831a44"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_017/_ibl_subjectTrials.table.56ba668d-a949-45e0-b938-26ea8e51fd8a.pqt2023-12-20T09:08:52.000Z"fa8ca306f0446ba6a1e80484a3fb7386"28782927d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_018/_ibl_subjectSessions.table.39abe813-33d0-4f64-8073-979da01b2e13.pqt2025-02-20T19:37:55.000Z"04fbd0e819e88447a9f8309ccd3851de"CRC64NVMEFULL_OBJECT81607d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_018/_ibl_subjectTrials.table.c23fff68-3e2d-4a48-98b0-681e15e6d14f.pqt2023-12-20T09:08:52.000Z"f53e0cc3fbde12c76e11cd179bb84bbf"35637647d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_019/_ibl_subjectSessions.table.8aa8de0a-a19f-45e3-af0e-951936e88f7f.pqt2025-02-20T19:37:55.000Z"4b07a155ce7429ebdaaea2082f1f47e6"CRC64NVMEFULL_OBJECT95097d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_019/_ibl_subjectTraining.table.cec2b274-b612-4e4f-99ff-3ee7613f54d2.pqt2023-12-20T09:08:52.000Z"581bbde5897c5118beb1e726ea6a06cd"33147d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_019/_ibl_subjectTrials.table.b163a094-e281-4b40-a225-dca60e0a863c.pqt2023-12-20T09:08:52.000Z"97696183be8c50686f90fce6310df437"55466427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_021/_ibl_subjectSessions.table.8f96dd8c-fd00-42d7-aae7-b53890085969.pqt2025-02-20T19:37:55.000Z"392d07da2fe976cc011bc25b3ca23024"CRC64NVMEFULL_OBJECT79487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_021/_ibl_subjectTrials.table.a475e7ae-5f8d-4e3a-9bce-e97eba83f73f.pqt2023-12-20T09:08:52.000Z"6a75f984ac76de6e4f28016fa56ce5e1"30324137d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_022/#2024-08-21#/_ibl_subjectTraining.table.fed39e68-6357-46e7-9567-3bccb4481171.pqt2024-09-16T15:08:25.000Z"291a67df0007ecbc11f6c5f18bad943c"31977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_022/#2024-08-21#/_ibl_subjectTrials.table.e75aa5ba-3fe6-4dc0-9c79-f07ea5b48a65.pqt2024-09-16T15:08:25.000Z"61e67e7fe7828d380077a5153a4fca3d"42456777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_022/_ibl_subjectSessions.table.c46923c2-a938-4f77-9704-5042d3d839b6.pqt2025-02-20T19:37:55.000Z"4a909117284c146c1c9bf1441aed509d"CRC64NVMEFULL_OBJECT70497d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_022/_ibl_subjectTraining.table.3e0b0660-f633-4120-84ce-4dcd17c15b0c.pqt2023-12-20T09:08:52.000Z"87614affaef4c06ee3b7eaf422bb5f4a"31987d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_022/_ibl_subjectTrials.table.4faab502-f692-4d6a-b9c9-19ec89f3aa15.pqt2023-12-20T09:08:52.000Z"e8671467e41c096a0ec090cc90093718"25193777d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_023/_ibl_subjectSessions.table.8123d2e0-a225-4e1e-9d21-745acdf8e77d.pqt2025-02-20T19:37:55.000Z"15454210603b974918ff2447f91ecabc"CRC64NVMEFULL_OBJECT85707d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_023/_ibl_subjectTrials.table.45910ff7-27a0-4c83-a407-2e66387c6ded.pqt2023-12-20T09:08:52.000Z"8a46a41a022ffdbd26bac2980639bcdd"24346877d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_024/_ibl_subjectSessions.table.0407031f-683b-41fa-b9d1-5c7d1d050e69.pqt2025-02-20T19:37:55.000Z"bdebfb3265fa6aea4aba2786d75a595c"CRC64NVMEFULL_OBJECT74947d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_024/_ibl_subjectTraining.table.36f9ed32-4103-4882-8fd0-6e0cf4979e87.pqt2023-12-20T09:08:52.000Z"ce3d45c00710db61d77928a7b4eee329"32507d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_024/_ibl_subjectTrials.table.af3eddc0-9f1d-4f71-a581-771d38ba510b.pqt2023-12-20T09:08:52.000Z"5e1b34e1d06c7481f015f427d10b94c4"27934857d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_025/_ibl_subjectSessions.table.387b06c2-ba3f-4ea1-8ee2-8a9c9ca666ff.pqt2025-02-20T19:37:55.000Z"e668719407400f688708414f6b4d6195"CRC64NVMEFULL_OBJECT72327d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_025/_ibl_subjectTraining.table.dff08a56-1e82-40bd-b50b-7ac21fa0695c.pqt2023-12-20T09:08:52.000Z"bcdba954fd101fa00a20ed4bd292b493"31427d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_025/_ibl_subjectTrials.table.980dad56-e1f4-4ad9-8e64-2e7aaae4b545.pqt2023-12-20T09:08:52.000Z"e84b9626cbf620f24259a00cdf08ab12"17344337d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_026/_ibl_subjectSessions.table.2751ccbf-c7e7-4e55-ab32-2355fba193c1.pqt2025-02-20T19:37:55.000Z"39d33f2ec910034218e5fb236aedecad"CRC64NVMEFULL_OBJECT74487d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_026/_ibl_subjectTraining.table.f0027994-d3cd-48df-baa4-8c0032366355.pqt2023-12-20T09:08:52.000Z"988a70f735f4211f7dbba41c9a6258e4"32017d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_026/_ibl_subjectTrials.table.113c0e2d-a414-4ab5-a1ad-ec8c2e608dd8.pqt2023-12-20T09:08:52.000Z"c3b0eec27657b21cc35aac100fdce2c7"21743937d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_029/_ibl_subjectSessions.table.62ec5d7f-62bc-4a44-add6-aed355548d1f.pqt2025-02-20T19:37:55.000Z"f47e868b67757b5808b1ce95a248053e"CRC64NVMEFULL_OBJECT76057d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_029/_ibl_subjectTraining.table.e3cac4b2-4006-4424-815b-3557baccafcf.pqt2023-12-20T09:08:52.000Z"10f57c7721ceb7d22cd7b2044d0cf880"32547d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Subjects/zadorlab/CSH_ZAD_029/_ibl_subjectTrials.table.0c3216b3-d1b4-42cd-857e-16d171b6a3cc.pqt2023-12-20T09:08:52.000Z"5663df840b35efdee65b232256235e0f"36395347d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Tags/2023_Q1_Biderman_Whiteway_et_al/_ibl_videoTracking.trainingDataPaw.7e79e865-f2fc-4709-b203-77dbdac6461f.zip2023-04-04T13:36:37.000Z"d4cdf6076a0a3c05cb067f212a3780e9-25"2067903687d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Tags/2023_Q1_Biderman_Whiteway_et_al/_ibl_videoTracking.trainingDataPupil.27dcdbb6-3646-4a50-886d-03190db68af3.zip2023-04-04T13:36:37.000Z"6eabf5e5140ae040ed7349dd41b4c664-14"1093413977d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARDaggregates/Tags/2026_Q1_Wang_Yu_et_al/2026-02-25T09:06:49.000Z"d41d8cd98f00b204e9800998ecf8427e"CRC64NVMEFULL_OBJECT07d61e228e49d6bf1f22e79a6857f960e58dadcc508db1811b7d3ad9af67cdaa3STANDARD